US20230149501A1 - Methods for reducing oxidative damage - Google Patents
Methods for reducing oxidative damage Download PDFInfo
- Publication number
- US20230149501A1 US20230149501A1 US17/493,551 US202117493551A US2023149501A1 US 20230149501 A1 US20230149501 A1 US 20230149501A1 US 202117493551 A US202117493551 A US 202117493551A US 2023149501 A1 US2023149501 A1 US 2023149501A1
- Authority
- US
- United States
- Prior art keywords
- cells
- arg
- dmt
- lys
- phe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 58
- 230000004792 oxidative damage Effects 0.000 title abstract description 42
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 128
- 241000124008 Mammalia Species 0.000 claims abstract description 40
- SFVLTCAESLKEHH-WKAQUBQDSA-N (2s)-6-amino-2-[[(2s)-2-[[(2r)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]amino]-n-[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]hexanamide Chemical compound CC1=CC(O)=CC(C)=C1C[C@H](NC(=O)[C@H](N)CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N)=O)CC1=CC=CC=C1 SFVLTCAESLKEHH-WKAQUBQDSA-N 0.000 claims description 193
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 20
- 229960003638 dopamine Drugs 0.000 claims description 10
- 210000002569 neuron Anatomy 0.000 claims description 10
- 230000003647 oxidation Effects 0.000 claims description 8
- 238000007254 oxidation reaction Methods 0.000 claims description 8
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 abstract description 77
- 210000000056 organ Anatomy 0.000 abstract description 22
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract description 21
- -1 tryptophan amino acid Chemical class 0.000 abstract description 21
- 125000003118 aryl group Chemical group 0.000 abstract description 19
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract description 18
- 125000000539 amino acid group Chemical group 0.000 abstract description 16
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract description 8
- 210000004027 cell Anatomy 0.000 description 228
- 235000001014 amino acid Nutrition 0.000 description 100
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 88
- 229940024606 amino acid Drugs 0.000 description 87
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 63
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 59
- 102000004196 processed proteins & peptides Human genes 0.000 description 57
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 56
- 238000011282 treatment Methods 0.000 description 56
- 241000699670 Mus sp. Species 0.000 description 50
- 230000002829 reductive effect Effects 0.000 description 47
- 239000003642 reactive oxygen metabolite Substances 0.000 description 37
- 230000000694 effects Effects 0.000 description 31
- 208000028867 ischemia Diseases 0.000 description 31
- 230000006907 apoptotic process Effects 0.000 description 30
- 210000004153 islets of langerhan Anatomy 0.000 description 30
- 210000003470 mitochondria Anatomy 0.000 description 27
- 210000002216 heart Anatomy 0.000 description 26
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 25
- 230000001965 increasing effect Effects 0.000 description 25
- 230000010410 reperfusion Effects 0.000 description 23
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 21
- 230000001640 apoptogenic effect Effects 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 20
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 19
- 238000002955 isolation Methods 0.000 description 19
- 210000004940 nucleus Anatomy 0.000 description 19
- 238000010186 staining Methods 0.000 description 19
- 239000003981 vehicle Substances 0.000 description 19
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 18
- 101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 18
- PFYWPQMAWCYNGW-UHFFFAOYSA-M [6-(dimethylamino)-9-(2-methoxycarbonylphenyl)xanthen-3-ylidene]-dimethylazanium;perchlorate Chemical compound [O-]Cl(=O)(=O)=O.COC(=O)C1=CC=CC=C1C1=C2C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C21 PFYWPQMAWCYNGW-UHFFFAOYSA-M 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 18
- 230000002438 mitochondrial effect Effects 0.000 description 17
- UEVAHGMTRWGMTB-JBXUNAHCSA-N (2s)-6-amino-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 UEVAHGMTRWGMTB-JBXUNAHCSA-N 0.000 description 16
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 16
- 238000011534 incubation Methods 0.000 description 16
- 230000003834 intracellular effect Effects 0.000 description 16
- 230000003859 lipid peroxidation Effects 0.000 description 16
- 102000051367 mu Opioid Receptors Human genes 0.000 description 16
- 108010018625 phenylalanylarginine Proteins 0.000 description 16
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 16
- 230000009467 reduction Effects 0.000 description 16
- 108010094098 tyrosyl-arginyl-phenylalanyl-lysinamide Proteins 0.000 description 16
- 108020001612 μ-opioid receptors Proteins 0.000 description 16
- 239000000872 buffer Substances 0.000 description 15
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 15
- 108090000672 Annexin A5 Proteins 0.000 description 14
- 102000004121 Annexin A5 Human genes 0.000 description 14
- 241000700199 Cavia porcellus Species 0.000 description 14
- 125000003275 alpha amino acid group Chemical group 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- FIAKHZXVLBNZLW-NFGXINMFSA-N (2s)-6-amino-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound CC1=CC(O)=CC(C)=C1C[C@H](N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(N)=O)CC1=CC=CC=C1 FIAKHZXVLBNZLW-NFGXINMFSA-N 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 210000000496 pancreas Anatomy 0.000 description 13
- 102220020162 rs397508045 Human genes 0.000 description 13
- 230000004083 survival effect Effects 0.000 description 13
- CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 12
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 12
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 12
- QRMZSPFSDQBLIX-UHFFFAOYSA-N homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- OZILORBBPKKGRI-RYUDHWBXSA-N Phe-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 OZILORBBPKKGRI-RYUDHWBXSA-N 0.000 description 11
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 10
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 9
- AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 description 9
- 239000012981 Hank's balanced salt solution Substances 0.000 description 9
- 206010021143 Hypoxia Diseases 0.000 description 9
- 102000035195 Peptidases Human genes 0.000 description 9
- 108091005804 Peptidases Proteins 0.000 description 9
- 239000004365 Protease Substances 0.000 description 9
- 239000003963 antioxidant agent Substances 0.000 description 9
- 235000006708 antioxidants Nutrition 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 235000018417 cysteine Nutrition 0.000 description 9
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 230000007954 hypoxia Effects 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 9
- 235000002639 sodium chloride Nutrition 0.000 description 9
- 238000002054 transplantation Methods 0.000 description 9
- 102000007330 LDL Lipoproteins Human genes 0.000 description 8
- 108010007622 LDL Lipoproteins Proteins 0.000 description 8
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 8
- 230000003078 antioxidant effect Effects 0.000 description 8
- 229940072107 ascorbate Drugs 0.000 description 8
- 235000010323 ascorbic acid Nutrition 0.000 description 8
- 239000011668 ascorbic acid Substances 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 230000003833 cell viability Effects 0.000 description 8
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 8
- 230000003447 ipsilateral effect Effects 0.000 description 8
- 235000020778 linoleic acid Nutrition 0.000 description 8
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 8
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000005502 peroxidation Methods 0.000 description 8
- ZDHRSPRSUBAAIO-FNORWQNLSA-N (E)-4-hydroxynon-2-en-1-ol Chemical compound CCCCCC(O)\C=C\CO ZDHRSPRSUBAAIO-FNORWQNLSA-N 0.000 description 7
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 7
- PECYZEOJVXMISF-UWTATZPHSA-N 3-amino-D-alanine Chemical compound NC[C@@H](N)C(O)=O PECYZEOJVXMISF-UWTATZPHSA-N 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 7
- 102000004039 Caspase-9 Human genes 0.000 description 7
- 108090000566 Caspase-9 Proteins 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 210000000170 cell membrane Anatomy 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 230000027829 mitochondrial depolarization Effects 0.000 description 7
- 239000012188 paraffin wax Substances 0.000 description 7
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 7
- 239000007845 reactive nitrogen species Substances 0.000 description 7
- 230000035899 viability Effects 0.000 description 7
- RDFMDVXONNIGBC-UHFFFAOYSA-N 2-aminoheptanoic acid Chemical compound CCCCCC(N)C(O)=O RDFMDVXONNIGBC-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 102000011727 Caspases Human genes 0.000 description 6
- 108010076667 Caspases Proteins 0.000 description 6
- FMGYKKMPNATWHP-UHFFFAOYSA-N Cyperquat Chemical compound C1=C[N+](C)=CC=C1C1=CC=CC=C1 FMGYKKMPNATWHP-UHFFFAOYSA-N 0.000 description 6
- 206010061216 Infarction Diseases 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
- 239000004472 Lysine Substances 0.000 description 6
- 206010028851 Necrosis Diseases 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 230000030833 cell death Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000004624 confocal microscopy Methods 0.000 description 6
- 230000005284 excitation Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000002991 immunohistochemical analysis Methods 0.000 description 6
- 230000007574 infarction Effects 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 210000005230 lumbar spinal cord Anatomy 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 238000000386 microscopy Methods 0.000 description 6
- 230000017074 necrotic cell death Effects 0.000 description 6
- 230000004770 neurodegeneration Effects 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 230000009261 transgenic effect Effects 0.000 description 6
- 229930182536 Antimycin Natural products 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 5
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 210000004960 anterior grey column Anatomy 0.000 description 5
- CQIUKKVOEOPUDV-IYSWYEEDSA-N antimycin Chemical compound OC1=C(C(O)=O)C(=O)C(C)=C2[C@H](C)[C@@H](C)OC=C21 CQIUKKVOEOPUDV-IYSWYEEDSA-N 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
- 235000009697 arginine Nutrition 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000003727 cerebral blood flow Effects 0.000 description 5
- 210000000805 cytoplasm Anatomy 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 230000000302 ischemic effect Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000004898 mitochondrial function Effects 0.000 description 5
- 208000015122 neurodegenerative disease Diseases 0.000 description 5
- 230000036542 oxidative stress Effects 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108010051110 tyrosyl-lysine Proteins 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- WJJGAKCAAJOICV-JTQLQIEISA-N (2s)-2-(dimethylamino)-3-(4-hydroxyphenyl)propanoic acid Chemical group CN(C)[C@H](C(O)=O)CC1=CC=C(O)C=C1 WJJGAKCAAJOICV-JTQLQIEISA-N 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 238000011765 DBA/2 mouse Methods 0.000 description 4
- 108010040476 FITC-annexin A5 Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- FADYJNXDPBKVCA-STQMWFEESA-N Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 FADYJNXDPBKVCA-STQMWFEESA-N 0.000 description 4
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 229960005261 aspartic acid Drugs 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 239000006172 buffering agent Substances 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 239000008148 cardioplegic solution Substances 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 238000001212 derivatisation Methods 0.000 description 4
- 150000001993 dienes Chemical class 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 229960002885 histidine Drugs 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 150000003335 secondary amines Chemical class 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- VQVUBYASAICPFU-UHFFFAOYSA-N (6'-acetyloxy-2',7'-dichloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(OC(C)=O)C=C1OC1=C2C=C(Cl)C(OC(=O)C)=C1 VQVUBYASAICPFU-UHFFFAOYSA-N 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 3
- JVJFIQYAHPMBBX-UHFFFAOYSA-N 4-hydroxynonenal Chemical compound CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 3
- 150000008574 D-amino acids Chemical class 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 150000008575 L-amino acids Chemical class 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 108010033284 arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide Proteins 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 230000006727 cell loss Effects 0.000 description 3
- 125000003636 chemical group Chemical group 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000012744 immunostaining Methods 0.000 description 3
- 238000007913 intrathecal administration Methods 0.000 description 3
- 108010038320 lysylphenylalanine Proteins 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 210000000107 myocyte Anatomy 0.000 description 3
- 210000001577 neostriatum Anatomy 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000000626 neurodegenerative effect Effects 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 150000003141 primary amines Chemical class 0.000 description 3
- 230000002000 scavenging effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 208000020431 spinal cord injury Diseases 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 231100000167 toxic agent Toxicity 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 3
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- OZSNQMIQTHGXPJ-QMMMGPOBSA-N (2s)-2-amino-3-[(2-aminobenzoyl)amino]propanoic acid Chemical compound OC(=O)[C@@H](N)CNC(=O)C1=CC=CC=C1N OZSNQMIQTHGXPJ-QMMMGPOBSA-N 0.000 description 2
- GIANIJCPTPUNBA-QMMMGPOBSA-N (2s)-3-(4-hydroxyphenyl)-2-nitramidopropanoic acid Chemical compound [O-][N+](=O)N[C@H](C(=O)O)CC1=CC=C(O)C=C1 GIANIJCPTPUNBA-QMMMGPOBSA-N 0.000 description 2
- TWJPSNFPBZSAEJ-VMPITWQZSA-N (e)-non-1-ene-1,4-diol Chemical compound CCCCCC(O)C\C=C\O TWJPSNFPBZSAEJ-VMPITWQZSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- XDFNWJDGWJVGGN-UHFFFAOYSA-N 2-(2,7-dichloro-3,6-dihydroxy-9h-xanthen-9-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC(Cl)=C(O)C=C2OC2=CC(O)=C(Cl)C=C21 XDFNWJDGWJVGGN-UHFFFAOYSA-N 0.000 description 2
- OQEBBZSWEGYTPG-UHFFFAOYSA-N 3-aminobutanoic acid Chemical compound CC(N)CC(O)=O OQEBBZSWEGYTPG-UHFFFAOYSA-N 0.000 description 2
- FBTSQILOGYXGMD-LURJTMIESA-N 3-nitro-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C([N+]([O-])=O)=C1 FBTSQILOGYXGMD-LURJTMIESA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- RFRWQEYZKDAYAD-UHFFFAOYSA-N 4-hydroxynona-2,4-dienal Chemical compound OC(C=CC=O)=CCCCC RFRWQEYZKDAYAD-UHFFFAOYSA-N 0.000 description 2
- JJMDCOVWQOJGCB-UHFFFAOYSA-N 5-aminopentanoic acid Chemical compound [NH3+]CCCCC([O-])=O JJMDCOVWQOJGCB-UHFFFAOYSA-N 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 102000000412 Annexin Human genes 0.000 description 2
- 108050008874 Annexin Proteins 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- QCZYYEFXOBKCNQ-STQMWFEESA-N Lys-Phe Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QCZYYEFXOBKCNQ-STQMWFEESA-N 0.000 description 2
- 238000000719 MTS assay Methods 0.000 description 2
- 231100000070 MTS assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 2
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 108700013394 SOD1 G93A Proteins 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- JXNRXNCCROJZFB-RYUDHWBXSA-N Tyr-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 JXNRXNCCROJZFB-RYUDHWBXSA-N 0.000 description 2
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 2
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960004926 chlorobutanol Drugs 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 235000004554 glutamine Nutrition 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 210000005003 heart tissue Anatomy 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 108010053037 kyotorphin Proteins 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 210000002161 motor neuron Anatomy 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 150000002994 phenylalanines Chemical class 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 201000011461 pre-eclampsia Diseases 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000011191 terminal modification Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 150000003668 tyrosines Chemical class 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- LSNDLIKCFHLFKO-JTQLQIEISA-N (2s)-2-azaniumyl-3-(4-hydroxy-2,6-dimethylphenyl)propanoate Chemical compound CC1=CC(O)=CC(C)=C1C[C@H](N)C(O)=O LSNDLIKCFHLFKO-JTQLQIEISA-N 0.000 description 1
- LCKZFWNZLABYEW-XQUALCHDSA-N (2s)-5-amino-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]pentanamide Chemical compound C([C@@H](C(=O)N[C@@H](CCCN)C(N)=O)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 LCKZFWNZLABYEW-XQUALCHDSA-N 0.000 description 1
- JVJFIQYAHPMBBX-FNORWQNLSA-N (E)-4-hydroxynon-2-enal Chemical compound CCCCCC(O)\C=C\C=O JVJFIQYAHPMBBX-FNORWQNLSA-N 0.000 description 1
- BLCJBICVQSYOIF-UHFFFAOYSA-N 2,2-diaminobutanoic acid Chemical group CCC(N)(N)C(O)=O BLCJBICVQSYOIF-UHFFFAOYSA-N 0.000 description 1
- CCTFAOUOYLVUFG-UHFFFAOYSA-N 2-(1-amino-1-imino-2-methylpropan-2-yl)azo-2-methylpropanimidamide Chemical compound NC(=N)C(C)(C)N=NC(C)(C)C(N)=N CCTFAOUOYLVUFG-UHFFFAOYSA-N 0.000 description 1
- QWCKQJZIFLGMSD-UHFFFAOYSA-N 2-Aminobutanoic acid Natural products CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 1
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 1
- XFDUHJPVQKIXHO-UHFFFAOYSA-N 3-aminobenzoic acid Chemical compound NC1=CC=CC(C(O)=O)=C1 XFDUHJPVQKIXHO-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 101100129088 Caenorhabditis elegans lys-2 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
- OFVBLKINTLPEGH-UHFFFAOYSA-N DL-beta-Homophenylalanine Chemical compound OC(=O)CC(N)CC1=CC=CC=C1 OFVBLKINTLPEGH-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000015782 Electron Transport Complex III Human genes 0.000 description 1
- 108010024882 Electron Transport Complex III Proteins 0.000 description 1
- 108091006149 Electron carriers Proteins 0.000 description 1
- 206010014498 Embolic stroke Diseases 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- RVKIPWVMZANZLI-UHFFFAOYSA-N H-Lys-Trp-OH Natural products C1=CC=C2C(CC(NC(=O)C(N)CCCCN)C(O)=O)=CNC2=C1 RVKIPWVMZANZLI-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- KDBDVESGGJYVEH-PMVMPFDFSA-N Lys-Trp-Phe Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CCCCN)C(O)=O)C1=CC=CC=C1 KDBDVESGGJYVEH-PMVMPFDFSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010053961 Mitochondrial toxicity Diseases 0.000 description 1
- 108010087066 N2-tryptophyllysine Proteins 0.000 description 1
- 102000002247 NADPH Dehydrogenase Human genes 0.000 description 1
- 108010014870 NADPH Dehydrogenase Proteins 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- CJAHQEZWDZNSJO-KKUMJFAQSA-N Phe-Lys-Cys Chemical compound NCCCC[C@@H](C(=O)N[C@@H](CS)C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 CJAHQEZWDZNSJO-KKUMJFAQSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 238000011831 SOD1-G93A transgenic mouse Methods 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- GRSCONMARGNYHA-PMVMPFDFSA-N Trp-Lys-Phe Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O GRSCONMARGNYHA-PMVMPFDFSA-N 0.000 description 1
- JZSLIZLZGWOJBJ-PMVMPFDFSA-N Trp-Phe-Lys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N JZSLIZLZGWOJBJ-PMVMPFDFSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 108010076089 accutase Proteins 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000004947 alkyl aryl amino group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 229940124326 anaesthetic agent Drugs 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000000576 arachnoid Anatomy 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 238000011237 bivariate analysis Methods 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000007323 disproportionation reaction Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000027721 electron transport chain Effects 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 208000019995 familial amyotrophic lateral sclerosis Diseases 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000001985 kidney epithelial cell Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 210000002311 liver mitochondria Anatomy 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 231100000296 mitochondrial toxicity Toxicity 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical class O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000002756 mu opiate receptor agonist Substances 0.000 description 1
- 229940126487 mu opioid receptor agonist Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 230000008599 nitrosative stress Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000020925 non fasting Nutrition 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 230000001019 normoglycemic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 229940127255 pan-caspase inhibitor Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-M peroxynitrite Chemical compound [O-]ON=O CMFNMSMUKZHDEY-UHFFFAOYSA-M 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 102000036213 phospholipid binding proteins Human genes 0.000 description 1
- 108091011000 phospholipid binding proteins Proteins 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 230000003244 pro-oxidative effect Effects 0.000 description 1
- 238000012342 propidium iodide staining Methods 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000003161 proteinsynthetic effect Effects 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010825 rotarod performance test Methods 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000010245 stereological analysis Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 150000003667 tyrosine derivatives Chemical group 0.000 description 1
- 229940040064 ubiquinol Drugs 0.000 description 1
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
Definitions
- Mitochondria are essential to cell survival as the main producers of ATP via oxidative phosphorylation.
- the mitochondria respirator chain is also a major source of oxidative free radicals.
- radical production can occur as a result of the reaction of mitochondrial electron carriers, such as ubiquinol, with oxygen to form a superoxide.
- Superoxides react by dismutation to hydrogen peroxide, which can decompose to hydroxyl radical.
- superoxides react with nitric oxide to form peroxynitrite and other reactive oxidants.
- Aging is associated not only with increased reactive oxygen species (ROS) production, but also a decrease in the endogenous antioxidant defense mechanisms. Mitochondria are particularly vulnerable to oxidative stress because they are continuously exposed to ROS. As a consequence, mitochondria decay is often associated with aging.
- ROS reactive oxygen species
- Free radicals including ROS, and reactive nitrogen species (RNS) produce diverse non-specific damage to biological molecules, including lipids, proteins, RNA and DNA. Such damage of these molecules has been implicated in numerous clinical disorders, such as atherosclerosis, preeclampsia, Alzheimer’s disease, Parkinson’s disease and arthritis.
- Antioxidant therapy can potentially delay the aging process, and be beneficial in a host of human diseases and conditions such as those described above.
- the development of specific mitochondrial therapies has been hampered by the difficulty of delivering antioxidant molecules to mitochondria in vivo. For example, the molecule must first be taken up across the plasma membrane into the cytoplasm, and then targeted selectively to mitochondria.
- antioxidants None of the currently available antioxidant compounds specifically target mitochondria.
- the natural antioxidants e.g., Vitamin E, coenzyme Q, polyphenols
- Vitamin E e.g., Vitamin E, coenzyme Q, polyphenols
- the present invention provides a method for reducing oxidative damage in a mammal in need thereof.
- the method comprises administering to the mammal an effective amount of an aromatic cationic peptide.
- the aromatic cationic peptide have (a) at least one net positive charge; (b) a minimum of three amino acids; (c) a maximum of about twenty amino acids; (d) a relationship between the minimum number of net positive charges (p m ) and the total number of amino acid residues (r) wherein 3p m is the largest number that is less than or equal to r+1; (e) a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 3a is the largest number that is less than or equal to p t +1, except that when a is 1, p t may also be 1; and (f) at least one tyrosine or tryptophan amino acid.
- the invention also provides a method of reducing oxidative damage in a removed organ of a mammal.
- the method comprises administering to the removed organ an effective amount of an aromatic-cationic peptide.
- the aromatic-cationic peptide have (a) at least one net positive charge; (b) a minimum of four amino acids; (c) a maximum of about twenty amino acids; (d) a relationship between the minimum number of net positive charges (p m ) and the total number of amino acid residues (r) wherein 3p m is the largest number that is less than or equal to r+1; (e) a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (p t ) wherein 2a is the largest number that is less than or equal to p t +1, except that when a is 1, p t may also be 1; and (f) at least one tyrosine or tryptophan amino acid.
- the invention provides a method of reducing oxidative damage in a mammal in need thereof.
- the method comprises administering) to the mammal an effective amount of an aromatic-cationic peptide.
- the aromatic-cationic peptide have (a) at least one net positive charge; (b) a minimum of three amino acids; (c) a maximum of about twenty amino acids; (d) a relationship between the minimum number of net positive charges (p m ) and the total number of amino acid residues (r) wherein 3p m is the largest number that is less than or equal to r+1; (e) a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (p t ) wherein 2a is the largest number that is less than or equal to p t +1, except that when a is 1, p t may also be 1, and (f) at least one tyrosine or tryptophan amino acid.
- the invention provides a method of reducing oxidative damage in a removed organ of a mammal.
- the method comprises administering to the removed organ an effective amount of an aromatic-cationic peptide.
- the aromatic cationic peptide have (a) at least one net positive charge; (b) a minimum of three amino acids; (c) a maximum of about twenty amino acids; (d) a relationship between the minimum number of net positive charges (p m ) and the total number of amino acid residues (r) wherein 3p m is the largest number that is less than or equal to r+1; (e) a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (p t ) wherein 3a is the largest number that is less than or equal to p t +1, except that when a is 1, p t may also be 1, and (f) at least one tyrosine or tryptophan amino acid.
- the invention provides a method of reducing, oxidative damage in a cell in need thereof.
- the aromatic cationic peptide have (a) at least one net positive charge; (b) a minimum of three amino acids; (c) a maximum of about twenty amino acids; (d) a relationship between the minimum number of net positive charges (p m ) and the total number of amino acid residues (r) wherein 3p m is the largest number that is less than or equal to r+1; (e) a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (p t ) wherein a is the largest number that is less than or equal to p t +1, except that when a is 1, p t may also be 1, and (f) at least one tyrosine or tryptophan amino acid.
- the invention provides a method of reducing oxidative damage in a cell in need thereof.
- the aromatic cationic peptide have (a) at least one net positive charge; (b) a minimum of three amino acids; (c) a maximum of about twenty amino acids; (d) a relationship between the minimum number of net positive charges (p m ) and the total number of amino acid residues (r) wherein 3p m is the largest number that is less than or equal to r+1; (e) a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (p t ) wherein 2a is the largest number that is less than or equal to p t +1, except that when a is 1, p t may also be 1, and (f) at least one tyrosine or tryptophan amino acid
- FIGS. 1 A- 1 B ( FIG. 1 A ) SS-02 and ( FIG. 1 B ) SS-05 dose-dependently scavenge H 2 O 2 .
- FIGS. 2 A- 2 B ( FIG. 2 A ) SS-02 dose-dependently inhibits linoleic acid peroxidation induced by ABAP and ( FIG. 2 B ) SS-02 SS-05, SS-29, SS-30, SS-31, SS-32 and Dmt reduced the rate of linoleic acid peroxidation induced by ABAP.
- FIGS. 3 A- 3 B ( FIG. 3 A ) SS-02 dose-dependently inhibits LDL oxidation induced by 10 mM CuSO 4 and ( FIG. 3 B ) SS-02, SS-05, SS-29, SS-30, SS-31, SS-32 and Dmt reduced rate of LDL oxidation.
- FIGS. 4 A- 4 B FIGS. 4 A- 4 B .
- FIG. 4 A SS-02 inhibits mitochondrial production of hydrogen peroxide as measured by luminol chemiluminescence under basal conditions and upon stimulation by antimycin.
- FIG. 4 B SS-02, SS-29, SS-30 and SS-31 reduced spontaneous generation of hydrogen peroxide generated by isolated mitochondria.
- FIGS. 5 A- 5 B ( FIG. 5 A ) SS-31 inhibits spontaneous production of hydrogen hydroperoxide by isolated mitochondria and ( FIG. 5 B ) SS-31 inhibits hydrogen peroxide production stimulated by antimycin.
- FIGS. 6 A- 6 C SS-31 dose-dependently decreased intracellular ROS (reactive oxygen species) ( FIG. 6 A ) and increased cell survival ( FIG. 6 B ) in N 2 A cells exposed to a high dose of the pro- oxidant t-butyl hydroperoxide (t-BHP; 0.5 mM), ( FIG. 6 C ) SS-02 also dose-dependently increased cell survival when N2A cells were exposed to 1 mM t-BHP.
- ROS reactive oxygen species
- FIGS. 7 A- 7 B SS-31 dose-dependently prevented loss of cell viability caused by low doses of t-BHP (0.05-0.1 mM) in neuronal ( FIG. 7 A ) SH-SY5Y and ( FIG. 7 B ) N 2 A cells.
- FIG. 8 SS-31 dose-dependently decreased the percent of cells showing increased caspase activity after treatment with a low dose of t-BHP for 12 h in N 2 A cells.
- FIG. 9 SS-31 dose-dependently reduced the rate of ROS accumulation in N 2 A cells with 0.1 mM t-BHP over a 4 h period.
- FIGS. 10 A- 10 C SS-31 inhibited lipid peroxidation caused by exposure of N 2 A cells to 1 mM t-BHP for 1 h.
- FIG. 10 A untreated cells
- FIG. 10 B cells treated with 1 mM t-BHP for 3 h
- FIG. 10 C cells treated with 1 mM t-BHP and 10 nM SS-31 for 3 h.
- FIG. 11 SS-31 prevented mitochondrial depolarization and ROS accumulation in N 2 A cells exposed to t-BHP.
- FIGS. 12 A- 12 D SS-31 prevents apoptosis induced by a low dose of t-BHP. Apoptosis was evaluated by confocal microscopy with the fluorescent probe Hoechst 33342.
- FIG. 12 A a representative field of cells not treated with t-BHP.
- FIG. 12 AA Fluorescent image showing a few cells with dense, fragmented chromatin indicative of apoptotic nuclei.
- FIG. 12 B A representative field of cells treated with 0.025 mM t-BHP for 24 h.
- FIG. 12 BB Fluorescent image showing an increased number of cells with apoptotic nuclei.
- FIG. 12 A Fluorescent image showing an increased number of cells with apoptotic nuclei.
- FIG. 12 C A representative field of cells treated with 0.025 mM t-BHP and 1 nM SS-31 for 24 h.
- FIG. 12 CC Fluorescent image showing a reduced number of cells with apoptotic nuclei.
- FIG. 12 D SS-31 dose-dependently reduced the percent of apoptotic cells caused by 24 h treatment with a low dose of T-BHP (0.05 mM).
- FIG. 13 A (a-e).
- SS-02 and SS-31 reduced lipid peroxidation in isolated guinea pig hearts subjected to warm reperfusion after a brief period of ischemia.
- Tissue slices were incubated with anti-HNE antibody.
- Background control staining without primary antibody.
- FIG. 13 B (a-e).
- SS-02 and SS-31 reduced lipid peroxidation in isolated guinea pig hearts subj ected to warm reperfusion after a brief period of ischemia.
- Tissue slices were incubated with anti-HNE antibody.
- Background control staining without primary antibody.
- FIG. 14 A SS-31 significantly improved coronary flow in isolated guinea pig hearts subjected to warm reperfusion after prolonged (18 h) cold ischemia.
- the shaded area represents 18 h of ischemia at 4° C.
- FIG. 14 B (a-c). Guinea pig hearts perfused with a cardioplegic solution (St. Thomas solution) without (a) or with (b) 1 nM SS-31 for 3 min and then subjected to 18 h of cold ischemia (4° C.), (c) background staining with primary antibody. The hearts were then reperfused with buffer at 34° C. for 90 min.
- a cardioplegic solution St. Thomas solution
- FIG. 14 C SS-31 prevents apoptosis in endothelial cells and myocytes in isolated guinea pig hearts subjected to warm reperfusion after prolonged (18 h) cold ischemia.
- Apoptosis was assessed by the TUNEL stain (green) and nuclei are visualized by DAPI (blue).
- FIG. 15 A SS-31 improves survival of islet cells isolated from mouse pancreas as measured by mitochondrial potential.
- SS-31 nM was added to all isolation buffers used throughout the isolation procedure. Mitochondrial potential was measured using TMRM (red) with confocal microscopy.
- FIGS. 15 B & 15 C SS-31 reduces apoptosis and increases viability in islet cells isolated from mouse pancreas as measured by flow cytometry.
- SS-31 (1 nM) was added to all isolation buffers used throughout the isolation procedure.
- Apoptosis was ascertained using annexin V and necrosis by propidium iodide (PI).
- FIGS. 16 A- 16 C SS-31 reduces oxidative damage in pancreatic islet cells caused by t- butylhydroperoxide (tBHP).
- Mouse pancreatic islet cells were untreated ( FIG. 16 A ), or treated with 25 ⁇ M tBHP without ( FIG. 16 B ) or with 1 nM SS-31 ( FIG. 16 C ).
- Mitochondrial potential was measured by TMRM (red) and reactive oxygen species were measured by DCF (green) using confocal microscopy.
- FIG. 17 A SS-31 protects dopamine cells against MPP ⁇ toxicity.
- SN-4741 cells were treated with buffer, 50 ⁇ M MPP ⁇ or 50 ⁇ M MPP ⁇ and 1 nM SS-31, for 48 h, and the incidence of apoptosis was determined by fluorescent microscopy with Hoechst 33342. The number of condensed fragmented nuclei was significantly increased by MPP ⁇ treatment. Concurrent treatment with SS-31 reduced the number of apoptotic cells.
- FIG. 17 B & FIG. 17 BB SS-31 dose-dependently prevented loss of dopamine neurons in mice treated with MPTP.
- SS-31 was administered 30 min before each MPTP injection, and at 1 h and 12 h after the last MPTP injection. Animals were sacrificed one week later and striatal brain reactions were immunostained for tyrosine hydroxylase activity (shown in black).
- FIGS. 17 C- 17 E SS-31 dose-dependently increased striatal dopamine, DOPAC (3,4- dihydroxyphenylacetic acid) and HVA (homovanillic acid) levels in mice treated with MPTP.
- Three doses of MPTP (10 mg/kg) was given to mice (n 12) 2 h apart.
- FIGS. 18 A- 18 B SS-31 reduced tBHP-induced LDH release in SH-SY5Y ( FIG. 18 A ) and N 2 A ( FIG. 18 B ) cells.
- Cells were treated with 100 ⁇ M tBHP alone, or with SS-31, for 24 h. ⁇ P ⁇ 0.05, ⁇ P ⁇ 0.01, ⁇ P ⁇ 0.001, compared to tBHP alone.
- FIGS. 19 A- 19 C SS-31 reduced tBHP-induced apoptosis as demonstrated by phosphatidylserine translocation.
- N 2 A cells were incubated with 50 ⁇ M tBHP for 6 h and stained with Annexin V and propidium iodide (PI).
- PI propidium iodide
- FIG. 19 B Cells treated with tBHP showed intense Annexin V staining (green) in most cells. Combined staining with Annexin V and PI (red) indicate late apoptotic cells.
- FIG. 19 C Concurrent treatment with 1 nM SS-31 resulted in a reduction in Annexin V- positive cells and no PI staining.
- FIGS. 20 A- 20 C SS-31 reduced tBHP-induced apoptosis as demonstrated by nuclear condensation.
- FIG. 20 A (a-c; a′-c′) N 2 A cells were treated with 50 ⁇ M tBHP alone or with SS-31 for 12 h. Cells were stained with Hoechst 33342 for 20 min., fixed, and imaged by fluorescent microscopy.
- Untreated cells show uniformly stained nuclei (a′).
- FIG. 20 B ( FIG. 20 B )-( FIG.
- FIGS. 21 A- 21 B SS-31 prevented caspase activation in N 2 A cells treated with tBHP.
- FIG. 21 A incubation of N 2 A cells with 100 ⁇ M tBHP for 24 h resulted in a significant increase in pancaspase activity that was dose-dependently prevented by co-incubation with SS-31 ( ⁇ P ⁇ 0.01 compared to tBHP alone).
- FIG. 21 B (a-c) N 2 A cells were treated with 50 ⁇ M tBHP for 12 h and stained with caspase-9 FLICATM kit containing red fluorescent inhibitor SR-LEHD-FMK and Hoechst 33342.
- FIGS. 22 A- 22 C SS-31 dose-dependently reduced intracellular ROS production in N 2 A cells treated with tBHP.
- FIG. 22 B (a-c) N 2 A cells were plated in glass bottom dishes and treated with 50 ⁇ M tBHP, alone or with 1 nM SS-31, for 6 h.
- FIG. 22 C Effect of 1 nM SS-31 in reducing intracellular ROS induced by 50 ⁇ M tBHP ( ⁇ P ⁇ 0.001 compared to untreated cells; ⁇ P ⁇ 0.05 compared to tBHP alone).
- FIGS. 23 A- 23 B SS-31 protected against tBHP-induced mitochondrial viability.
- FIG. 23 A SS-31 protected mitochondrial viability in N 2 A cells treated with tBHP for 24 h. Mitochondrial viability was evaluated using the MTT assay ( ⁇ P ⁇ 0.01 compared to untreated cells, ⁇ P ⁇ 0.05, P ⁇ 0.01 compared to tBHP alone).
- FIG. 23 B SS-31 protected mitochondrial viability in SH-SY5Y cells treated with tBHP for 25 h ( ⁇ P ⁇ 0.01 compared to untreated cells; ⁇ P ⁇ 0.01 compared to tBHP alone).
- FIG. 24 Increased hydrogen peroxide (H 2 O 2 ) sensitivity of G93A-SOD transfected murine neuroblastoma (N 2 A) cells as compared to wildtype SOD-transfected N 2 A cells after addition of 0.5 or 1 mM H 2 O 2 for 1 h.
- Cell death was quantified by measurement of the percentage of H 2 O 2 -induced LDH release of total cellular LDH-content.
- FIG. 25 B Mean survival (days) of G93A mice treated with vehicle or SS-31 5 mg/kg/day. (Data are mean ⁇ SD, p ⁇ 0.05, Student’s t-test).
- FIG. 26 Effect of SS-31 mg/kg/day on motor performance (seconds) tested by rotarod (Values are mean ⁇ standard error of means of the mice still alive at the respective time point): it was significantly improved between day (d) 110 and day 130 in SS-31-treated animals as compared to the vehicle-treated group (p ⁇ 0.005, Repeated Measures ANOVA followed by Fisher’s PLSD).
- FIGS. 27 A & 27 B Attenuation of motor neuron loss by SS-31 in the ventral horn of the lumbar spinal cord of G93A mice.
- Photomicrographs show cresyl violet stained sections through the ventral horn of the lumbar spinal cord from non-transgenic control (A) and G93A mice treated with vehicle (PBS) (B) or SS-31 (C) at 110 days of age.
- Stereological analysis revealed significantly reduced numbers of surviving neurons in G93A mice treated with vehicle as compared to non-transgenic controls ( ⁇ , p ⁇ 0.001). This cell loss was significantly ameliorated by treatment with SS-31 ( ⁇ ,p ⁇ 0.01). Values are mean ⁇ standard error of means. Differences among means were analyzed using ANOVA followed by Newman-Keuls post hoc test.
- FIGS. 28 A- 28 C 4-hydroxynonenol immunostaining. Photomicrographs of representative sections through the ventral horn of the lumbar spinal cord of wild-type control ( FIG. 28 A ), and G93A mice treated with vehicle ( FIG. 28 B ) or SS-31 ( FIG. 28 C ) show generalized reduction of 4- hydroxynonenal staining in neurons and neurophils in drug-treated mice.
- FIGS. 29 A- 29 C Nitrotyrosine immunostaining. Photomicrographs of representative sections through the ventral horn of the lumbar spinal cord of wild-type control ( FIG. 29 A ), and G93A mice treated with vehicle ( FIG. 29 B ) or SS-31 ( FIG. 29 C ) show generalized reduction of nitrotyrosine staining in neurons and neurophils in drug-treated mice.
- FIGS. 30 A- 30 F Temporal changes of cysteine ( FIG. 30 A , FIG. 30 B ), ascorbate ( FIG. 30 C , FIG. 30 D ) and GSH ( FIG. 30 E , FIG. 30 F ) levels in post-ischemic brain.
- Contral contralateral side; Ipsil, ipsilateral side; 0 h, sham non-ischemic animal.
- FIGS. 31 A- 31 C Effect of SS-31 peptide on ischemia-induced changes in cysteine ( FIG. 31 A ) ascorbate ( FIG. 31 B ), and GSH ( FIG. 31 C ) levels
- C57BL/6 mice were subjected to 30 min MCAO and treated with vehicle, SS-31 (2 mg/kg body weight) or SS-20 (2 mg/kg body eight) peptide immediately after reperfusion.
- FIGS. 32 A- 32 F Effect of SS-31 peptide on ischemia-induced infarct size and swelling in C57BL/6 mice. Shown are representative serial sections (1.2 mm apart) stained with Cresyl Violet from mice subjected to 30 min ( FIG. 32 A ) and 20 min ( FIG. 32 B ) MCAO and treated with vehicle (Veh) or SS-31 (2 mg/kg body weight) immediately after reperfusion, 6 h, 24 h, and 48 h. Infarct volumes (( FIG. 32 C ) and swelling ( FIG. 32 D ) were estimated at 72 h postischemia from 12 serial sections (600 Bm apart) per animal. Mean % cerebral blood flow (CBF) reduction during MCAO ( FIG.
- CBF cerebral blood flow
- FIGS. 33 A- 33 B SS peptides penetrate islet cells, co-localize with mitochondria and preserve islet mitochondrial membrane potential.
- FIG. 33 A Islet cell uptake of SS-31. DBA/2 islet cells were incubated with 1 nM of tritium labeled SS-31 and 1 ⁇ M unlabeled SS-31 at 37° C. for 1 h. Following incubation, radioactivity was measured in the medium and in cell lysates and the radioactive counts in the medium were subtracted from radioactive counts in the cell lysate and normalized to protein content. In four consecutive experiments, the mean ⁇ (SE) [ 3 H]SS-31 uptake was 70.2+/31 10.3 pmol/mg, of proteins ( FIG.
- SS-31 preserves islet mitochondrial potential.
- DBA/2 mice were treated with SS-31 (3 mg/kg s.c. BID) or vehicle control 24 hours prior to pancreas harvest for islet isolation.
- SS-31 treated groups had 1 nM SS-31 added to the islet isolation reagents.
- TMRM uptake was evaluated using confocal laser scanning microscopy. Fluorescent (i) and phase (ii) images of TMRM uptake in control mice demonstrate reduced fluorescent uptake indicating mitochondrial depolarization. In sharp contrast, fluorescent (iii) and phase (iv) images of TMRM uptake in SS-31 treated mice demonstrate increased uptake and preserved mitochondrial potential indicative of SS-31 protective effect.
- FIGS. 34 A- 34 D SS-31 reduces islet cell apoptosis.
- DBA/2 mice were pre-treated (24 and 12-hours hours prior to pancreas harvest and islet isolation) with SS-31 (3 mg/kg, s.c., BID) or vehicle control.
- SS-31 (1 nM was added to reagents used for the isolation of islets from SS-31-treated mice.
- the islets were dissociated in to single cells with trypsin/EDTA and were stained with Annexin V-FITC (AnV) and propidium iodide (PI) and analyzed with the use of dual parameter low cytometry.
- FIG. 1 Annexin V-FITC
- PI propidium iodide
- FIGS. 35 A- 35 C Reversal of diabetes following transplantation of a marginal mass of syngeneic islets.
- Diabetic DBA/2 mice received 200 syngeneic islet cells under the right kidney capsule. Reversal of diabetes was defined as random nonfasting blood glucose levels below 200 mg/dl on 3-consecutive days.
- FIG. 35 A Blood glucose levels of each individual control mouse following transplantation of 200 syngeneic islets.
- FIG. 35 B Blood glucose levels of each individual SS-31 treated mouse following transplantation of 200 syngeneic islets.
- FIG. 35 C Reversal of diabetes following transplantation of a marginal islet cell mass in SS-31 treatment vs. control. Number of normoglycemic mice by day 1, 3, 5, 10 and 14 post transplantation and two-tailed P-valued calculated using chisquared bivariate analysis are shown.
- the invention is based on the surprising discovery by the inventors that certain aromatic-cationic peptides reduce oxidative damage. Reducing oxidative damage is important since free radicals, such as ROS and RNS, produce diverse non-specific damage to lipids, proteins. RNA, and DNA oxidative damage caused by free radicals is associated with several diseases and conditions in mammals.
- aromatic-cationic peptides useful in the present invention are water-soluble and highly polar. Despite these properties, the peptides can readily penetrate cell membranes.
- aromatic-cationic peptides useful in the present invention include a minimum of three amino acids, and preferably include a minimum of four amino acids, covalently joined by peptide bonds.
- the maximum number of amino acids present in the aromatic-cationic peptides of the present invention is about twenty amino acids covalently joined by peptide bonds.
- the maximum number of amino acids is about twelve, more preferably about nine, and most preferably about six.
- the number of amino acids present in the peptides is four.
- amino acids of the aromatic-cationic peptides useful in the present invention can be any amino acid.
- amino acid is used to refer to any organic molecule that contains at least one amino group and at least one carboxyl group. Preferably, at least one amino group is at the ⁇ position relative to the carboxyl group.
- the amino acids may be naturally occurring.
- Naturally occurring amino acids include, for example, the twenty most common levorotatory (L) amino acids normally found in mammalian proteins, i.e., alanine (Ala), arginine (Arg), asparagine (Asn) aspartic acid (Asp), cysteine (Cys), glutamine (Glu), glutamic acid (Glu), glycine (Gly), histidine (His), isoleucine (Ileu), leucine (Leu), lysine (Lys), methionine (Met), phenylalanine (Phe), proline (Pro), serine (Ser), threonine (Thr), trypotophan, (Trp), tyrosine (Tyr), and valine (Val).
- amino acids that are synthesized in metabolic processes not associated with protein synthesis.
- amino acids ornithine and citrulline are synthesized in mammalian metabolism during the production of urea.
- the peptides useful in the present invention can contain one or more non-naturally occurring amino acids.
- the non-naturally occurring amino acids may be L-, dextrorotatory (D), or mixtures thereof.
- the peptide has no amino acids that are naturally occurring.
- Non-naturally occurring amino acids are those amino acids that typically are not synthesized in normal metabolic processes in living organisms, and do not naturally occur in proteins.
- the non-naturally occurring amino acids useful in the present invention preferably are also not recognized by common proteases.
- the non-naturally occurring amino acid can be present at any position in the peptide.
- the non-naturally occurring amino acid can be at the N-terminus, the C-terminus, or at any position between the N-terminus and the C-terminus.
- the non-natural amino acids may, for example, comprise alkyl, aryl, or alkylaryl groups.
- alkyl amino acids include ⁇ -aminobutyric acid, ⁇ -aminobutyric acid, ⁇ -aminobutyric acid, ⁇ -aminovaleric acid, and ⁇ -aminocaproic acid.
- aryl amino acids include ortho-, meta, and para-aminobenzoic acid.
- alkylaryl amino acids include ortho-, meta-, and para-aminophenyleacetic acid, and ⁇ -phenyl- ⁇ -aminobutyric acid.
- Non-naturally occurring amino acids also include derivatives of naturally occurring amino acids.
- the derivatives of naturally occurring amino acids may, for example, include the addition of one or more chemical groups to the naturally occurring amino acid.
- one or more chemical groups can be added to one or more of the 2′, 3′, 4′, 5′, or 6′ position of the aromatic ring of a phenylalanine or tyrosine residue, or the 4′, 5′, 6′ or 7′ position of the benzo ring of a tryptophan residue.
- the group can be any chemical group that can be added to an aromatic ring.
- Some examples of such groups include branched or unbranched C 1 -C 4 alkyl, such as methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, or t-butyl, C 1 -C 4 alkyloxy (i.e., alkoxy), amino, C 1 -C 4 alkylamino and C 1 -C 4 dialkylamino (e.g., methylamino dimethylamino), nitro, hydroxyl, halo (i.e., fluoro, chloro, bromio, or iodo).
- Some specific examples of non-naturally occurring derivatives of naturally occurring amino acids include norvaline (Nva), norleucine (Nle), and hydroxyproline (Hyp).
- Another example of a modification of an amino acid in a peptide useful in the methods of the present invention is the derivatization of a carboxyl group of an aspartic acid or a glutamic acid residue of the peptide.
- derivatization is amidation with ammonia or with a primary or secondary amine, e.g. methylamine, ethylamine, dimethylamine or diethylamine.
- Another example of derivatization includes esterification with, for example, methyl or ethyl alcohol.
- Another such modification includes derivatization of an amino group of a lysine, arginine, or histidine residue.
- amino groups can be acylated.
- suitable acyl groups include, for example, a benzoyl group or an alkanoyl group comprising any of the C 1 -C 4 alkyl groups mentioned above, such as an acetyl or propionyl group.
- the non-naturally occurring amino acids are preferably resistant, and more preferably insensitive, to common proteases.
- non-naturally occurring amino acids that are resistant or insensitive to proteases include the dextrorotatory (D-) form of any of the above-mentioned naturally occurring L-amino acids, as well as L- and/or D-naturally occurring amino acids.
- the D-amino acids do normally occur in proteins although they are found in certain peptide antibiotics that are synthesized by means other than the normal ribosomal protein synthetic machinery of the cell.
- the 1-amino acids are considered to be non-naturally occurring amino acids.
- the peptides useful in the methods of the invention should have less than five, preferably less than four, more preferably less than three, and most preferably, less than two contiguous L-amino acids recognized by common proteases, irrespective of whether the amino acids are naturally or non-naturally occurring.
- the peptide has only D-amino acids, and no L-amino acids.
- the peptide contains protease sensitive sequences of amino acids, at least one of the amino acids is preferably a non-naturally-occurring D-amino acid, thereby conferring protease resistance.
- An example of a protease sensitive sequence includes two or more contiguous basic amino acids that are readily cleaved by common proteases, such as endopeptidases and trypsin. Examples of basic amino acids include arginine, lysine and histidine.
- At least one of the amino acids present in the aromatic-cationic peptide is a tyrosine or tryptophan residue, or a derivative thereof.
- the aromatic-cationic peptides have a minimum number of net positive charges at physiological pH in comparison to the total number of amino acid residues in the peptide.
- the minimum number of net positive charges at physiological pH will be referred to below as (p m ).
- the total number of amino acid residues in the peptide will be referred to below as (r).
- physiological pH refers to the normal pH in the cells of the tissues and organs of the mammalian body.
- physiological pH refers to the normal pH in the cells of the tissues and organs of the mammalian body.
- physiological pH of a human is normally approximately 7.4, but normal physiological pH in mammals may be any pH from about 7.0 to about 7.8.
- Net charge refers to the balance of the number of positive charges and the number of negative charges carried by the amino acids present in the peptide. In this specification, it is understood that net charges are measured at physiological pH.
- the naturally occurring amino acids that are positively charged at physiological pH include L- lysine, L-arginine, L-histidine.
- the naturally occurring amino acids that are negatively charged at physiological pH include L-aspartic acid and L-glutamic acid.
- a peptide has a positively charged N-terminal amino group and a negatively charged C-terminal carboxyl group. The charges cancel each other out at physiological pH.
- the aromatic-cationic peptides have a relationship between the minimum number of net positive charges at physiological pH (p m ) and the total number of amino acid residues (r) wherein 3p m is the largest number that is less than or equal to r+1.
- the relationship between the minimum number of net positive charges (p m ) ad the total number of amino acid residues (r) is as follows:
- the aromatic-cationic peptides have a relationship between the minimum number of net positive charges (p m ) and the total number of amino acid residues (r) wherein 2p m is the largest number that is less than or equal to r+1.
- the relationship between the minimum number of net positive charges (p m ) and the total number of amino acid residues (r) is as follows:
- the minimum number of net positive charges (p m ) and the total number of amino acid residues (r) are equal.
- the peptides have three or four amino acid residues and a minimum of one net positive charge, preferably, a minimum of two net positive charges and more preferably a minimum of three net positive charges.
- aromatic-cationic peptides have a minimum number of aromatic groups in comparison to the total number of net positive charges (pt).
- the minimum number of aromatic groups will be referred to below as (a).
- Naturally occurring amino acids that have an aromatic group include the amino acids histidine, tryptophan, tyrosine, and phenylalanine.
- the hexapeptide Lys-Gln-Tyr-Arg-Phe-Trp has a net positive charge of two (contributed by the lysine and arginine residues) and three aromatic groups (contributed by tyrosine, phenylalanine and tryptophan residues).
- the aromatic-cationic peptides useful in the methods of the present invention have a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges at physiological pH (p t ) wherein 3a is the largest number that is less than or equal to p t +1, except that when p t is 1, a may also be 1.
- the relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (p t ) is as follows:
- the aromatic-cationic peptides have a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (p t ) wherein 2a is the largest number that is less than or equal to p t +1.
- the relationship between the minimum number of aromatic amino acid residues (a) and the total number of net positive charges (p t ) is as follows:
- the number of aromatic groups (a) and the total number of net positive charges (pt) are equal.
- Carboxyl groups are preferably amidated with, for example, ammonia to form the C-terminal amide
- the terminal carboxyl group of the C-terminal amino acid may be amidated with any primary or secondary amine.
- the primary or secondary amine may, for example, be an alkyl, especially a branched or unbranched C 1 -C 4 alkyl, or an aryl amine.
- amino acid at the C-terminus of the peptide may be converted to an amido, N-methylamido, N-ethylamido, N,N-dimethylyamido, N,N-diethylamido, N-methyl-N-ethylamido N- phenylamido or N-phenyl-N-ethylamido group.
- the free carboxylate groups of the asparagine glutamine, aspartic acid, and glutamic acid residues not occurring at the C-terminus of the aromatic-cationic peptides of the present invention may also be amidated wherever they occur within the peptide.
- the amidation at these internal positions may be with ammonia or any of the primary or secondary amines described above.
- the aromatic-cationic peptide useful in the methods of the present invention is a tripeptide having two net positive charges and at least one aromatic amino acid. In a particular embodiment, the aromatic-cationic peptide useful in the methods of the present invention is a tripeptide having two net positive charges and two aromatic amino acids.
- Aromatic-cationic peptides useful in the methods of the present invention include, but are not limited to, the following peptide examples:
- the peptides useful in the methods of the present invention have mu-opioid receptor agonist activity (i.e., activate the mu-opioid receptor). Activation of the mu-opioid receptor typically elicits an analgesic effect.
- an aromatic-cationic peptide having mu-opioid receptor activity is preferred.
- an aromatic-cationic peptide that activates the mu-opioid receptor can be beneficial to use during short-term treatment, such as in an acute disease or condition.
- the acute diseases and conditions can be associated with moderate or severe pain.
- the analgesic effect of the aromatic-cationic peptide may be beneficial in the treatment regiment of the patient or other mammal, although an aromatic-cationic peptide which does not activate the mu-opioid receptor may also be used with or without an analgesic according to clinical requirements.
- an aromatic-cationic peptide that does not have mu-opioid receptor activity is preferred.
- an aromatic-cationic peptide that activates the mu-opioid receptor may be contraindicated.
- the potentially adverse or addictive effects of the aromatic-cationic peptide may preclude the use of an aromatic-cationic peptide that activates the mu-opioid receptor in the treatment regimen of a human patients or other mammal.
- aromatic-cationic peptide that does not activate the mu-opioid receptor may be an appropriate treatment.
- Traumatic injury may include traumatic brain and spinal cord injury.
- chronic diseases or conditions include coronary artery disease and any neurodegenerative disorders, such as those described below.
- Peptides useful in the methods of the present invention which have mu-opioid receptor activity are typically those peptides which have a trysine residue or a tyrosine derivative at the N-terminus (i.e., the first amino acid position).
- Preferred derivatives of tyrosine include 2′-methyltyrosine (Mmt); 2′,6′-dimethlyltyrosine (2′,6′Dmt), 3′,5′- dimethyltryosine (3′5′Dmt); N,2′,6′-trimethyltyrosine (Tmt); and 2′-hydroxy-6′- methyltryosine (Hmt).
- a peptide that has mu-opioid receptor activity has the formula Tyr-D-Arg-Phe-Lys-NH 2 (for convenience represented by the acronym: DALDA, which is referred to herein as SS-01.
- DALDA has a net positive charge of three, contributed by the amino acids tyrosine, arginine, and lysine and has two aromatic groups contributed by the amino acids phenylalanine and tyrosine.
- the tyrosine of DALDA can be a modified derivative of tyrosine such as in 2′,6′-dimethyltyrosine to produce the compound having the formula 2′,6′-Dmt-Arg-Phe-Lys-NH 2 (i.e., Dmt 1 -DALDA, which is referred to herein as SS-02).
- Peptides that do not have mu-opioid receptor activity generally do not have a tyrosine residue or a derivative of tyrosine at the N-terminus (i.e., amino acid position one).
- the amino acid at the N-terminus can be any naturally occurring or non-naturally occurring amino acid other than tyrosine.
- the amino acid at the N-terminus is phenylalanine or its derivative.
- Preferred derivatives of phenylalanine include 2′-methylphenylalanine (Mmp), 2′,6′-dimethylphenylalanine (Dmp), N,2′,6′-trimethylphenylalanine (Tmp) and 2′-hydroxy-6′-methylphenylalanine (Hmp).
- the amino acid residue at the N-terminus is arginine.
- An example of such a peptide is D-Arg-2′6′-Dmt-Lys-Phe-NH 2 (referred to in this specification as SS-31).
- Another aromatic-cationic peptide that does not have mu-opioid receptor activity has the formula Phe-D-Arg-Dmt-Lys-NH 2 .
- the N-terminal phenylalanine can be a derivative of phenylalanine such as 2′,6′-dimethylphenylalanine (2′6′Dmp).
- DALDA containing 2′,6′-dimethylphenylalanine at amino acid position one has the formula 2′,6′-Dmp-D-Arg-Dmt-Lys-NH 2 .
- the amino acid sequence of Dmt 1 -DALDA (SS-02) is rearranged such that Dmt is not at the N-terminus.
- An example of such an aromatic-cationic peptide that does not have mu-opioid receptor activity has the formula D-Arg-2′6′Dmt-Lys- Phe-NH 2 (SS-31).
- DALDA, SS-31, and their derivatives can further include functional analogs.
- a peptide is considered a functional analog of DALDA or SS-31 if the analog has the same function as DALDA or SS-31.
- the analog may, for example, be a substitution variant of DALDA or SS-31, wherein one or more amino acid is substituted by another amino acid.
- Suitable substitution variants of DALDA or SS-31 include conservative amino acid substitutions.
- Amino acids may be grouped according to their physicochemical characteristics as follows:
- Non-polar amino acids Ala(A) Ser(S) Thr(T) Pro(P) Gly(G);
- Aromatic amino acids Phe(F) Tyr(Y) Trp(W) His(H).
- substitutions of an amino acid link peptide by another amino acid in the same group is referred to as a conservative substitution and may preserve the physicochemical characteristics of the original peptide.
- substitutions of an amino acid in a peptide by another amino acid in a different group is generally more likely to alter the characteristics of the original peptide.
- Examples of analogs useful in the practice of the present invention that activate mu-opioid receptors include, but are not limited to, the aromatic-cationic peptides shown in Table 1.
- Examples of analogs useful in the practice of the present invention that do not activate mu-opioid receptors include, but are not limited to, the aromatic-cationic peptides shown in Table 2.
- amino acids of the peptides shown in table 1 and 2 may be in either the L- or the D-configuration.
- the peptides described above are useful in reducing oxidative damage in a mammal in need thereof.
- Mammals in need of reducing oxidative damage are those mammals suffering from a disease, condition or treatment associated with oxidative damage.
- the oxidative damage is caused by free radicals, such as reactive oxygen species (ROS) and/or reactive nitrogen species (RNS).
- ROS and RNS include hydroxyl radical (HO), superoxide anion radical (O 2 - ) nitric oxide (NO) hydrogen peroxide (H 2 O 2 ), hypochlorous acid (HOC1) and peroxynitrite anion. (ONOO - ).
- a mammal in need thereof may be a mammal undergoing a treatment associated with oxidative damage.
- the mammal may be undergoing reperfusion.
- Reperfusion refers to the restoration of blood flow to any organ or tissue in which the flow of blood is decreased or blocked. The restoration of blood flow during reperfusion leads to respiratory burst and formation of free radicals.
- Decreased or blocked blood flow may be due to hypoxia or ischemia.
- the loss or severe reduction in blood supply during hypoxia or ischemia may, for example, be due to thromboembolic stroke, coronary atherosclerosis, or peripheral vascular disease.
- ischemia or hypoxia Numerous organs and tissues are subject to ischemia or hypoxia. Examples of such organs include brain, heart, kidney, intestine and prostate.
- the tissue affected is typically muscle, such as cardiac, skeletal, or smooth muscle.
- cardiac muscle ischemia or hypoxia is commonly caused by atherosclerotic or thrombotic blockages which lead to the reduction or loss of oxygen delivery to the cardiac tissues by the cardiac arterial and capillary blood supply.
- cardiac ischemia or hypoxia may cause pain and necrosis of the affected cardiac muscle, and ultimately may lead to cardiac failure.
- Ischemia or hypoxia in skeletal muscle or smooth muscle may arise from similar causes.
- ischemia or hypoxia in intestinal smooth muscle or skeletal muscle of the limbs may also be caused by atherosclerotic or thrombotic blockages.
- the restoration of blood flow can occur by any method known to those in the art.
- reperfusion of ischemic cardiac tissues may arise from angioplasty, coronary artery bypass graft, or the use of thrombolytic drugs. Reducing oxidative damage associated with ischemia/hypoxia and reperfusion is important because the tissue damage associated with ischemia/hypoxia and reperfusion is associated with, for example, myocardial infarction, stroke and hemorrhagic shock.
- a mammal in need thereof can be a mammal with a disease or condition associated with oxidative damage.
- the oxidative damage can occur in any cell, tissue or organ of the mammal.
- cells, tissues or organs include, but are not limited to, endothelial cells, epithelial cells, nervous system cells, skin, heart, lung, kidney and liver.
- lipid peroxidation and an inflammatory process are associated with oxidative damage for a disease or condition.
- Lipid peroxidation refers to oxidative modification of lipids.
- the lipids can be present in the membrane of a cell. This modification of membrane lipids typically results in change and/or damage to the membrane function of a cell.
- lipid peroxidation can also occur in lipids or lipoproteins exogenous of a cell. For example, low-density lipoproteins are susceptible to lipid per-oxidation.
- An example of a condition associated with lipid peroxidation is atherosclerosis. Reducing oxidative damage associated with atherosclerosis is important since atherosclerosis is implicated in, for example, heart attacks and coronary artery disease.
- Inflammatory process refers to the activation of the immune system.
- the immune system is activated by an antigenic substance.
- the antigenic substance can be any substance recognized by the immune system, and include self-derived particles and foreign-derived particles. Examples of diseases or conditions occurring from an inflammatory process to self-derived particles include arthritis and multiple sclerosis. Examples of foreign particles include viruses and bacteria.
- the virus can be any virus which activates an inflammatory process, and associated with oxidative damage.
- viruses include, hepatitis A, B or C virus, human immunodeficiency virus, influenza virus, and bovine diarrhea virus.
- hepatitis virus can elicit an inflammatory process and formation of free radicals, thereby damaging the liver.
- the bacteria can be any bacteria, and include gram-negative or gram-positive bacteria.
- Gram-negative bacteria contain lipopolysaccharide in the bacteria wall. Examples of gram-negative bacterial include Escherichia coli , Klebsiella pneumoniae , Proteus species, Pseudomonas aeruginosa , Serratia , and Bacteroides . Examples of gram-positive bacteria include pneumococci and streptococci .
- sepsis An example of an inflammatory process associated with oxidative stress caused by a bacteria is sepsis. Typically, sepsis occurs when gram-negative bacteria enter the bloodstream.
- Liver damage caused by a toxic agent is another condition associated with an inflammatory process and oxidative stress.
- the toxic agent can be any agent which causes damage to the liver.
- the toxic agent can cause apoptosis and/or necrosis of liver cells.
- examples of such agents include alcohol, and medication, such as prescription and non-prescription drugs taken to treat a disease or condition.
- the methods of the present invention can also be used in reducing oxidative damage associated with any neurodegenerative disease or condition.
- the neurodegenerative disease can affect any cell, tissue or organ of the central and peripheral nervous system. Examples of such cells, tissues and organs include, the brain, spinal cord, neurons, ganglia, Schwann cells, astrocytes, oligodendrocytes and microglia.
- the neurodegenerative condition can be an acute condition, such as a stroke or a traumatic brain or spinal cord injury.
- the neurodegenerative disease or condition can be a chronic neurodegenerative condition.
- the free radicals can, for example, cause damage to a protein.
- An example of such a protein is amyloid ⁇ -protein.
- Examples of chronic neurodegenerative diseases associated with damage by free radicals include Parkinson’s disease, Alzheimer’s disease, Huntington’s disease and Amyotrophic Lateral Sclerosis (also known as Lou Gherig’s disease).
- Other conditions which can be treated in accordance with the present invention include preeclampsia, diabetes, and symptoms of and conditions associated with aging, such as macular degeneration, wrinkles.
- the peptides useful in the present invention may also be used in reducing oxidative damage in an organ of a mammal prior to transplantation.
- a removed organ when subjected to reperfusion after transplantation can be susceptible to oxidative damage. Therefore, the peptides can be used to reduce oxidative damage from reperfusion of the transplanted organ.
- the removed organ can be any organ suitable for transplantation. Examples of such organs include, the heart, liver, kidney, lung, and pancreatic islets.
- the removed organ is placed in a suitable medium, such as in a standard buffered solution commonly used in the art.
- a removed heart can be placed in a cardioplegic solution containing the peptides described above.
- concentration of peptides in the standard buffered solution can be easily determined by those skilled in the art. Such concentrations may be, for example, between about 0.01 nM to about 10 ⁇ M, preferably about 0.1 nM to about 10 ⁇ M, more preferably about 1 ⁇ M to about 5 ⁇ M, and even more preferably about 1 nM to about 100 nM.
- the invention provides a method for reducing oxidative damage in a cell in need thereof.
- Cells in need of reducing oxidative damage are generally those cells in which the cell membrane or DNA of the cell has been damaged by free radicals, for example, ROS and/or RNS.
- free radicals for example, ROS and/or RNS.
- Examples of cells capable of being subjected to oxidative damage include the cells described herein. Suitable examples of cells include pancreatic islet cells, myocytes, endothelial cells, neuronal cells, stem cells, etc.
- the cells can be tissue culture cells. Alternatively the cells may be obtained from a mammal. In one instance, the cells can be damaged by oxidative damage as a result of an insult. Such insults include, for example, a disease or condition (e.g., diabetes, etc.) or ultraviolet radiation (e.g., sun, etc.). For example pancreatic islet cells damaged by oxidative damage as a result of diabetes can be obtained from a mammal.
- a disease or condition e.g., diabetes, etc.
- ultraviolet radiation e.g., sun, etc.
- pancreatic islet cells damaged by oxidative damage as a result of diabetes can be obtained from a mammal.
- the peptides described above can be administered to the cells by any method known to those skilled in the art.
- the peptides can be incubated with the cells under suitable conditions.
- Stick conditions can be readily determined by those skilled in the art.
- the treated cells may be capable of regenerating.
- Such regenerated cells may be administered back into the mammal as a therapeutic treatment for a disease or condition.
- a disease or condition is diabetes.
- Oxidative damage is considered to be “reduced” if the amount of oxidative damage in a mammal, a removed organ, or a cell is decreased after administration of an effective amount of the aromatic cationic peptides described above.
- the oxidative damage is considered to be reduced if the oxidative damage is decreased by at least about 10%, preferably at least about 25%, more preferably at least about 50%, even more preferably at least about 75%, and most preferably at least about 90%.
- peptides useful in the methods of the present invention may be chemically synthesized by any of the methods well known in the art. Suitable methods for synthesizing the protein include, for example those described by Stuart and Young in “Solid Phase Peptide Synthesis,” Second Edition, Pierce Chemical Company (1984), and in “Solid Phase Peptide Synthesis,” Methods Enzymol. 289, Academic Press, Inc, New York (1997).
- the peptide useful in the methods of the present invention is administered to a mammal in an amount effective in reducing oxidative damage.
- the effective amount is determined during pre-clinical trials and clinical trials by methods familiar to physicians and clinicians.
- An effective amount of a peptide useful in the methods of the present invention, preferably in a pharmaceutical composition, may be administered to a mammal in need thereof by any of a number of well-known methods for administering pharmaceutical compounds.
- the peptide may be administered systemically or locally.
- the peptide is administered intravenously.
- the aromatic-cationic peptides useful in the methods of the present invention may be administered via rapid intravenous bolus injection.
- the peptide is administered as a constant rate intravenous infusion.
- the peptide can be injected directly into coronary artery during for example, angioplasty of or coronary bypass surgery, or applied onto coronary stents.
- the peptide may also be administered orally, topically, intranasally, intramuscularly, subcutaneously, or transdermally.
- transdermal administration of the aromatic-cationic peptides by methods of the present invention is by iontophoresis, in which the charged peptide is delivered across the skin by an electric current.
- intracerebroventricularly or intrathecally Other routes of administration include intracerebroventricularly or intrathecally.
- intracerebroventiculatly refers to administration into the ventricular system of the brain.
- Intrathecally refers to administration into the space under the arachnoid membrane of the spinal cord.
- This intracerebroventicular or intrathecal administration may be preferred for those diseases and conditions which affect the organs or tissues of the central nervous system.
- intrathecal administration is used for traumatic spinal cord injury.
- the peptides useful in the methods of the invention may also be administered to mammals by sustained release as is known in the art.
- Sustained release administration is a method of drug delivery to achieve a certain level of the drug over a particular period of time. The level typically is measured by serum or plasma concentration.
- any formulation known in the art of pharmacy is suitable for administration of the aromatic-cationic peptides useful in the methods of the present invention.
- liquid or solid formulations may be used.
- Some examples of formulations include tablets, gelatin capsules, pills, troches, elixirs, suspensions, syrups, wafers, chewing gum and the like.
- the peptides can be mixed with a suitable pharmaceutical carrier (vehicle) or excipient as understood by practitioners in the art.
- suitable pharmaceutical carrier include starch, milk, sugar, certain types of clay, gelatin, lactic acid, stearic acid or salts thereof, including magnesium or calcium stearate, talc, vegetable fats or oils, gums and glycols.
- formulations of the aromatic-cationic peptides useful in the methods of the present invent oils may utilize conventional diluents, carriers, or excipients etc., such as are known in the art can be employed to deliver the peptides.
- the formulations may comprise one or more of the following: a stabilizing a surfactant, preferably a nonionic surfactant, and optionally a salt and/or a buffering agent.
- the peptide may be delivered in the form of an aqueous solution, or in a lyophilized form.
- the stabilizer may, for example, be an amino acid, such as for instance, glycine; or an oligosaccharide, such as for example, sucrose, tetralose, lactose or a dextran.
- the stabilizer may be a sugar alcohol, such as for instance, mannitol; or a combination thereof.
- the stabilizer or combination of stabilizers constitutes from about 0.1% to about 10% weight for weight of the peptide.
- the surfactant is preferably a nonionic surfactant, such as a polysorbate.
- suitable surfactants include Tween20, Tween80; a polyethylene glycol or a polyoxyethylene polyoxypropylene glycol, such as Pluronic F-68 at from about 0.001% (w/v) to about 10% (w/v).
- the salt or buttering agent may be any salt or buffering agent such as for example, sodium chloride, or sodium/potassium phosphate, respectively.
- the buttering agent maintains the pH of the pharmaceutical composition in the range of about 5.5 to about 7.5.
- the salt and/or buffering agent is also useful to maintain the osmolality at a level suitable for administration to a human or an animal.
- the salt or buffering agent is present at a roughly isotonic concentration of about 150 mM to about 300 mM.
- the formulations of the peptides useful in the methods of the present invention may additionally contain one or more conventional additive.
- additives include a solubilizer such as, for example, glycerol; an antioxidant such as for example, benzalkonium chloride (a mixture of quaternary ammonium compounds, known as “quats”), benzyl alcohol, chloretone or chlorobutanol; anaesthetic agent such as for example a morphine derivative; or an isotonic agent etc., such as described above.
- a solubilizer such as, for example, glycerol
- an antioxidant such as for example, benzalkonium chloride (a mixture of quaternary ammonium compounds, known as “quats”), benzyl alcohol, chloretone or chlorobutanol
- anaesthetic agent such as for example a morphine derivative
- an isotonic agent etc. such as described above.
- the pharmaceutical compositions may be stored under nitrogen gas in vials
- the mammal treated in accordance with the invention can be any mammal, including, for example, farm animals, such as sheep, pigs, cows, and horses pet animals such as dogs and cats, laboratory animals, such as rats, mice and rabbits.
- the mammal is a human.
- the cellular uptake of [ 3 H][Dmt 1 ]DALDA was studied using a human intestinal epithelial cell line (Caco-2), and confirmed with SH-SY5Y (human neuroblastoma cell), HEK293 (human embryonic kidney cell) and CRFK cells (kidney epithelial cell). Monolayers of cells were grown on 12-well plates (5 ⁇ 10 5 cells/well) coated with collagen for 3 days. On day 4, cells were washed twice with pre-warmed HBSS, and then incubated with 0.2 ml of HBSS containing either 250 nM [ 3 H][Dmt 1 ]DALDA at 37° C. for 4° C. for various times up to 1 h.
- [ 3 H][Dmt 1 ]DALDA was observed in cell lysate as early as 5 min, and steady state levels were achieved by 30 min.
- the total amount of [ 3 H][Dmt 1 ]DALDA recovered in the cell lysate after 1 h incubation represented about 1% of the total drug.
- the uptake of [ 3 H][Dmt 1 ]DALDA was slower at 4° C. compared to 37° C., but reached 76.5% by 45 min and 86.3% by 1 h.
- the internalization of [ 3 H][Dmt 1 ]DALDA was not limited to Caco-2 cells, but was also observed in SH-SY5Y, HEK293 and CRFK cells.
- the intracellular concentration of [Dmt 1 ]DALDA was estimated to be approximately 50 times higher than extracellular concentration.
- cells were incubated with a range of [Dmt 1 ]DALDA concentrations (1 ⁇ M-3 mM) for 1 h at 37° C. At the end of the incubation period, cells were washed 4 times with HBSS, and 0.2 ml of 0.1 N NaOH with 1% SDS was added to each well. The cell contents were then transferred to scintillation vials and radioactivity counted. To distinguish between internalized radioactivity from surface-associated radioactivity, an acid- wash step was included. Prior to cell lysis, cells were incubated with 0.2 ml of 0.2 M acetic acid/0.05 M NaCl for 5 min on ice.
- Cells were then washed three times with ice-cold HBSS and covered with 200 ⁇ l of PBS, and microscopy was performed within 10 min at room temperature using a Nikon confocal laser scanning microscope with a C-Apochromat 63x/1.2 W corr objective. Excitation was performed at 340 nm by means of a UV laser, and emission was measured at 520 nm. For optical sectioning in z-direction, 5-10 frames with 2.0 ⁇ m were made.
- CLSM confirmed the uptake of fluorescent Dmt-D-Arg-Phe-dnsDap-NH 2 into Caco-2 cells after incubation with 0.1 ⁇ M [Dmt 1 ,DnsDap 4 ]DALDA for 1 h at 37° C.
- the uptake of the fluorescent peptide was similar at 37° C. and 4° C.
- the fluorescence appeared diffuse throughout the cytoplasm but was completely excluded from the nucleus.
- the analog contained ⁇ -anthraniloyl-1- ⁇ , ⁇ -diaminopropionic acid in place of the lysine reside at position 4.
- the cells were grown as described in Example 1 and were plated on (35 mm) glass bottom dishes (MatTek Corp., Ashland, Mass.) for 2 days. The medium was then removed and cells were incubated with 1 ml of HBSS containing 0.1 ⁇ M of [Dmt 1 ,AtnDap 4 ]DALDA at 37° C. for 15 min to 1 h.
- TMRM tetramethylrhodamine methyl ester
- excitation was performed at 350 nm by means of a UV laser, and emission was measured at 520 nm.
- excitation was performed at 356 nm, and emission was measured at 560 nm.
- CLSM showed the uptake of fluorescent [Dmt 1 ,AtnDap 4 ]DALDA into Caco-2 cells after incubation for as little as 15 min at 37° C. The uptake of dye was completely excluded from the nucleus, but the blue dye showed a streaky distribution within the cytoplasm. Mitochondria were labeled red with TMRM. The distribution of [Dmt 1 ,AtnDap 4 ]DALDA to mitochondria was demonstrated by the overlap of the [Dmt 1 ,AtnDap 4 ]DALDA distribution and the TMRM distribution.
- Linoleic acid peroxidation was induced by a water-soluble initiator.
- ABAP (2,2′-azobis(2-amidinopropane)
- lipid peroxidation was detected by the formation of conjugated dienes, monitored spectrophotometrically at 236 nm (B. Longoni, W. A. Pryor, P. Marchiafava, Biochem. Biophys. Res. Commun. 233, 778-780 (1997)).
- SS-29 is Dmt-D-Cit-Phe Lys-NH 2 .
- SS-30 is Phe-D-Arg-Dmt-Lys-NH 2 ,
- SS-32 is Dmt-D-Arg-Phe-Ahp(2-aminoheptanoic acid)-NH 2 .
- SS-29 is Dmt-D-Cit-Phe-Lys-NH 2
- SS- 30 is Phe-D-Arg-Dmt-Lys-NH 2
- SS-32 is Dmt-D-Arg-Phe-Ahp(2-aminoheptanoic acid)-NH 2 .
- 0.1 mg mitochondrial protein was added to 0.5 ml potassium phosphate buffer (100 mM, pH 8.0) in the absence or presence of SS peptides (100 ⁇ M). 25 mM luminol and 0.7 IU horseradish peroxidase were added, and chemilumunescence was monitored with a Chronolog Model 560 aggregometer (Havertown, Pa.) for 20 min at 37° C. The amount of H 2 O 2 produced was quantified as the area under the curve (AUC) over 20 min, and all data were normalized to AUC produced by mitochondria alone.
- AUC area under the curve
- Example 7 - SS-31 Inhibits H 2 O 2 Generation by Isolated Mitochondria (FIG. 5 )
- H 2 O 2 was measured using luminol chemiluminescence as described previously (Y, Li, H. Zhu, M. A. Trush, Biochim. Biophys. Acta 1428, 1-12 (1999)).
- 0.1 mg mitochondrial protein was added to 0.5 ml potassium phosphate buffer (100 mM, pH 8.0) in the absence or presence of SS-31.
- 25 mM luminol and 0.7 IU horseradish peroxidase were added, and chemilumunescence was monitored with a Chronolog Model 560 aggregometer (Havertown, Pa.) for 20 min at 37° C.
- the amount of H 2 O 2 produced was quantified as the area under the curve (AUC) over 20 min, and all data were normalized to AUC produced by mitochondria alone.
- Example 8 - SS-02 and SS-31 Reduced Intracellular ROS and Increased Cell Survival (FIG. 6 )
- neuronal N 2 A cells were plated in 96-well plates at a density of 1 ⁇ 10 4 /well and allowed to grow for 2 days before treatment with tBHP (0.5 or 1 mM) for 40 min. Cells were washed twice and replaced with medium alone or medium containing varying concentrations of SS- 02 or SS-31 for 4 hr. Intracellular ROS was measured by carboxy-H2DCFDA (Molecular Probes, Portland, Oreg.). Cell death was assessed by a cell proliferation assay (MTS assay, Promega, Madison, Wis.).
- Neuronal N 2 A and SH-SY5Y cells were plated in 96-well plate at a density of 1 ⁇ 10 4 /well and allowed to grow for 2 days before treatment with t-butyl hydroperoxide (tBHP) (0.05-0.1 mM) with or without SS-31 (10 - 12 M to 10 - 9 M for 24 h. Cell death was assessed by a cell proliferation assay (MTS assay, Promega, Madison, Wis.).
- tBHP t-butyl hydroperoxide
- N 2 A and SH-SY5Y cells with low doses of t-BHP (0.05-0.1 mM) for 24 h resulted in a decrease in cell viability.
- A 0.05 mM t-BHP induced 50% loss of cell viability in N 2 A cells and 30% in SH-SY5Y cells.
- B 0.1 mM t-BHP resulted in a greater reduction in cell viability in SH-SY5Y cells.
- Concurrent treatment of cells with SS-31 resulted in a dose-dependent reduction of t-BHP-induced cytotoxicity. Complete protection against t-BHP was achieved by 1 nM SS-31.
- N 2 A cells were grown on 96-well plates, treated with t-BHP (0.05 mM) in the absence or presence of SS-31 (10 -11 M-10 -8 M) at 37° C. for 12-24 h. All treatments were carried out in quadriplicates. N 2 A cells were incubated with t-BHP (50 mM) with or without SS-31 at 37° C. for 12 h. Cells were gently lifted from the plates with a cell detachment solution (Accutase, Innovative Cell Technologies, Inc., San Diego, Calif.) and washed twice in PBS.
- a cell detachment solution (Accutase, Innovative Cell Technologies, Inc., San Diego, Calif.) and washed twice in PBS.
- Caspase activity was assayed using the FLICA kit (Immunochemistry Technologies LLC, Bloomington, Minn.) According to the manufacturer’s recommendation, cells were resuspended (approx. 5 ⁇ 10 6 cells/ml) in PBS and labeled with pan-caspase inhibitor FAM-VAD-FMK for 1 h at 37° C. under 5% CO 2 and protected from the light. Cells were then rinsed to remove the unbound reagent and fixed. Fluorescence intensity in the cells was measured by a laser scanning cytometer (Beckman-Coulter XL, Beckman Coulter, Inc., Fullerton, Calif.) using the standard emission filters for green (FL1). For each run, 10,000 individual events were collected and stored in list-mode files for off-line analysis.
- FLICA kit Immunochemistry Technologies LLC, Bloomington, Minn.
- Caspase activation is the initiating trigger of the apoptotic cascade, and our results showed a significant increase in caspase activity after incubation of SH-SY5Y cells with 50 mM t-BHP for 12 h which was dose-dependently inhibited by increasing concentrations of SS-31.
- DCFH-DA Intracellular ROS was evaluated using the fluorescent probe DCFH-DA (5-(and-6)- carboxy-2′,7′-dichlorodihydrofluorescein diacetate).
- DCFH-DA enters cells passively and is then deacetylated to nonfluorescent DCFH.
- DCFH reacts with ROS to form DCF, the fluorescent product.
- N 2 A cells in 96 sell plates were washed with HBSS and loaded with 10 ⁇ M of DCFDA for 30 min. for 30 min. at 37° C. Cells were washed 3 times with BSS and exposed to 0.1 mM of t-BHP, alone or with SS-31.
- the oxidation of DCF was monitored in real time by a fluorescence microplate reader (Molecular Devices) using 485 nm for excitation and 530 nm for emission.
- SS-31 inhibited lipid peroxidation in N 2 A cells treated with t-BHP. Lipid peroxidation was evaluated by measuring HNE Michael adducts. 4-HNE is one of the major aldehydic products of the peroxidation of membrane polyunsaturated fatty acids. N 2 A cells were seeded on glass bottom dish 1 day before t-BHP treatment (1 mM, 3 h, 37° C., 5% CO 2 ) in the presence of absence of SS-31 (10 -8 to 10 -10 M). Cells were then washed twice with PBS and fixed 30 min with 4% paraformaldehyde in PBS at RT and then washed 3 times with PBS.
- Cells were then permeabilized, treated with rabbit-anti-HNE antibody followed by the secondary antibody (goat anti-rabbit IgG conjugated to biotin). Cells were mounted in Vectashield and imaged using a Zeiss fluorescence microscope using an excitation wavelength of 460 ⁇ 20 nm and a longpass filter of 505 nm for emission.
- Example 13 - SS-02 Inhibits Loss of Mitochondrial Potential in Cells Exposed to Hydrogen Peroxide
- Caco-2 cells were treated with tBHP (1 mM) in the absence or presence of SS-02 (0.1 ⁇ M) for 4 h, and then incubated with TMRM and examined under LSCM.
- TMRM mitochondrial depolarization
- the mitochondria are clearly visualized as fine streaks throughout the cytoplasm.
- the TMRM fluorescence is much reduced, suggesting generalized depolarization.
- concurrent treatment with SS-02 protected against mitochondrial depolarization caused by tBHP.
- Example 14 - SS-31 Prevents Loss of Mitochondrial Potential and Increased ROS Accumulation in N 2 A Cells Caused by Exposure to t-BHP (FIG. 11 )
- Example 15 - SS-31 Prevents Apoptosis Caused by Oxidative Stress (FIG. 12 )
- SH-SY5Y cells were grown on 96-well plates, treated with t-BHP (0.025 mM) in the absence or presence of SS-31 (10 -12 M-10 -9 M) at 37° C. for 24 h. All treatments were carried out in quadriplicates. Cells were then stained with 2 mg/ml Hoechst 33342 for 20 min, fixed with 4% paraformaldehyde, and imaged using a Zeiss fluorescent microscope (Axiovert 200 M) equipped with the Zeiss Acroplan x20 objective. Nuclear morphology was evaluated using an excitation wavelength of 350 ⁇ 10 nm and a longpass filter of 400 nm for emission. All images were processed and analyzed using the MetaMorph software (Universal Imaging Corp., West Chester, Pa.). Uniformly stained nuclei were scored as healthy, viable neurons, while condensed or fragmented nuclei were scored as apoptotic.
- SS-31 prevents apoptosis induced by a low dose of t-BHP.
- Apoptosis was evaluated by confocal microscopy with the fluorescent probe Hoechst 33342 (A1) a representative field of cells not treated with t-BHP.
- A2) Fluorescent image showing a few cells with dense, fragmented chromatin indicative of apoptotic nuclei.
- A3) A representative field of cells treated with 0.025 mM t-BHP for 24 h.
- A4 Fluorescent image showing an increased number of cells with apoptotic nuclei.
- A5 A representative field of cells treated with 0.025 mM t- BHP and 1 nM SS-31 for 24 h.
- A6) Fluorescent image showing a reduced number of cells with apoptotic nuclei.
- Example 16 - SS-31 Prevents Lipid Peroxidation in Hearts Subjected to Brief Intervals of Ischemia- Reperfusion. (FIG. 13 )
- HNE 4-hydroxy-2-nonenol
- Example 17 - SS-31 Increases Coronary Flow and Reduces Lipid Peroxidation and Apoptosis in Hearts Subjected to Prolonged Cold Ischemia Followed by Warm Reperfusion (FIG. 14 )
- Isolated guinea pig hearts were perfused in a retrograde manner in a Langendorff apparatus with a cardioplegic solution (St. Thomas solution) without or with SS-31 (1 nM) for 3 min. and then clamped and stored at 4° C. for 18 h. Subsequently, the hearts were remounted in the Langendorff apparatus and reperfused with Krebs-Henseleit solution at 34° C. for 90 min. Hearts were then rapidly fixed and paraffin-embedded.
- C SS-31 prevents apoptosis in endothelial cells and myocytes in isolated guinea pig hearts subjected to warm reperfusion after prolonged (18 h) cold ischemia. Apoptosis was assessed by the TUNEL stain (green) and nuclei are visualized by DAPI (blue).
- Example 18 - SS-31 Improves Survival of Islet Cells Isolated From Mouse Pancreas (FIG. 15 )
- SS-31 improves mitochondrial potential in islet cells isolated from mouse pancreas. Pancreas was harvested from mice and islet cells were prepared according standard procedures. In some studies, SS-31 (1 nM) was added to all isolation buffers used throughout the isolation procedure. Mitochondrial potential was measured using TMRM (red) and visualized by confocal microscopy.
- SS-31 reduces apoptosis and increases viability in islet cells isolated from mouse pancreas. Pancreas was harvested from mice and islet cells were prepared according standard procedures. In some studies, SS-31 (1 nM) was added to all isolation buffers used throughout the isolation procedure. Apoptosis was ascertained by flow cytometry using annexin V and necrosis by propidium iodide.
- Mouse pancreatic islet cells were untreated (a), or treated with 25 ⁇ M tBHP without or with 1 nM SS-31 (c). Mitochondrial potential was measured by TMRM (red) and reactive oxygen species were measured by DCF (green) using confocal microscopy.
- MPTP is a neurotoxin that selectively destroys striatal dopamine neurons and can be used as an animal model of Parkinson’s Disease.
- MPP + a metabolite of MPTP, targets mitochondria, inhibits complex I of the electron transport chain and increases ROS production.
- MPP + is used in cell culture studied because cells are unable to metabolize MPTP to the active metabolite.
- MPTP is used for animal studies.
- SS-31 protects dopamine cells against MPP + toxicity.
- SN-4741 cells were treated with buffer, 50 ⁇ M MPP + or 50 ⁇ M MPP + and 1 nM SS-31, for 48 h, and the incidence of apoptosis was determined by fluorescent microscopy with Hoechst 33342. The number of condensed fragmented nuclei was significantly increased by MPP+ treatment. Concurrent treatment with SS-31 reduced the number of apoptotic cells.
- FIG. 19 A shows that untreated N2A cells showed little to no Annexin V staining (green). Incubation of N 2 A cells with 50 mM tBHP for 6 h resulted in Annexin V staining on the membranes of most cells ( FIG. 19 B ). Combined staining with Annexin V and propidium iodide (red) showed many late apoptotic cells ( FIG. 19 B ).
- Intracellular ROS production is an early and critical event in oxidant-induced cytotoxicity.
- Treatment of N 2 A cells with 100 ⁇ M tBHP resulted in rapid increase in intracellular ROS, as measured by DCF fluorescence, over 4 h at 37° C. ( FIG. 22 A ).
- the reduction in intracellular ROS was confirmed by fluorescent microscopy with DCF ( FIG. 22 B ).
- Treatment with N 2 A cells with 50 ⁇ M tBHP caused significant increase in DCF fluorescence (green), and this was significantly reduced by co-incubation with 1 nM SS-31 ( FIG. 22 C ).
- Example 26 Increased Hydrogen Peroxide (H 2 O 2 ) Sensitivity of G93A-SOD Transfected Murine Neuroblastoma (N2a) Cells (FIG. 24 )
- cysteine, ascorbate and GSH levels were determined 6 h after 30 min transient middle cerebral artery occlusion (MCAO) in mice treated intraperitoneally (i.p.) with saline (vehicle), SS-31 (2 mg/kg) or SS-20 (2 mg/kg) upon reperfusion.
- Values in FIG. 31 are expressed as percent increase (cysteine) and percent depletion (ascorbate and GSH) in the ipsilateral side compared to the contralateral side. Absolute values were originally expressed as nmoles/mg protein as shown in FIG. 30 and converted to percent difference.
- the percent ipsilateral cysteine increase was similar among vehicle-, SS-31-, and SS-20-treated groups ( FIG. 31 A ). Percent ipsilateral depletion of ascorbate was marginally but not significantly affected in both SS-31 and SS-20-treated animals ( FIG. 31 B ). In contrast, ischemia-induced GSH depletion in the cortex was significantly attenuated in SS-31-treated animals compared to the vehicle-treated group ( FIG. 31 C ).
- the degree of ipsilateral GSH depletion in SS-20-treated mice was not significantly different from that of vehicle-treated mice ( FIG. 31 C ).
- the data show that SS-31 assists in maintaining antioxidant status and protects against ischemia-induced depletion of GSH in the cortex.
- mice were subjected to 30 or 20 min MCAO and then treated with vehicle or SS-31 (2 mg/kg, i.p.) upon reperfusion) and at 6 h, 24 h, 48 h after MCAO.
- Infarct volumes and hemispheric swelling were determined at 3 days after ischemia.
- SS-31 treatment resulted in moderate but significant reduction in infarct volume following both 30 min (24% reduction) and 20 min (30% reduction) ischemia, ( FIGS. 32 A-C ).
- Treatment with SS-31 also significantly attenuated hemispheric swelling in both 30 and 20 min ischemic paradigms ( FIG. 32 D ).
- CBF cerebral blood flow
- FIG. 33 A shows that SS-31 readily penetrates intact mouse islets; in four consecutive experiments, the mean ( ⁇ SE) of [ 3 H]SS-31 uptake was 70.2 ⁇ 10.3 pmol/mg of protein.
- Example 34 - SS-31 Prevents Mitochondrial Depolarization (FIG. 33 )
- TMRM a fluorescent cationic indicator is taken up into mitochondria in a potential dependent manner.
- FIG. 33 B confocal laser scanning microscopic imaging of TMRM treated islets shows that the islets from mice treated with SS-31 exhibit greater uptake of TMRM compared to islets from mice not treated with SS-31.
- islet donor mice were pre-treated with SS-31.
- Example 36 - SS-31 Reduces Islet Cell Apoptosis (FIG. 34 )
- SS-31 treatment in addition to enhancing islet yield resulted in a significant decrease in early as well as late, islet cell apoptosis.
- Dual parameter flow cytometry analyses of islet cells stained with both Annexin V and propidium iodide demonstrated that the treatment of islet donor mice with SS-31 reduced the percentage of early apoptotic cells (Annexin V alone positive cells) from 11.4 ⁇ 2.4% to 5.5 ⁇ 1.0% ( FIG. 34 A , P 0.03).
- SS-31 treatment reduced late apoptosis/early necrosis (Annexin V+/PI+cells) from 22.7 ⁇ 4.7% to 12.6 ⁇ 1.8 ( FIG.
- Example 37 - SS-31 Improves Post-Transplant Islet Graft Function (FIG. 35 )
- the SS-31 treatment associated decrease in islet cell apoptosis and enhanced viability had a beneficial functional consequence.
- 0 of 8 recipients of islets isolated from pancreas harvested from the control mice had successful reversal of hyperglycemia (defined as three consecutive blood glucose levels ⁇ 200 mg/dl), whereas sustained normoglycemia occurred in 5 of ten recipients of islets isolated from pancreas from the SS-31 treated donor mice ( FIG. 35 ).
Abstract
The invention provides a method for reducing oxidative damage in a mammal, a removed organ, or a cell in need thereof. The method comprises administering an effective amount of an aromatic cationic peptide. The aromatic cationic peptide has (a) at least one net positive charge; (b) a minimum of three amino acids; (c) a maximum of about twenty amino acids, (d) a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3 pm is the largest number that is less than or equal to r+1; (e) a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 3a or 2a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1; and (f) at least one tyrosine or tryptophan amino acid.
Description
- This application is a continuation of U.S. Pat. Application No. 16/798,085, filed Feb. 21, 2020, which is continuation of U.S. Pat. Application No. 15/956,941, filed Apr. 19, 2018, which is a continuation of U.S. Pat. Application No. 14/955,412, filed Dec. 1, 2015, now U.S. Pat. No. 9,950,026, which is a continuation of U.S. Pat. Application No. 14/100626, filed Dec. 9, 2013, now U.S. Pat. No. 9,623,069, which is a continuation of U.S. Pat. Application No. 12/843,333, filed Jul. 26, 2010, now U.S. Pat. No. 8,618,061, which is a continuation of U.S. Pat. Application No. 11/428,188, filed Jun. 30, 2006, now U.S. Pat. No. 7,781,405, which is a continuation application of U.S. Pat. Application No. 11/040,242 filed on Jan. 21, 2005, now U.S. Pat. No. 7,550,439, which claims priority to U.S. Provisional Pat. Application No. 60/538,841 filed on Jan. 23, 2004, the contents of which are hereby incorporated by reference in their entireties.
- This invention was made with government support from the National Institute on Drug Abuse under Grant No. PO1 DA08924. The U.S. government has certain rights in this invention.
- Mitochondria are essential to cell survival as the main producers of ATP via oxidative phosphorylation. However, the mitochondria respirator chain is also a major source of oxidative free radicals. For example, radical production can occur as a result of the reaction of mitochondrial electron carriers, such as ubiquinol, with oxygen to form a superoxide. Superoxides react by dismutation to hydrogen peroxide, which can decompose to hydroxyl radical. In addition, superoxides react with nitric oxide to form peroxynitrite and other reactive oxidants.
- Aging is associated not only with increased reactive oxygen species (ROS) production, but also a decrease in the endogenous antioxidant defense mechanisms. Mitochondria are particularly vulnerable to oxidative stress because they are continuously exposed to ROS. As a consequence, mitochondria decay is often associated with aging.
- Free radicals, including ROS, and reactive nitrogen species (RNS) produce diverse non-specific damage to biological molecules, including lipids, proteins, RNA and DNA. Such damage of these molecules has been implicated in numerous clinical disorders, such as atherosclerosis, preeclampsia, Alzheimer’s disease, Parkinson’s disease and arthritis.
- Antioxidant therapy can potentially delay the aging process, and be beneficial in a host of human diseases and conditions such as those described above. However, the development of specific mitochondrial therapies has been hampered by the difficulty of delivering antioxidant molecules to mitochondria in vivo. For example, the molecule must first be taken up across the plasma membrane into the cytoplasm, and then targeted selectively to mitochondria.
- None of the currently available antioxidant compounds specifically target mitochondria. The endogenous antioxidants, superoxide dismutase and catalase, are poorly absorbed orally, have short half-lives, and do not cross the blood-brain barrier. The natural antioxidants (e.g., Vitamin E, coenzyme Q, polyphenols) are not water-soluble and tend to accumulate in cell membranes and only cross the blood-brain barrier slowly.
- Therefore, there is a need for improved methods of reducing oxidative damage with antioxidative compounds that cross cell membranes. In addition, it would also be beneficial for the antioxidative compounds to specifically target mitochondria.
- These and other objectives have been met by the present invention which provide a method for reducing oxidative damage in a mammal in need thereof. The method comprises administering to the mammal an effective amount of an aromatic cationic peptide. The aromatic cationic peptide have (a) at least one net positive charge; (b) a minimum of three amino acids; (c) a maximum of about twenty amino acids; (d) a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; (e) a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 3a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1; and (f) at least one tyrosine or tryptophan amino acid.
- In another embodiment, the invention also provides a method of reducing oxidative damage in a removed organ of a mammal. The method comprises administering to the removed organ an effective amount of an aromatic-cationic peptide. The aromatic-cationic peptide have (a) at least one net positive charge; (b) a minimum of four amino acids; (c) a maximum of about twenty amino acids; (d) a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; (e) a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1; and (f) at least one tyrosine or tryptophan amino acid.
- In a further embodiment, the invention provides a method of reducing oxidative damage in a mammal in need thereof. The method comprises administering) to the mammal an effective amount of an aromatic-cationic peptide. The aromatic-cationic peptide have (a) at least one net positive charge; (b) a minimum of three amino acids; (c) a maximum of about twenty amino acids; (d) a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; (e) a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1, and (f) at least one tyrosine or tryptophan amino acid.
- In yet a further embodiment the invention provides a method of reducing oxidative damage in a removed organ of a mammal. The method comprises administering to the removed organ an effective amount of an aromatic-cationic peptide. The aromatic cationic peptide have (a) at least one net positive charge; (b) a minimum of three amino acids; (c) a maximum of about twenty amino acids; (d) a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; (e) a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 3a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1, and (f) at least one tyrosine or tryptophan amino acid.
- In yet another embodiment, the invention provides a method of reducing, oxidative damage in a cell in need thereof. The aromatic cationic peptide have (a) at least one net positive charge; (b) a minimum of three amino acids; (c) a maximum of about twenty amino acids; (d) a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; (e) a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1, and (f) at least one tyrosine or tryptophan amino acid.
- In an additional embodiment, the invention provides a method of reducing oxidative damage in a cell in need thereof. The aromatic cationic peptide have (a) at least one net positive charge; (b) a minimum of three amino acids; (c) a maximum of about twenty amino acids; (d) a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; (e) a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1, and (f) at least one tyrosine or tryptophan amino acid
-
FIGS. 1A-1B . (FIG. 1A ) SS-02 and (FIG. 1B ) SS-05 dose-dependently scavenge H2O2. -
FIGS. 2A-2B . (FIG. 2A ) SS-02 dose-dependently inhibits linoleic acid peroxidation induced by ABAP and (FIG. 2B ) SS-02 SS-05, SS-29, SS-30, SS-31, SS-32 and Dmt reduced the rate of linoleic acid peroxidation induced by ABAP. -
FIGS. 3A-3B . (FIG. 3A ) SS-02 dose-dependently inhibits LDL oxidation induced by 10 mM CuSO4 and (FIG. 3B ) SS-02, SS-05, SS-29, SS-30, SS-31, SS-32 and Dmt reduced rate of LDL oxidation. -
FIGS. 4A-4B . (FIG. 4A ) SS-02 inhibits mitochondrial production of hydrogen peroxide as measured by luminol chemiluminescence under basal conditions and upon stimulation by antimycin. (FIG. 4B ) SS-02, SS-29, SS-30 and SS-31 reduced spontaneous generation of hydrogen peroxide generated by isolated mitochondria. -
FIGS. 5A-5B . (FIG. 5A ) SS-31 inhibits spontaneous production of hydrogen hydroperoxide by isolated mitochondria and (FIG. 5B ) SS-31 inhibits hydrogen peroxide production stimulated by antimycin. -
FIGS. 6A-6C . SS-31 dose-dependently decreased intracellular ROS (reactive oxygen species) (FIG. 6A ) and increased cell survival (FIG. 6B ) in N2A cells exposed to a high dose of the pro- oxidant t-butyl hydroperoxide (t-BHP; 0.5 mM), (FIG. 6C ) SS-02 also dose-dependently increased cell survival when N2A cells were exposed to 1 mM t-BHP. -
FIGS. 7A-7B . SS-31 dose-dependently prevented loss of cell viability caused by low doses of t-BHP (0.05-0.1 mM) in neuronal (FIG. 7A ) SH-SY5Y and (FIG. 7B ) N2A cells. -
FIG. 8 . SS-31 dose-dependently decreased the percent of cells showing increased caspase activity after treatment with a low dose of t-BHP for 12 h in N2A cells. -
FIG. 9 . SS-31 dose-dependently reduced the rate of ROS accumulation in N2A cells with 0.1 mM t-BHP over a 4 h period. -
FIGS. 10A-10C . SS-31 inhibited lipid peroxidation caused by exposure of N2A cells to 1 mM t-BHP for 1 h. (FIG. 10A ) untreated cells; (FIG. 10B ) cells treated with 1 mM t-BHP for 3 h; (FIG. 10C ) cells treated with 1 mM t-BHP and 10 nM SS-31 for 3 h. -
FIG. 11 . SS-31 prevented mitochondrial depolarization and ROS accumulation in N2A cells exposed to t-BHP. -
FIGS. 12A-12D . SS-31 prevents apoptosis induced by a low dose of t-BHP. Apoptosis was evaluated by confocal microscopy with the fluorescent probe Hoechst 33342. (FIG. 12A ) a representative field of cells not treated with t-BHP. (FIG. 12AA ) Fluorescent image showing a few cells with dense, fragmented chromatin indicative of apoptotic nuclei. (FIG. 12B ) A representative field of cells treated with 0.025 mM t-BHP for 24 h. (FIG. 12BB ) Fluorescent image showing an increased number of cells with apoptotic nuclei. (FIG. 12C ) A representative field of cells treated with 0.025 mM t-BHP and 1 nM SS-31 for 24 h. (FIG. 12CC ) Fluorescent image showing a reduced number of cells with apoptotic nuclei. (FIG. 12D ) SS-31 dose-dependently reduced the percent of apoptotic cells caused by 24 h treatment with a low dose of T-BHP (0.05 mM). -
FIG. 13A (a-e). SS-02 and SS-31 reduced lipid peroxidation in isolated guinea pig hearts subjected to warm reperfusion after a brief period of ischemia. Immunohistochemical analysis of 4-hydroxy-2-nonenol (HNE)-modified proteins in paraffin sections from guinea pig hearts aerobically perfused 30 min with (a) buffer; (b) 100 nM SS-02; (c) 100 nM SS-20 and (d) 1 nM SS-31, then subjected to 30 min ischemia and reperfused for 90 min with corresponding peptides. Tissue slices were incubated with anti-HNE antibody. (e) Background control: staining without primary antibody. -
FIG. 13B (a-e). SS-02 and SS-31 reduced lipid peroxidation in isolated guinea pig hearts subj ected to warm reperfusion after a brief period of ischemia. Immunohistochemical analysis of 4-hydroxynonenol (HNE)-modified proteins in paraffin sections from guinea pig hearts aerobically perfused 30 min with buffer, then subjected to 30 min ischemia and reperfused with (a) buffer; (b) 100 nM SS-02; (c) 100 nM SS-20 and (d) 1 nM SS-31 for 90 min. Tissue slices were incubated with anti-HNE antibody. (e) Background control: staining without primary antibody. -
FIG. 14A . SS-31 significantly improved coronary flow in isolated guinea pig hearts subjected to warm reperfusion after prolonged (18 h) cold ischemia. The shaded area represents 18 h of ischemia at 4° C. -
FIG. 14B (a-c). Guinea pig hearts perfused with a cardioplegic solution (St. Thomas solution) without (a) or with (b) 1 nM SS-31 for 3 min and then subjected to 18 h of cold ischemia (4° C.), (c) background staining with primary antibody. The hearts were then reperfused with buffer at 34° C. for 90 min. -
FIG. 14C . SS-31 prevents apoptosis in endothelial cells and myocytes in isolated guinea pig hearts subjected to warm reperfusion after prolonged (18 h) cold ischemia. Guinea pig hearts perfused with a cardioplegic solution (St. Thomas solution) without or with nM SS-31 for 3 min and then subjected to 18 h of cold ischemia (4° C.). The hearts were then reperused with buffer at 34° C. for 90 min. Apoptosis was assessed by the TUNEL stain (green) and nuclei are visualized by DAPI (blue). -
FIG. 15A . SS-31 improves survival of islet cells isolated from mouse pancreas as measured by mitochondrial potential. SS-31 (nM) was added to all isolation buffers used throughout the isolation procedure. Mitochondrial potential was measured using TMRM (red) with confocal microscopy. -
FIGS. 15B & 15C . SS-31 reduces apoptosis and increases viability in islet cells isolated from mouse pancreas as measured by flow cytometry. SS-31 (1 nM) was added to all isolation buffers used throughout the isolation procedure. Apoptosis was ascertained using annexin V and necrosis by propidium iodide (PI). -
FIGS. 16A-16C . SS-31 reduces oxidative damage in pancreatic islet cells caused by t- butylhydroperoxide (tBHP). Mouse pancreatic islet cells were untreated (FIG. 16A ), or treated with 25 µM tBHP without (FIG. 16B ) or with 1 nM SS-31 (FIG. 16C ). Mitochondrial potential was measured by TMRM (red) and reactive oxygen species were measured by DCF (green) using confocal microscopy. -
FIG. 17A . SS-31 protects dopamine cells against MPP∗ toxicity. SN-4741 cells were treated with buffer, 50 µM MPP∗ or 50 µM MPP∗ and 1 nM SS-31, for 48 h, and the incidence of apoptosis was determined by fluorescent microscopy with Hoechst 33342. The number of condensed fragmented nuclei was significantly increased by MPP∗ treatment. Concurrent treatment with SS-31 reduced the number of apoptotic cells. -
FIG. 17B &FIG. 17BB . SS-31 dose-dependently prevented loss of dopamine neurons in mice treated with MPTP. Three doses of MPTP (10 mg/kg) was given to mice (n=12) 2 h apart. SS-31 was administered 30 min before each MPTP injection, and at 1 h and 12 h after the last MPTP injection. Animals were sacrificed one week later and striatal brain reactions were immunostained for tyrosine hydroxylase activity (shown in black). -
FIGS. 17C-17E . SS-31 dose-dependently increased striatal dopamine, DOPAC (3,4- dihydroxyphenylacetic acid) and HVA (homovanillic acid) levels in mice treated with MPTP. Three doses of MPTP (10 mg/kg) was given to mice (n=12) 2 h apart. SS-31 was administered 30 min before each MPTP injection, and at 1 h and 12 h after the last injection. Animals were sacrificed one week later and dopamine, DOPAC and HVA levels were quantified by high pressure liquid chromatography. -
FIGS. 18A-18B . SS-31 reduced tBHP-induced LDH release in SH-SY5Y (FIG. 18A ) and N2A (FIG. 18B ) cells. Cells were treated with 100 µM tBHP alone, or with SS-31, for 24 h. ∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001, compared to tBHP alone. -
FIGS. 19A-19C . SS-31 reduced tBHP-induced apoptosis as demonstrated by phosphatidylserine translocation. N2A cells were incubated with 50 µM tBHP for 6 h and stained with Annexin V and propidium iodide (PI). (19A) Untreated cells showed little Annexin V stain and no PI stain. (FIG. 19B ) Cells treated with tBHP showed intense Annexin V staining (green) in most cells. Combined staining with Annexin V and PI (red) indicate late apoptotic cells. (FIG. 19C ) Concurrent treatment with 1 nM SS-31 resulted in a reduction in Annexin V- positive cells and no PI staining. -
FIGS. 20A-20C . SS-31 reduced tBHP-induced apoptosis as demonstrated by nuclear condensation. (FIG. 20A )(a-c; a′-c′) N2A cells were treated with 50 µM tBHP alone or with SS-31 for 12 h. Cells were stained with Hoechst 33342 for 20 min., fixed, and imaged by fluorescent microscopy. (a) Untreated cells show uniformly stained nuclei (a′). (b) Cells treated with tBHP were smaller and showed nuclear fragmentation and condensation (b′). (c) Cells treated with tBHP and 1 nM SS-31 had less nuclear changes (c′). (FIG. 20B )-(FIG. 20C ) SS-31 dose-dependently reduced percent of apoptotic cells in N2A cells. Apoptotic cells were counted using MetaMorph software. ∗P<0.01 compared to untreated cells; ∗P<0.01 compared to tBHP alone. (SS) SS-31 dose-dependently reduced percent of apoptotic cells in SH-SY5Y cells. SH-SY5Y cells were treated with 25 µM tBHP for 24 h. ∗P<0.01 compared to untreated cells; ∗P<0.01 compared to tBHP alone. -
FIGS. 21A-21B . SS-31 prevented caspase activation in N2A cells treated with tBHP. (FIG. 21A ) incubation of N2A cells with 100 µM tBHP for 24 h resulted in a significant increase in pancaspase activity that was dose-dependently prevented by co-incubation with SS-31 (∗P<0.01 compared to tBHP alone). (FIG. 21B )(a-c) N2A cells were treated with 50 µM tBHP for 12 h and stained with caspase-9 FLICA™ kit containing red fluorescent inhibitor SR-LEHD-FMK and Hoechst 33342. (Panel a) Untreated cells showed no caspase-9 stain and uniformly stained nuclei. (Panel b) cells treated with tBHP showed intense caspase-9 activity (red) in cells that also show condensed nuclei. (Panel c) Cells treated with tBHP and 1 nM SS-31 showed fewer caspase-9 positive cells and fewer condensed nuclei. -
FIGS. 22A-22C . SS-31 dose-dependently reduced intracellular ROS production in N2A cells treated with tBHP. (FIG. 22A ) N2A cells were loaded with DCFDA, and then exposed to 100 µM tBHP alone, or with SS-31. Intracellular ROS was quantified by the formation of fluorescent DCF. Results shown are mean values (n=3). (FIG. 22B )(a-c) N2A cells were plated in glass bottom dishes and treated with 50 µM tBHP, alone or with 1 nM SS-31, for 6 h. Cells were loaded with DCFDA (10 µM) and imaged by confocal laser scanning microscopy using ex/em of 495/525 nm. (FIG. 22C ) Effect of 1 nM SS-31 in reducing intracellular ROS induced by 50 µM tBHP (∗P<0.001 compared to untreated cells; ∗P<0.05 compared to tBHP alone). -
FIGS. 23A-23B . SS-31 protected against tBHP-induced mitochondrial viability. (FIG. 23A ) SS-31 protected mitochondrial viability in N2A cells treated with tBHP for 24 h. Mitochondrial viability was evaluated using the MTT assay (∗P<0.01 compared to untreated cells, ∗P<0.05, P<0.01 compared to tBHP alone). (FIG. 23B ) SS-31 protected mitochondrial viability in SH-SY5Y cells treated with tBHP for 25 h (∗P<0.01 compared to untreated cells; ∗∗P<0.01 compared to tBHP alone). -
FIG. 24 . Increased hydrogen peroxide (H2O2) sensitivity of G93A-SOD transfected murine neuroblastoma (N2A) cells as compared to wildtype SOD-transfected N2A cells after addition of 0.5 or 1 mM H2O2 for 1 h. Cell death was quantified by measurement of the percentage of H2O2-induced LDH release of total cellular LDH-content. H2O2-induced LDH release was significantly reduced by treatment of the cells with 1 to 100 µM SS-31 after incubation with H2O2. Values are means +S.D., n=4-5, ∗p<0.1, ∗∗p<0.05, Student’s t-test. Black columns wildtype-SOD1-transfected cells, grey columns: G93A-SOD1 transfected N2A cells -
FIGS. 25A-25B . (FIG. 25A ) Cumulative probability of disease on set and survival with SS-31 5 mg/kg/day treatment (n=14) started at symptom onset as compared to vehicle treatment (n=14). Survival was significantly improved by SS-31 (p<0.05, Mantel-Cox log-rank test). (FIG. 25B ) Mean survival (days) of G93A mice treated with vehicle or SS-31 5 mg/kg/day. (Data are mean±SD, p<0.05, Student’s t-test). -
FIG. 26 . Effect of SS-31 mg/kg/day on motor performance (seconds) tested by rotarod (Values are mean±standard error of means of the mice still alive at the respective time point): it was significantly improved between day (d) 110 andday 130 in SS-31-treated animals as compared to the vehicle-treated group (p<0.005, Repeated Measures ANOVA followed by Fisher’s PLSD). -
FIGS. 27A & 27B . Attenuation of motor neuron loss by SS-31 in the ventral horn of the lumbar spinal cord of G93A mice. Photomicrographs show cresyl violet stained sections through the ventral horn of the lumbar spinal cord from non-transgenic control (A) and G93A mice treated with vehicle (PBS) (B) or SS-31 (C) at 110 days of age. Stereological analysis revealed significantly reduced numbers of surviving neurons in G93A mice treated with vehicle as compared to non-transgenic controls (∗∗∗, p<0.001). This cell loss was significantly ameliorated by treatment with SS-31 (∗∗,p<0.01). Values are mean±standard error of means. Differences among means were analyzed using ANOVA followed by Newman-Keuls post hoc test. -
FIGS. 28A-28C . 4-hydroxynonenol immunostaining. Photomicrographs of representative sections through the ventral horn of the lumbar spinal cord of wild-type control (FIG. 28A ), and G93A mice treated with vehicle (FIG. 28B ) or SS-31 (FIG. 28C ) show generalized reduction of 4- hydroxynonenal staining in neurons and neurophils in drug-treated mice. -
FIGS. 29A-29C . Nitrotyrosine immunostaining. Photomicrographs of representative sections through the ventral horn of the lumbar spinal cord of wild-type control (FIG. 29A ), and G93A mice treated with vehicle (FIG. 29B ) or SS-31 (FIG. 29C ) show generalized reduction of nitrotyrosine staining in neurons and neurophils in drug-treated mice. -
FIGS. 30A-30F . Temporal changes of cysteine (FIG. 30A ,FIG. 30B ), ascorbate (FIG. 30C ,FIG. 30D ) and GSH (FIG. 30E ,FIG. 30F ) levels in post-ischemic brain. C57BL/6 mice were subjected to 30 min MCAO. Values are expressed as nmol/mg protein in cortex (FIG. 30A ,FIG. 30C ,FIG. 30E ) and striatum (FIG. 30B ,FIG. 30D ,FIG. 30F ). Error bars indicate SEM (n=4 animals per group). #<0.05 vs 0 h Contral, ∗p<0.05 vs corresponding Contral, one-way ANOVA with post hoc Fisher’s PLSD test. Contral, contralateral side; Ipsil, ipsilateral side; 0 h, sham non-ischemic animal. -
FIGS. 31A-31C . Effect of SS-31 peptide on ischemia-induced changes in cysteine (FIG. 31A ) ascorbate (FIG. 31B ), and GSH (FIG. 31C ) levels, C57BL/6 mice were subjected to 30 min MCAO and treated with vehicle, SS-31 (2 mg/kg body weight) or SS-20 (2 mg/kg body eight) peptide immediately after reperfusion. Mice were sacrificed at 6 h postischemia. Values are expressed as percent increase (cysteine) or percent depletion (ascorbate and GSH) in ipsilateral side versus contralateral side. Error bars indicate SEM (n=4-6 animals per group). Note that a difference was observed in percent GSH depletion SS-31-treated cortex. ∗p<0.05 vs vehicle treated group (Veh), one-way ANOVA with post hoc Fisher’s PLSD test. -
FIGS. 32A-32F . Effect of SS-31 peptide on ischemia-induced infarct size and swelling in C57BL/6 mice. Shown are representative serial sections (1.2 mm apart) stained with Cresyl Violet from mice subjected to 30 min (FIG. 32A ) and 20 min (FIG. 32B ) MCAO and treated with vehicle (Veh) or SS-31 (2 mg/kg body weight) immediately after reperfusion, 6 h, 24 h, and 48 h. Infarct volumes ((FIG. 32C ) and swelling (FIG. 32D ) were estimated at 72 h postischemia from 12 serial sections (600 Bm apart) per animal. Mean % cerebral blood flow (CBF) reduction during MCAO (FIG. 32E ) and % reperfusion at 10 min postischemia (FIG. 32F ) shows no difference between two groups. Error bars indicate SEM (n=11 animals per group). ∗p<0.05 from vehicle treated group (Veh), one-way ANOVA with post hoc Fisher’s PLSD test. -
FIGS. 33A-33B . SS peptides penetrate islet cells, co-localize with mitochondria and preserve islet mitochondrial membrane potential. (FIG. 33A ) Islet cell uptake of SS-31. DBA/2 islet cells were incubated with 1 nM of tritium labeled SS-31 and 1 µM unlabeled SS-31 at 37° C. for 1 h. Following incubation, radioactivity was measured in the medium and in cell lysates and the radioactive counts in the medium were subtracted from radioactive counts in the cell lysate and normalized to protein content. In four consecutive experiments, the mean± (SE) [3H]SS-31 uptake was 70.2+/31 10.3 pmol/mg, of proteins (FIG. 33B )(i-iv) SS-31 preserves islet mitochondrial potential. DBA/2 mice were treated with SS-31 (3 mg/kg s.c. BID) orvehicle control 24 hours prior to pancreas harvest for islet isolation. SS-31 treated groups had 1 nM SS-31 added to the islet isolation reagents. Following isolation, TMRM uptake was evaluated using confocal laser scanning microscopy. Fluorescent (i) and phase (ii) images of TMRM uptake in control mice demonstrate reduced fluorescent uptake indicating mitochondrial depolarization. In sharp contrast, fluorescent (iii) and phase (iv) images of TMRM uptake in SS-31 treated mice demonstrate increased uptake and preserved mitochondrial potential indicative of SS-31 protective effect. -
FIGS. 34A-34D . SS-31 reduces islet cell apoptosis. DBA/2 mice were pre-treated (24 and 12-hours hours prior to pancreas harvest and islet isolation) with SS-31 (3 mg/kg, s.c., BID) or vehicle control. SS-31 (1 nM was added to reagents used for the isolation of islets from SS-31-treated mice. The islets were dissociated in to single cells with trypsin/EDTA and were stained with Annexin V-FITC (AnV) and propidium iodide (PI) and analyzed with the use of dual parameter low cytometry. (FIG. 34A ) Percentage of cell undergoing early apoptosis (AnV+cells); P=0.03. (FIG. 34B ) Percentage of cells undergoing late apoptosis/early necrosis (AnV+/PI+cells); P=0.03. (FIG. 34C ) Percentage of necrotic cells (PI+cells); P=1.0 (FIG. 34D ) Percentage of viable cells (AnV-/PI-cells); P=0.03. Data from individual pancreatic islet isolations and mean±SE are shown, N=number of separate islet isolations. Two-tailed P-values were calculated using Mann-Whitney t-test. -
FIGS. 35A-35C . Reversal of diabetes following transplantation of a marginal mass of syngeneic islets. Diabetic DBA/2 mice received 200 syngeneic islet cells under the right kidney capsule. Reversal of diabetes was defined as random nonfasting blood glucose levels below 200 mg/dl on 3-consecutive days. (FIG. 35A ) Blood glucose levels of each individual control mouse following transplantation of 200 syngeneic islets. (FIG. 35B ) Blood glucose levels of each individual SS-31 treated mouse following transplantation of 200 syngeneic islets. (FIG. 35C ) Reversal of diabetes following transplantation of a marginal islet cell mass in SS-31 treatment vs. control. Number of normoglycemic mice byday - The invention is based on the surprising discovery by the inventors that certain aromatic-cationic peptides reduce oxidative damage. Reducing oxidative damage is important since free radicals, such as ROS and RNS, produce diverse non-specific damage to lipids, proteins. RNA, and DNA oxidative damage caused by free radicals is associated with several diseases and conditions in mammals.
- The aromatic-cationic peptides useful in the present invention are water-soluble and highly polar. Despite these properties, the peptides can readily penetrate cell membranes.
- The aromatic-cationic peptides useful in the present invention include a minimum of three amino acids, and preferably include a minimum of four amino acids, covalently joined by peptide bonds.
- The maximum number of amino acids present in the aromatic-cationic peptides of the present invention is about twenty amino acids covalently joined by peptide bonds. Preferably, the maximum number of amino acids is about twelve, more preferably about nine, and most preferably about six. Optimally, the number of amino acids present in the peptides is four.
- The amino acids of the aromatic-cationic peptides useful in the present invention can be any amino acid. As used herein the term “amino acid” is used to refer to any organic molecule that contains at least one amino group and at least one carboxyl group. Preferably, at least one amino group is at the α position relative to the carboxyl group.
- The amino acids may be naturally occurring. Naturally occurring amino acids include, for example, the twenty most common levorotatory (L) amino acids normally found in mammalian proteins, i.e., alanine (Ala), arginine (Arg), asparagine (Asn) aspartic acid (Asp), cysteine (Cys), glutamine (Glu), glutamic acid (Glu), glycine (Gly), histidine (His), isoleucine (Ileu), leucine (Leu), lysine (Lys), methionine (Met), phenylalanine (Phe), proline (Pro), serine (Ser), threonine (Thr), trypotophan, (Trp), tyrosine (Tyr), and valine (Val).
- Other naturally occurring amino acids include, for example, amino acids that are synthesized in metabolic processes not associated with protein synthesis. For example, the amino acids ornithine and citrulline are synthesized in mammalian metabolism during the production of urea.
- The peptides useful in the present invention can contain one or more non-naturally occurring amino acids. The non-naturally occurring amino acids may be L-, dextrorotatory (D), or mixtures thereof. Optimally, the peptide has no amino acids that are naturally occurring.
- Non-naturally occurring amino acids are those amino acids that typically are not synthesized in normal metabolic processes in living organisms, and do not naturally occur in proteins. In addition, the non-naturally occurring amino acids useful in the present invention preferably are also not recognized by common proteases.
- The non-naturally occurring amino acid can be present at any position in the peptide. For example, the non-naturally occurring amino acid can be at the N-terminus, the C-terminus, or at any position between the N-terminus and the C-terminus.
- The non-natural amino acids may, for example, comprise alkyl, aryl, or alkylaryl groups. Some examples of alkyl amino acids include α-aminobutyric acid, β-aminobutyric acid, γ-aminobutyric acid, Δ-aminovaleric acid, and ε-aminocaproic acid. Some examples of aryl amino acids include ortho-, meta, and para-aminobenzoic acid. Some examples of alkylaryl amino acids include ortho-, meta-, and para-aminophenyleacetic acid, and γ-phenyl-β-aminobutyric acid.
- Non-naturally occurring amino acids also include derivatives of naturally occurring amino acids. The derivatives of naturally occurring amino acids may, for example, include the addition of one or more chemical groups to the naturally occurring amino acid.
- For example, one or more chemical groups can be added to one or more of the 2′, 3′, 4′, 5′, or 6′ position of the aromatic ring of a phenylalanine or tyrosine residue, or the 4′, 5′, 6′ or 7′ position of the benzo ring of a tryptophan residue. The group can be any chemical group that can be added to an aromatic ring. Some examples of such groups include branched or unbranched C1-C4 alkyl, such as methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, or t-butyl, C1-C4 alkyloxy (i.e., alkoxy), amino, C1-C4 alkylamino and C1-C4 dialkylamino (e.g., methylamino dimethylamino), nitro, hydroxyl, halo (i.e., fluoro, chloro, bromio, or iodo). Some specific examples of non-naturally occurring derivatives of naturally occurring amino acids include norvaline (Nva), norleucine (Nle), and hydroxyproline (Hyp).
- Another example of a modification of an amino acid in a peptide useful in the methods of the present invention is the derivatization of a carboxyl group of an aspartic acid or a glutamic acid residue of the peptide. One example of derivatization is amidation with ammonia or with a primary or secondary amine, e.g. methylamine, ethylamine, dimethylamine or diethylamine. Another example of derivatization includes esterification with, for example, methyl or ethyl alcohol.
- Another such modification includes derivatization of an amino group of a lysine, arginine, or histidine residue. For example, such amino groups can be acylated. Some suitable acyl groups include, for example, a benzoyl group or an alkanoyl group comprising any of the C1-C4 alkyl groups mentioned above, such as an acetyl or propionyl group.
- The non-naturally occurring amino acids are preferably resistant, and more preferably insensitive, to common proteases. Examples of non-naturally occurring amino acids that are resistant or insensitive to proteases include the dextrorotatory (D-) form of any of the above-mentioned naturally occurring L-amino acids, as well as L- and/or D-naturally occurring amino acids. The D-amino acids do normally occur in proteins although they are found in certain peptide antibiotics that are synthesized by means other than the normal ribosomal protein synthetic machinery of the cell. As used herein, the 1-amino acids are considered to be non-naturally occurring amino acids.
- In order to minimize protease sensitivity, the peptides useful in the methods of the invention should have less than five, preferably less than four, more preferably less than three, and most preferably, less than two contiguous L-amino acids recognized by common proteases, irrespective of whether the amino acids are naturally or non-naturally occurring. Optimally, the peptide has only D-amino acids, and no L-amino acids.
- If the peptide contains protease sensitive sequences of amino acids, at least one of the amino acids is preferably a non-naturally-occurring D-amino acid, thereby conferring protease resistance. An example of a protease sensitive sequence includes two or more contiguous basic amino acids that are readily cleaved by common proteases, such as endopeptidases and trypsin. Examples of basic amino acids include arginine, lysine and histidine.
- It is important that at least one of the amino acids present in the aromatic-cationic peptide is a tyrosine or tryptophan residue, or a derivative thereof.
- It is also important that the aromatic-cationic peptides have a minimum number of net positive charges at physiological pH in comparison to the total number of amino acid residues in the peptide. The minimum number of net positive charges at physiological pH will be referred to below as (pm). The total number of amino acid residues in the peptide will be referred to below as (r).
- The minimum number of net positive charges discussed below are all at physiological pH. The term “physiological pH” as used herein refers to the normal pH in the cells of the tissues and organs of the mammalian body. For instance, the physiological pH of a human is normally approximately 7.4, but normal physiological pH in mammals may be any pH from about 7.0 to about 7.8.
- “Net charge” as used herein refers to the balance of the number of positive charges and the number of negative charges carried by the amino acids present in the peptide. In this specification, it is understood that net charges are measured at physiological pH. The naturally occurring amino acids that are positively charged at physiological pH include L- lysine, L-arginine, L-histidine. The naturally occurring amino acids that are negatively charged at physiological pH include L-aspartic acid and L-glutamic acid.
- Typically, a peptide has a positively charged N-terminal amino group and a negatively charged C-terminal carboxyl group. The charges cancel each other out at physiological pH.
- In one embodiment of the present invention, the aromatic-cationic peptides have a relationship between the minimum number of net positive charges at physiological pH (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1. In this embodiment the relationship between the minimum number of net positive charges (pm) ad the total number of amino acid residues (r) is as follows:
-
(r) 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 (pm) 1 1 2 2 2 3 3 3 4 4 4 5 5 5 6 6 6 7 - In another embodiment, the aromatic-cationic peptides have a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 2pm is the largest number that is less than or equal to r+1. In this embodiment, the relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) is as follows:
-
(r) 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 (pm) 2 2 3 3 4 4 5 5 6 6 7 7 8 8 9 9 10 10 - In one embodiment, the minimum number of net positive charges (pm) and the total number of amino acid residues (r) are equal. In another embodiment, the peptides have three or four amino acid residues and a minimum of one net positive charge, preferably, a minimum of two net positive charges and more preferably a minimum of three net positive charges.
- It is also important that the aromatic-cationic peptides have a minimum number of aromatic groups in comparison to the total number of net positive charges (pt). The minimum number of aromatic groups will be referred to below as (a).
- Naturally occurring amino acids that have an aromatic group include the amino acids histidine, tryptophan, tyrosine, and phenylalanine. For example, the hexapeptide Lys-Gln-Tyr-Arg-Phe-Trp has a net positive charge of two (contributed by the lysine and arginine residues) and three aromatic groups (contributed by tyrosine, phenylalanine and tryptophan residues).
- In one embodiment of the present invention, the aromatic-cationic peptides useful in the methods of the present invention have a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges at physiological pH (pt) wherein 3a is the largest number that is less than or equal to pt+1, except that when pt is 1, a may also be 1. In this embodiment, the relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) is as follows:
-
(p+) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 (a) 1 1 1 1 2 2 2 3 3 3 4 4 4 5 5 5 6 6 6 7 - In another embodiment, the aromatic-cationic peptides have a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2a is the largest number that is less than or equal to pt+1. In this embodiment, the relationship between the minimum number of aromatic amino acid residues (a) and the total number of net positive charges (pt) is as follows:
-
(p+) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 (a) 1 1 2 2 3 3 4 4 5 5 6 6 7 7 8 8 9 9 10 10 - In another embodiment, the number of aromatic groups (a) and the total number of net positive charges (pt) are equal.
- Carboxyl groups, especially the terminal carboxyl group of a C-terminal amino acid, are preferably amidated with, for example, ammonia to form the C-terminal amide, Alternatively, the terminal carboxyl group of the C-terminal amino acid may be amidated with any primary or secondary amine. The primary or secondary amine may, for example, be an alkyl, especially a branched or unbranched C1-C4 alkyl, or an aryl amine. Accordingly, the amino acid at the C-terminus of the peptide may be converted to an amido, N-methylamido, N-ethylamido, N,N-dimethylyamido, N,N-diethylamido, N-methyl-N-ethylamido N- phenylamido or N-phenyl-N-ethylamido group.
- The free carboxylate groups of the asparagine glutamine, aspartic acid, and glutamic acid residues not occurring at the C-terminus of the aromatic-cationic peptides of the present invention may also be amidated wherever they occur within the peptide. The amidation at these internal positions may be with ammonia or any of the primary or secondary amines described above.
- In one embodiment, the aromatic-cationic peptide useful in the methods of the present invention is a tripeptide having two net positive charges and at least one aromatic amino acid. In a particular embodiment, the aromatic-cationic peptide useful in the methods of the present invention is a tripeptide having two net positive charges and two aromatic amino acids.
- Aromatic-cationic peptides useful in the methods of the present invention include, but are not limited to, the following peptide examples:
- Lys-D-Arg-Tyr-NH2,
- D-Tyr-Trp-Lys-NH2,
- Trp-D-Lys-Tyr-Arg-NH2,
- Tyr-His-D-Gly-Met,
- Tyr-D-Arg-Phe-Lys-Glu-NH2,
- Met-Tyr-D-Arg-Phe-Arg,
- D-Hi s-Glu-Ly s-Tyr-D-Phe-Arg,
- Lys-D-Gln-Tyr-Arg-D-Phe-Trp-NH2,
- Phe-D-Arg-Lys-Trp-Tyr-D-Arg-His,
- Gly-D-Phe-Lys-His-D-Arg-Tyr-NH2,
- Val-D-Lys-His-Tyr-D-Phe-Ser-Tyr-Arg-NH2,
- Trp-Lys-Phe-D-Asp-Arg-Tyr-D-His-Lys,
- Lys-Trp-D-Tyr-Arg-Asn-Phe-Tyr-D-His-NH2,
- Thr-Gly-Tyr-Arg-D-His-Phe-Trp-D-His-Lys,
- Asp-D-Trp-Lys-Tyr-D-His-Phe-Arg-D-Gly-Lys-NH2,
- D-His-Lys-Tyr-D-Phe-Glu-D-Asp-D-Asp-D-His-D-Lys-Arg-Trp-NH2,
- Ala-D-Phe-D-Arg-Tyr-Lys-D-Trp-His-D-Tyr-Gly-Phe,
- Tyr-D-His-Phe-D-Arg-Asp-Lys-D-Arg-His-Trp-D-His-Phe,
- Phe-Phe-D-Tyr-Arg-Glu-Asp-D-Lys-Arg-D-Arg-His-Phe-NH2,
- Phe-Tyr-Lys-D-Arg-Trp-His-D-Lys-D-Lys-Glu-Arg-D-Tyr-Thr,
- Tyr-Asp-D-Lys-Tyr-Phe-D-Lys-D-Arg-Phe-Pro-D-Tyr-His-Lys,
- Glu-Arg-D-Lys-Tyr-D-Val-Phe-D-His-Trp-Arg-D-Gly-Tyr-Arg-D-Met-NH2,
- Arg-D-Leu-D-Tyr-Phe-Lys-Glu-D-Lys-Arg-D-Trp-Lys-D-Phe-Tyr-D-Arg-Gly,
- D-Glu-Asp-Lys-D-Arg-D-His-Phe-Phe-D-Val-Tyr-Arg-Tyr-D-Tyr-Arg-His-Phe-NH2,
- Asp-Arg-D-Phe-Cys-Phe-D-Arg-D-Lys-Tyr-Arg-D-Tyr-Trp-D-His-Tyr-D-Phe-Lys-Phe,
- His-Tyr-D-Arg-Trp-Lys-Phe-D-Asp-Ala-Arg-Cys-D-Tyr-His-Phe-D-Lys-Tyr-His-Ser-NH2,
- Gly-Ala-Lys-Phe-D-Lys-Glu-Arg-Tyr-His-D-Arg-D-Arg-Asp-Tyr-Trp-D-His-Trp-His-D-Lys-Asp, and
- Thr-Tyr-Arg-D-Lys-Trp-Tyr-Glu-Asp-D-Lys-D-Arg-His-Phe-D-Tyr-Gly-Val-Ile-D-His-Arg-Tyr-Lys-NH2.
- In one embodiment, the peptides useful in the methods of the present invention have mu-opioid receptor agonist activity (i.e., activate the mu-opioid receptor). Activation of the mu-opioid receptor typically elicits an analgesic effect.
- In certain instances, an aromatic-cationic peptide having mu-opioid receptor activity is preferred. For example, during short-term treatment, such as in an acute disease or condition, it may be beneficial to use an aromatic-cationic peptide that activates the mu-opioid receptor. For example, the acute diseases and conditions can be associated with moderate or severe pain. In these instances, the analgesic effect of the aromatic-cationic peptide may be beneficial in the treatment regiment of the patient or other mammal, although an aromatic-cationic peptide which does not activate the mu-opioid receptor may also be used with or without an analgesic according to clinical requirements.
- Alternatively, in other instances, an aromatic-cationic peptide that does not have mu-opioid receptor activity is preferred. For example, during long-term treatment, such as in a chronic disease state or condition, the use of an aromatic-cationic peptide that activates the mu-opioid receptor may be contraindicated. In these instances, the potentially adverse or addictive effects of the aromatic-cationic peptide may preclude the use of an aromatic-cationic peptide that activates the mu-opioid receptor in the treatment regimen of a human patients or other mammal.
- Potential adverse effects may include sedation, constipation, nervous system depression and respiratory depression. In such instances aromatic-cationic peptide that does not activate the mu-opioid receptor may be an appropriate treatment.
- Examples of acute conditions include heart attack, stroke and traumatic injury. Traumatic injury may include traumatic brain and spinal cord injury.
- Examples of chronic diseases or conditions include coronary artery disease and any neurodegenerative disorders, such as those described below.
- Peptides useful in the methods of the present invention which have mu-opioid receptor activity are typically those peptides which have a trysine residue or a tyrosine derivative at the N-terminus (i.e., the first amino acid position). Preferred derivatives of tyrosine include 2′-methyltyrosine (Mmt); 2′,6′-dimethlyltyrosine (2′,6′Dmt), 3′,5′- dimethyltryosine (3′5′Dmt); N,2′,6′-trimethyltyrosine (Tmt); and 2′-hydroxy-6′- methyltryosine (Hmt).
- In a particular preferred embodiment, a peptide that has mu-opioid receptor activity has the formula Tyr-D-Arg-Phe-Lys-NH2 (for convenience represented by the acronym: DALDA, which is referred to herein as SS-01. DALDA has a net positive charge of three, contributed by the amino acids tyrosine, arginine, and lysine and has two aromatic groups contributed by the amino acids phenylalanine and tyrosine. The tyrosine of DALDA can be a modified derivative of tyrosine such as in 2′,6′-dimethyltyrosine to produce the compound having the
formula 2′,6′-Dmt-Arg-Phe-Lys-NH2 (i.e., Dmt1-DALDA, which is referred to herein as SS-02). - Peptides that do not have mu-opioid receptor activity generally do not have a tyrosine residue or a derivative of tyrosine at the N-terminus (i.e., amino acid position one). The amino acid at the N-terminus can be any naturally occurring or non-naturally occurring amino acid other than tyrosine.
- In one embodiment, the amino acid at the N-terminus is phenylalanine or its derivative. Preferred derivatives of phenylalanine include 2′-methylphenylalanine (Mmp), 2′,6′-dimethylphenylalanine (Dmp), N,2′,6′-trimethylphenylalanine (Tmp) and 2′-hydroxy-6′-methylphenylalanine (Hmp). In another preferred embodiment, the amino acid residue at the N-terminus is arginine. An example of such a peptide is D-Arg-2′6′-Dmt-Lys-Phe-NH2 (referred to in this specification as SS-31).
- Another aromatic-cationic peptide that does not have mu-opioid receptor activity has the formula Phe-D-Arg-Dmt-Lys-NH2. Alternatively, the N-terminal phenylalanine can be a derivative of phenylalanine such as 2′,6′-dimethylphenylalanine (2′6′Dmp). DALDA containing 2′,6′-dimethylphenylalanine at amino acid position one has the
formula 2′,6′-Dmp-D-Arg-Dmt-Lys-NH2. - In a preferred embodiment, the amino acid sequence of Dmt1-DALDA (SS-02) is rearranged such that Dmt is not at the N-terminus. An example of such an aromatic-cationic peptide that does not have mu-opioid receptor activity has the formula D-Arg-2′6′Dmt-Lys- Phe-NH2 (SS-31).
- DALDA, SS-31, and their derivatives can further include functional analogs. A peptide is considered a functional analog of DALDA or SS-31 if the analog has the same function as DALDA or SS-31. The analog may, for example, be a substitution variant of DALDA or SS-31, wherein one or more amino acid is substituted by another amino acid.
- Suitable substitution variants of DALDA or SS-31 include conservative amino acid substitutions. Amino acids may be grouped according to their physicochemical characteristics as follows:
- (a) Non-polar amino acids: Ala(A) Ser(S) Thr(T) Pro(P) Gly(G);
- (b) Acidic amino acids: Asn(N) Asp(D) Glu(E) Gln(Q);
- (c) Basic amino acids: His(H) Arg(R) Lys(K);
- (d) Hydrophobic amino acids: Met(M) Leu(L) Ile(I) Val(V); and
- (e) Aromatic amino acids: Phe(F) Tyr(Y) Trp(W) His(H).
- Substitutions of an amino acid link peptide by another amino acid in the same group is referred to as a conservative substitution and may preserve the physicochemical characteristics of the original peptide. In contrast, substitutions of an amino acid in a peptide by another amino acid in a different group is generally more likely to alter the characteristics of the original peptide.
- Examples of analogs useful in the practice of the present invention that activate mu-opioid receptors include, but are not limited to, the aromatic-cationic peptides shown in Table 1.
-
TABLE 1 Amino Acid Position 1 Amino Acid Position 2 Amino Acid Position 3 Amino Acid Position 4 Amino Acid Position 5 (if present) C-Terminal Modification Tyr D-Arg Phe Lys NH2 Tyr D-Arg Phe Orn NH2 Tyr D-Arg Phe Dab NH2 Tyr D-Arg Phe Dap NH2 2′6′Dmt D-Arg Phe Lys NH2 2′6′Dmt D-Arg Phe Lys Cys NH2 2′6′Dmt D-Arg Phe Lys-NH(CH2)2-NH-dns NH2 2′6′Dmt D-Arg Phe Lys-NH(CH2)2-NH-atn NH2 2′6′Dmt D-Arg Phe dnsLys NH2 2′6′Dmt D-Cit Phe Lys NH2 2′6′Dmt D-Cit Phe Ahp NH2 2′6′Dmt D-Arg Phe Orn NH2 2′6′Dmt D-Arg Phe Dab NH2 2′6′Dmt D-Arg Phe Dap NH2 2′6′Dmt D-Arg Phe Ahp(2-aminoheptanoic acid) NH2 Bio-2′6′Dmt D-Arg Phe Lys NH2 3′5′Dmt D-Arg Phe Lys NH2 3′5′Dmt D-Arg Phe Orn NH2 3′5′Dmt D-Arg Phe Dab NH2 3′5′Dmt D-Arg Phe Dap NH2 3′5′Dmt D-Arg Tyr Lys NH2 Tyr D-Arg Tyr Orn NH2 Tyr D-Arg Tyr Dab NH2 Tyr D-Arg Tyr Dap NH2 2′6′Dmt D-Arg Tyr Lys NH2 2′6′Dmt D-Arg Tyr Orn NH2 2′6′Dmt D-Arg Tyr Dab NH2 2′6′Dmt D-Arg Tyr Dap NH2 2′6′Dmt D-Arg 2′6′Dmt Lys NH2 2′6′Dmt D-Arg 2′6′Dmt Orn NH2 2′6′Dmt D-Arg 2′6′Dmt Dab NH2 2′6′Dmt D-Arg 2′6′Dmt Dap NH2 3′5′Dmt D-Arg 3′5′Dmt Arg NH2 3′5′Dmt D-Arg 3′5′Dmt Lys NH2 3′5′Dmt D-Arg 3′5′Dmt Orn NH2 3′5′Dmt D-Arg 3′5′Dmt Dab NH2 Tyr D-Lys Phe Dap NH2 Tyr D-Lys Phe Arg NH2 Tyr D-Lys Phe Lys NH2 Tyr D-Lys Phe Orn NH2 2′6′Dmt D-Lys Phe Dab NH2 2′6′Dmt D-Lys Phe Dap NH2 2′6′Dmt D-Lys Phe Arg NH2 2′6′Dmt D-Lys Phe Lys NH2 2′6′Dmt D-Lys Phe Orn NH2 2′6′Dmt D-Lys Phe Dab NH2 2′6′Dmt D-Lys Phe Dap NH2 2′6′Dmt D-Lys Phe Arg NH2 3′5′Dmt D-Lys Phe Orn NH2 3′5′Dmt D-Lys Phe Dab NH2 3′5′Dmt D-Lys Phe Dap NH2 3′5′Dmt D-Lys Phe Arg NH2 Tyr D-Lys Tyr Lys NH2 Tyr D-Lys Tyr Orn NH2 Tyr D-Lys Tyr Dab NH2 Tyr D-Lys Tyr Dap NH2 2′6′Dmt D-Lys Tyr Lys NH2 2′6′Dmt D-Lys Tyr Orn NH2 2′6′Dmt D-Lys Tyr Dab NH2 2′6′Dmt D-Lys Tyr Dap 2′6′Dmt D-Lys 2′6′Dmt Lys 2′6′Dmt D-Lys 2′6′Dmt Orn NH2 2′6′Dmt D-Lys 2′6′Dmt Dab NH2 2′6′Dmt D-Lys 2′6′Dmt Dap NH2 2′6′Dmt D-Arg Phe dnsDap NH2 2′6′Dmt D-Arg Phe atnDap NH2 3′5′Dmt D-Lys 3′5′Dmt Lys NH2 3′5′Dmt D-Lys 3′5′Dmt Orn NH2 3′5′Dmt D-Lys 3′5′Dmt Dab NH2 3′5′Dmt D-Lys 3′5′Dmt Dap NH2 Tyr D-Lys Phe Arg NH2 Tyr D-Orn Phe Arg NH2 Tyr D-Dab Phe Arg NH2 Tyr D-Dap Phe Arg NH2 2′6′Dmt D-Arg Phe Arg NH2 2′6′Dmt D-Lys Phe Arg NH2 2′6′Dmt D-Orn Phe Arg NH2 2′6′Dmt D-Dab Phe Arg NH2 3′5′Dmt D-Dap Phe Arg NH2 3′5′Dmt D-Arg Phe Arg NH2 3′5′Dmt D-Lys Phe Arg NH2 3′5′Dmt D-Orn Phe Arg NH2 Tyr D-Lys Tyr Arg NH2 Tyr D-Orn Tyr Arg NH2 Tyr D-Dab Tyr Arg NH2 Tyr D-Dap Tyr Arg NH2 2′6′Dmt D-Arg 2′6′Dmt Arg NH2 2′6′Dmt D-Lys 2′6′Dmt Arg NH2 2′6′Dmt D-Orn 2′6′Dmt Arg NH2 2′6′Dmt D-Dab 2′6′Dmt Arg NH2 3′5′Dmt D-Dap 3′5′Dmt Arg NH2 3′5′Dmt D-Arg 3′5′Dmt Arg NH2 3′5′Dmt D-Lys 3′5′Dmt Arg NH2 3′5′Dmt D-Orn 3′5′Dmt Arg NH2 Mmt D-Arg Phe Lys NH2 Mmt D-Arg Phe Orn NH2 Mmt D-Arg Phe Dab NH2 Mmt D-Arg Phe Dap NH2 Tmt D-Arg Phe Lys NH2 Tmt D-Arg Phe Orn NH2 Tmt D-Arg Phe Dab NH2 Tmt D-Arg Phe Dap NH2 Hmt D-Arg Phe Lys NH2 Hmt D-Arg Phe Orn NH2 Hmt D-Arg Phe Dab NH2 Hmt D-Arg Phe Dap NH2 Mmt D-Lys Phe Lys NH2 Mmt D-Lys Phe Orn NH2 Mmt D-Lys Phe Dab NH2 Mmt D-Lys Phe Dap NH2 Mmt D-Lys Phe Arg NH2 Tmt D-Lys Phe Lys NH2 Tmt D-Lys Phe Orn NH2 Tmt D-Lys Phe Dab NH2 Tmt D-Lys Phe Dap NH2 Tmt D-Lys Phe Arg NH2 Hmt D-Lys Phe Lys NH2 Hmt D-Lys Phe Orn NH2 Hmt D-Lys Phe Dab NH2 Hmt D-Lys Phe Dap NH2 Hmt D-Lys Phe Arg NH2 Mmt D-Lys Phe Arg NH2 Mmt D-Orn Phe Arg NH2 Mmt D-Dab Phe Arg NH2 Mmt D-Dap Phe Arg NH2 Mmt D-Arg Phe Arg NH2 Tmt D-Lys Phe Arg NH2 Tmt D-Orn Phe Arg NH2 Tmt D-Dab Phe Arg NH2 Tmt D-Dap Phe Arg NH2 Tmt D-Arg Phe Arg NH2 Hmt D-Lys Phe Arg NH2 Hmt D-Orn Phe Arg NH2 Hmt D-Dab Phe Arg NH2 Hmt D-Dap Phe Arg NH2 Hmt D-Arg Phe Arg NH2 Dab = diaminobutyric acid Dap = diaminopropionic acid Dmt = dimethyltyrosine Mmt = 2′-methyltyrosine Tmt = N,2′,6′-trimethyltyrosine Hmt = 2′-hydroxy,6′-methyltyrosine dnsDap = β-dansyl-L-α,β-diaminopropionic acid atnDap = β-anthraniloyl-L-α,β-diaminopropionic acid Bio = biotin - Examples of analogs useful in the practice of the present invention that do not activate mu-opioid receptors include, but are not limited to, the aromatic-cationic peptides shown in Table 2.
-
TABLE 2 Amino Acid Position 1 Amino Acid Position 2 Amino Acid Position 3 Amino Acid Position 4 Amino Acid Position 5 (if present) C-Terminal Modification D-Arg Dmt Lys Phe NH2 D-Arg Dmt Phe Lys NH2 D-Arg Phe Lys Dmt NH2 D-Arg Phe Dmt Lys NH2 D-Arg Lys Dmt Phe NH2 D-Arg Lys Phe Dmt NH2 Phe Lys Dmt D-Arg NH2 Phe Lys D-Arg Dmt NH2 Phe D-Arg Dmt Lys NH2 Phe D-Arg Lys Dmt NH2 Phe Dmt D-Arg Lys NH2 Phe Dmt Lys D-Arg NH2 Lys Phe D-Arg D-Arg NH2 Lys Phe Dmt D- D-Arg NH2 Lys Dmt Arg Phe NH2 Lys Dmt Phe D-Arg NH2 Lys D-Arg Phe Dmt NH2 Lys D-Arg Dmt Phe NH2 D-Arg Dmt D-Arg Phe NH2 D-Arg Dmt D-Arg Dmt NH2 D-Arg Dmt D-Arg Tyr NH2 D-Arg Dmt D-Arg Trp NH2 Trp D-Arg Phe Lys NH2 Trp D-Arg Tyr Lys NH2 Trp D-Arg Trp Lys NH2 Trp D-Arg Dmt Lys NH2 D-Arg Trp Lys Phe NH2 D-Arg Trp Phe Lys NH2 D-Arg Trp Lys Dmt NH2 D-Arg Trp Dmt Lys NH2 D-Arg Lys Trp Phe NH2 D-Arg Lys Trp Dmt NH2 NH2 - The amino acids of the peptides shown in table 1 and 2 may be in either the L- or the D-configuration.
- The peptides described above are useful in reducing oxidative damage in a mammal in need thereof. Mammals in need of reducing oxidative damage are those mammals suffering from a disease, condition or treatment associated with oxidative damage. Typically, the oxidative damage is caused by free radicals, such as reactive oxygen species (ROS) and/or reactive nitrogen species (RNS). Examples of ROS and RNS include hydroxyl radical (HO), superoxide anion radical (O2 -) nitric oxide (NO) hydrogen peroxide (H2O2), hypochlorous acid (HOC1) and peroxynitrite anion. (ONOO-).
- In one embodiment, a mammal in need thereof may be a mammal undergoing a treatment associated with oxidative damage. For example, the mammal may be undergoing reperfusion. Reperfusion refers to the restoration of blood flow to any organ or tissue in which the flow of blood is decreased or blocked. The restoration of blood flow during reperfusion leads to respiratory burst and formation of free radicals.
- Decreased or blocked blood flow may be due to hypoxia or ischemia. The loss or severe reduction in blood supply during hypoxia or ischemia may, for example, be due to thromboembolic stroke, coronary atherosclerosis, or peripheral vascular disease.
- Numerous organs and tissues are subject to ischemia or hypoxia. Examples of such organs include brain, heart, kidney, intestine and prostate. The tissue affected is typically muscle, such as cardiac, skeletal, or smooth muscle. For instance, cardiac muscle ischemia or hypoxia is commonly caused by atherosclerotic or thrombotic blockages which lead to the reduction or loss of oxygen delivery to the cardiac tissues by the cardiac arterial and capillary blood supply. Such cardiac ischemia or hypoxia may cause pain and necrosis of the affected cardiac muscle, and ultimately may lead to cardiac failure.
- Ischemia or hypoxia in skeletal muscle or smooth muscle may arise from similar causes. For example, ischemia or hypoxia in intestinal smooth muscle or skeletal muscle of the limbs may also be caused by atherosclerotic or thrombotic blockages.
- The restoration of blood flow (reperfusion) can occur by any method known to those in the art. For instance, reperfusion of ischemic cardiac tissues may arise from angioplasty, coronary artery bypass graft, or the use of thrombolytic drugs. Reducing oxidative damage associated with ischemia/hypoxia and reperfusion is important because the tissue damage associated with ischemia/hypoxia and reperfusion is associated with, for example, myocardial infarction, stroke and hemorrhagic shock.
- In another embodiment, a mammal in need thereof can be a mammal with a disease or condition associated with oxidative damage. The oxidative damage can occur in any cell, tissue or organ of the mammal. Examples of cells, tissues or organs include, but are not limited to, endothelial cells, epithelial cells, nervous system cells, skin, heart, lung, kidney and liver. For example, lipid peroxidation and an inflammatory process are associated with oxidative damage for a disease or condition.
- Lipid peroxidation refers to oxidative modification of lipids. The lipids can be present in the membrane of a cell. This modification of membrane lipids typically results in change and/or damage to the membrane function of a cell. In addition, lipid peroxidation can also occur in lipids or lipoproteins exogenous of a cell. For example, low-density lipoproteins are susceptible to lipid per-oxidation. An example of a condition associated with lipid peroxidation is atherosclerosis. Reducing oxidative damage associated with atherosclerosis is important since atherosclerosis is implicated in, for example, heart attacks and coronary artery disease.
- Inflammatory process refers to the activation of the immune system. Typically, the immune system is activated by an antigenic substance. The antigenic substance can be any substance recognized by the immune system, and include self-derived particles and foreign-derived particles. Examples of diseases or conditions occurring from an inflammatory process to self-derived particles include arthritis and multiple sclerosis. Examples of foreign particles include viruses and bacteria.
- The virus can be any virus which activates an inflammatory process, and associated with oxidative damage. Examples of viruses include, hepatitis A, B or C virus, human immunodeficiency virus, influenza virus, and bovine diarrhea virus. For example, hepatitis virus can elicit an inflammatory process and formation of free radicals, thereby damaging the liver.
- The bacteria can be any bacteria, and include gram-negative or gram-positive bacteria. Gram-negative bacteria contain lipopolysaccharide in the bacteria wall. Examples of gram-negative bacterial include Escherichia coli, Klebsiella pneumoniae, Proteus species, Pseudomonas aeruginosa, Serratia, and Bacteroides. Examples of gram-positive bacteria include pneumococci and streptococci.
- An example of an inflammatory process associated with oxidative stress caused by a bacteria is sepsis. Typically, sepsis occurs when gram-negative bacteria enter the bloodstream.
- Liver damage caused by a toxic agent is another condition associated with an inflammatory process and oxidative stress. The toxic agent can be any agent which causes damage to the liver. For example, the toxic agent can cause apoptosis and/or necrosis of liver cells. Examples of such agents include alcohol, and medication, such as prescription and non-prescription drugs taken to treat a disease or condition.
- The methods of the present invention can also be used in reducing oxidative damage associated with any neurodegenerative disease or condition. The neurodegenerative disease can affect any cell, tissue or organ of the central and peripheral nervous system. Examples of such cells, tissues and organs include, the brain, spinal cord, neurons, ganglia, Schwann cells, astrocytes, oligodendrocytes and microglia.
- The neurodegenerative condition can be an acute condition, such as a stroke or a traumatic brain or spinal cord injury. In another embodiment, the neurodegenerative disease or condition can be a chronic neurodegenerative condition. In a chronic neurodegenerative condition, the free radicals can, for example, cause damage to a protein. An example of such a protein is amyloid β-protein. Examples of chronic neurodegenerative diseases associated with damage by free radicals include Parkinson’s disease, Alzheimer’s disease, Huntington’s disease and Amyotrophic Lateral Sclerosis (also known as Lou Gherig’s disease).
- Other conditions which can be treated in accordance with the present invention include preeclampsia, diabetes, and symptoms of and conditions associated with aging, such as macular degeneration, wrinkles.
- In another embodiment, the peptides useful in the present invention may also be used in reducing oxidative damage in an organ of a mammal prior to transplantation. For example, a removed organ, when subjected to reperfusion after transplantation can be susceptible to oxidative damage. Therefore, the peptides can be used to reduce oxidative damage from reperfusion of the transplanted organ.
- The removed organ can be any organ suitable for transplantation. Examples of such organs include, the heart, liver, kidney, lung, and pancreatic islets. The removed organ is placed in a suitable medium, such as in a standard buffered solution commonly used in the art.
- For example, a removed heart can be placed in a cardioplegic solution containing the peptides described above. The concentration of peptides in the standard buffered solution can be easily determined by those skilled in the art. Such concentrations may be, for example, between about 0.01 nM to about 10 µM, preferably about 0.1 nM to about 10 µM, more preferably about 1 µM to about 5 µM, and even more preferably about 1 nM to about 100 nM.
- In yet another embodiment, the invention provides a method for reducing oxidative damage in a cell in need thereof. Cells in need of reducing oxidative damage are generally those cells in which the cell membrane or DNA of the cell has been damaged by free radicals, for example, ROS and/or RNS. Examples of cells capable of being subjected to oxidative damage include the cells described herein. Suitable examples of cells include pancreatic islet cells, myocytes, endothelial cells, neuronal cells, stem cells, etc.
- The cells can be tissue culture cells. Alternatively the cells may be obtained from a mammal. In one instance, the cells can be damaged by oxidative damage as a result of an insult. Such insults include, for example, a disease or condition (e.g., diabetes, etc.) or ultraviolet radiation (e.g., sun, etc.). For example pancreatic islet cells damaged by oxidative damage as a result of diabetes can be obtained from a mammal.
- The peptides described above can be administered to the cells by any method known to those skilled in the art. For example, the peptides can be incubated with the cells under suitable conditions. Stick conditions can be readily determined by those skilled in the art.
- Due to reduction of oxidative damage, the treated cells may be capable of regenerating. Such regenerated cells may be administered back into the mammal as a therapeutic treatment for a disease or condition. As mentioned above, one such condition is diabetes.
- Oxidative damage is considered to be “reduced” if the amount of oxidative damage in a mammal, a removed organ, or a cell is decreased after administration of an effective amount of the aromatic cationic peptides described above. Typically, the oxidative damage is considered to be reduced if the oxidative damage is decreased by at least about 10%, preferably at least about 25%, more preferably at least about 50%, even more preferably at least about 75%, and most preferably at least about 90%.
- The peptides useful in the methods of the present invention may be chemically synthesized by any of the methods well known in the art. Suitable methods for synthesizing the protein include, for example those described by Stuart and Young in “Solid Phase Peptide Synthesis,” Second Edition, Pierce Chemical Company (1984), and in “Solid Phase Peptide Synthesis,” Methods Enzymol. 289, Academic Press, Inc, New York (1997).
- The peptide useful in the methods of the present invention is administered to a mammal in an amount effective in reducing oxidative damage. The effective amount is determined during pre-clinical trials and clinical trials by methods familiar to physicians and clinicians.
- An effective amount of a peptide useful in the methods of the present invention, preferably in a pharmaceutical composition, may be administered to a mammal in need thereof by any of a number of well-known methods for administering pharmaceutical compounds.
- The peptide may be administered systemically or locally. In one embodiment, the peptide is administered intravenously. For example, the aromatic-cationic peptides useful in the methods of the present invention may be administered via rapid intravenous bolus injection. Preferably, however, the peptide is administered as a constant rate intravenous infusion.
- The peptide can be injected directly into coronary artery during for example, angioplasty of or coronary bypass surgery, or applied onto coronary stents.
- The peptide may also be administered orally, topically, intranasally, intramuscularly, subcutaneously, or transdermally. In a preferred embodiment, transdermal administration of the aromatic-cationic peptides by methods of the present invention is by iontophoresis, in which the charged peptide is delivered across the skin by an electric current.
- Other routes of administration include intracerebroventricularly or intrathecally. intracerebroventiculatly refers to administration into the ventricular system of the brain. Intrathecally refers to administration into the space under the arachnoid membrane of the spinal cord. This intracerebroventicular or intrathecal administration may be preferred for those diseases and conditions which affect the organs or tissues of the central nervous system. In a preferred embodiment, intrathecal administration is used for traumatic spinal cord injury.
- The peptides useful in the methods of the invention may also be administered to mammals by sustained release as is known in the art. Sustained release administration is a method of drug delivery to achieve a certain level of the drug over a particular period of time. The level typically is measured by serum or plasma concentration.
- A description of methods for delivering a compound by controlled release can be found in PCT Application No. WO 02/083106. The PCT application is incorporated herein by reference in its entirety.
- Any formulation known in the art of pharmacy is suitable for administration of the aromatic-cationic peptides useful in the methods of the present invention. For oral administration, liquid or solid formulations may be used. Some examples of formulations include tablets, gelatin capsules, pills, troches, elixirs, suspensions, syrups, wafers, chewing gum and the like. The peptides can be mixed with a suitable pharmaceutical carrier (vehicle) or excipient as understood by practitioners in the art. Examples of carriers and excipients include starch, milk, sugar, certain types of clay, gelatin, lactic acid, stearic acid or salts thereof, including magnesium or calcium stearate, talc, vegetable fats or oils, gums and glycols.
- For systemic, intracerebroventricular, intrathecal, topical, intranasal, subcutaneous, or transdermal administration, formulations of the aromatic-cationic peptides useful in the methods of the present invent oils may utilize conventional diluents, carriers, or excipients etc., such as are known in the art can be employed to deliver the peptides. For example, the formulations may comprise one or more of the following: a stabilizing a surfactant, preferably a nonionic surfactant, and optionally a salt and/or a buffering agent. The peptide may be delivered in the form of an aqueous solution, or in a lyophilized form.
- The stabilizer may, for example, be an amino acid, such as for instance, glycine; or an oligosaccharide, such as for example, sucrose, tetralose, lactose or a dextran. Alternatively, the stabilizer may be a sugar alcohol, such as for instance, mannitol; or a combination thereof. Preferably the stabilizer or combination of stabilizers constitutes from about 0.1% to about 10% weight for weight of the peptide.
- The surfactant is preferably a nonionic surfactant, such as a polysorbate. Some examples of suitable surfactants include Tween20, Tween80; a polyethylene glycol or a polyoxyethylene polyoxypropylene glycol, such as Pluronic F-68 at from about 0.001% (w/v) to about 10% (w/v).
- The salt or buttering agent may be any salt or buffering agent such as for example, sodium chloride, or sodium/potassium phosphate, respectively. Preferably, the buttering agent maintains the pH of the pharmaceutical composition in the range of about 5.5 to about 7.5. The salt and/or buffering agent is also useful to maintain the osmolality at a level suitable for administration to a human or an animal. Preferably the salt or buffering agent is present at a roughly isotonic concentration of about 150 mM to about 300 mM.
- The formulations of the peptides useful in the methods of the present invention may additionally contain one or more conventional additive. Some examples of such additives include a solubilizer such as, for example, glycerol; an antioxidant such as for example, benzalkonium chloride (a mixture of quaternary ammonium compounds, known as “quats”), benzyl alcohol, chloretone or chlorobutanol; anaesthetic agent such as for example a morphine derivative; or an isotonic agent etc., such as described above. As a further precaution against oxidation or other spoilage, the pharmaceutical compositions may be stored under nitrogen gas in vials sealed with impermeable stoppers.
- The mammal treated in accordance with the invention can be any mammal, including, for example, farm animals, such as sheep, pigs, cows, and horses pet animals such as dogs and cats, laboratory animals, such as rats, mice and rabbits. In a preferred embodiment, the mammal is a human.
- The cellular uptake of [3H][Dmt1]DALDA was studied using a human intestinal epithelial cell line (Caco-2), and confirmed with SH-SY5Y (human neuroblastoma cell), HEK293 (human embryonic kidney cell) and CRFK cells (kidney epithelial cell). Monolayers of cells were grown on 12-well plates (5×105 cells/well) coated with collagen for 3 days. On
day 4, cells were washed twice with pre-warmed HBSS, and then incubated with 0.2 ml of HBSS containing either 250 nM [3H][Dmt1]DALDA at 37° C. for 4° C. for various times up to 1 h. - [3H][Dmt1]DALDA was observed in cell lysate as early as 5 min, and steady state levels were achieved by 30 min. The total amount of [3H][Dmt1]DALDA recovered in the cell lysate after 1 h incubation represented about 1% of the total drug. The uptake of [3H][Dmt1]DALDA was slower at 4° C. compared to 37° C., but reached 76.5% by 45 min and 86.3% by 1 h. The internalization of [3H][Dmt1]DALDA was not limited to Caco-2 cells, but was also observed in SH-SY5Y, HEK293 and CRFK cells. The intracellular concentration of [Dmt1]DALDA was estimated to be approximately 50 times higher than extracellular concentration.
- In a separate experiment, cells were incubated with a range of [Dmt1]DALDA concentrations (1 µM-3 mM) for 1 h at 37° C. At the end of the incubation period, cells were washed 4 times with HBSS, and 0.2 ml of 0.1 N NaOH with 1% SDS was added to each well. The cell contents were then transferred to scintillation vials and radioactivity counted. To distinguish between internalized radioactivity from surface-associated radioactivity, an acid- wash step was included. Prior to cell lysis, cells were incubated with 0.2 ml of 0.2 M acetic acid/0.05 M NaCl for 5 min on ice.
- The uptake of [Dmt1]DALDA into Caco-2 cells was confirmed by confocal laser scanning microscopy (CLSM) using a fluorescent analog of [Dmt1]DALDA (Dmt-D-Arg-Phe-dnsDap-NH2; where dnsDap=β-dansyl-1-α,β-diaminopropionic acid). Cells were grown as described above and were plated on (35 mm) glass bottom dishes (MatTek Corp., Ashland, Mass.) for 2 days. The medium was then removed and cells were incubated with 1 ml of HBSS containing 0.1 µM to 1.0 µM of the fluorescent peptide analog at 37° C. for 1 h. Cells were then washed three times with ice-cold HBSS and covered with 200 µl of PBS, and microscopy was performed within 10 min at room temperature using a Nikon confocal laser scanning microscope with a C-Apochromat 63x/1.2 W corr objective. Excitation was performed at 340 nm by means of a UV laser, and emission was measured at 520 nm. For optical sectioning in z-direction, 5-10 frames with 2.0 µm were made.
- CLSM confirmed the uptake of fluorescent Dmt-D-Arg-Phe-dnsDap-NH2 into Caco-2 cells after incubation with 0.1 µM [Dmt1,DnsDap4]DALDA for 1 h at 37° C. The uptake of the fluorescent peptide was similar at 37° C. and 4° C. The fluorescence appeared diffuse throughout the cytoplasm but was completely excluded from the nucleus.
- To examine the subcellular distribution of [Dmt1]DALDA, the fluorescent analog, [Dmt1, AtnDap4]DALDA (Dmt-D-Arg-Phe-atnDap-NH2; where atn=β-anthraniloyl-1-α,β-diamino-propionic acid) was prepared. The analog contained β-anthraniloyl-1-α,β-diaminopropionic acid in place of the lysine reside at
position 4. The cells were grown as described in Example 1 and were plated on (35 mm) glass bottom dishes (MatTek Corp., Ashland, Mass.) for 2 days. The medium was then removed and cells were incubated with 1 ml of HBSS containing 0.1 µM of [Dmt1,AtnDap4]DALDA at 37° C. for 15 min to 1 h. - Cells were also incubated with tetramethylrhodamine methyl ester (TMRM, 25 nM), a dye for staining mitochondria, for 15 min at 37° C. Cells were then washed three times with ice-cold HBSS and covered with 200 µl of PBS, and microscopy was performed within 10 min at room temperature using a Nikon confocal laser scanning microscope with a C-Apochromat 63x/1.2 W corr objective.
- For [Dmt1,AtnDap4]DALDA, excitation was performed at 350 nm by means of a UV laser, and emission was measured at 520 nm. For TMRM, excitation was performed at 356 nm, and emission was measured at 560 nm.
- CLSM showed the uptake of fluorescent [Dmt1,AtnDap4]DALDA into Caco-2 cells after incubation for as little as 15 min at 37° C. The uptake of dye was completely excluded from the nucleus, but the blue dye showed a streaky distribution within the cytoplasm. Mitochondria were labeled red with TMRM. The distribution of [Dmt1,AtnDap4]DALDA to mitochondria was demonstrated by the overlap of the [Dmt1,AtnDap4]DALDA distribution and the TMRM distribution.
- Effect of SS-02 and SS-05 (Dmt-D-Arg-Phe Orn-NH2) on H2O2 as measured by luminol-induced chemiluminescence, 25 µM luminol and 0.7 IU horseradish peroxidase were added to the solution of H2O2 (4.4 nmol) and peptide, and chemiluminescence was monitored with a Chronolog Model 560 aggregometer (Havertown, Pa.) for 20 min at 37° C.
- Results show that SS-02 and SS-05 dose-dependently inhibited the luminol response suggesting that these peptides can scavenge H2O2.
- Linoleic acid peroxidation was induced by a water-soluble initiator. ABAP (2,2′-azobis(2-amidinopropane)), and lipid peroxidation was detected by the formation of conjugated dienes, monitored spectrophotometrically at 236 nm (B. Longoni, W. A. Pryor, P. Marchiafava, Biochem. Biophys. Res. Commun. 233, 778-780 (1997)).
- 5 ml of 0.5 M ABAP and varying concentrations of SS-02 were incubated in 2.4 ml linoleic acid suspension until autoxidation rate became constant. Results show that SS-02 dose-dependently inhibited the peroxidation of linoleic acid.
- Various peptides were added in concentration of 100 µM. The data are presented as the slope of diene formation. With the exception of SS-20 (Phe-D-Arg-Phe-Lys-NH2), SS-21 (Cyclohexyl-D-Arg-Phe-Lys-NH2) and SS-22 (Ala-D-Arg-Phe-Lys-NH2), all other SS peptides reduced the rate of linoleic acid peroxidation. Note that SS-20, SS-21 and SS-22 do not contain either tyrosine or dimethyltyrosine residues. SS-01, which contains Tyr rather than Dmt is not as effective in preventing linoleic acid peroxidation. SS-29 is Dmt-D-Cit-Phe Lys-NH2. SS-30 is Phe-D-Arg-Dmt-Lys-NH2, SS-32 is Dmt-D-Arg-Phe-Ahp(2-aminoheptanoic acid)-NH2.
- Human LDL (low density lipoprotein) was prepared fresh from stored plasma. LDL oxidation was induced catalytically by the addition of 10 mM CuSO4, and the formation of conjugated dienes was monitored at 24 nm for 5 h at 37° C. (B. Moosmann and C. Behl, Mol Pharmacol., 61, 260-268 (2002)).
- (A) Results show that SS-02 dose-dependently inhibited the rate of LDL oxidation.
- (B) Various peptides were added in concentration of 100 µM. With the exception of SS-20 (Phe-D-Arg-Phe-Lys NH2) SS-21. (Cyclohexyl-D-Arg-Phe-Lys-NH2) and SS-22 (Ala- D-Arg-Phe-Lys-NH2), all other SS peptides reduced the rate of linoleic acid peroxidation (reduced rate of formation of conjugated dienes). Note that SS-20, SS-21 and SS-22 do not contain either tyrosine or dimethyltyrosine residues. SS-29 is Dmt-D-Cit-Phe-Lys-NH2, SS- 30 is Phe-D-Arg-Dmt-Lys-NH2, SS-32 is Dmt-D-Arg-Phe-Ahp(2-aminoheptanoic acid)-NH2.
- Because mitochondria are a major source of ROS production, the effect of SS-02 on H2O2 formation in isolated mitochondria under basal conditions as well as after treatment with antimycin, a complex III inhibitor was examined. Livers were harvested from mice and homogenized in ice-cold buffer and centrifuged at 13800×g for 10 m. The pellet was washed once and then re-suspended in 0.3 ml of wash butter and placed on ice until use H2O2 was measured using luminol chemiluminescence as described previously (Y. Li, H. Zhu, M. A. Trush, Biochim. Biophys. Acta 1428, 1-12 (1999)). 0.1 mg mitochondrial protein was added to 0.5 ml potassium phosphate buffer (100 mM, pH 8.0) in the absence or presence of SS peptides (100 µM). 25 mM luminol and 0.7 IU horseradish peroxidase were added, and chemilumunescence was monitored with a Chronolog Model 560 aggregometer (Havertown, Pa.) for 20 min at 37° C. The amount of H2O2 produced was quantified as the area under the curve (AUC) over 20 min, and all data were normalized to AUC produced by mitochondria alone.
- (A) The amount of H2O2 production was significantly reduced in the presence of 10 µM SS-02. Addition of antimycin (1 µM) significantly increased H2O2 production by isolated mitochondria, and the increase was completely blocked by 1.0 µM Dmt1-DALDA (also referred to as dDALDA in the specification).
- (B) The amount of H2O2 generated was significantly reduced by peptides SS-02, SS-29, SS-30 and SS-31. SS-21 and SS-22 had no effect on H2O2 production. Note that SS- 21 and SS-22 do not contain a tyrosine or dimethyltryosine residue. The amino acid Dmt dimethyltyrosine) alone also inhibited H2O2 generated.
- H2O2 was measured using luminol chemiluminescence as described previously (Y, Li, H. Zhu, M. A. Trush, Biochim. Biophys. Acta 1428, 1-12 (1999)). 0.1 mg mitochondrial protein was added to 0.5 ml potassium phosphate buffer (100 mM, pH 8.0) in the absence or presence of SS-31. 25 mM luminol and 0.7 IU horseradish peroxidase were added, and chemilumunescence was monitored with a Chronolog Model 560 aggregometer (Havertown, Pa.) for 20 min at 37° C. The amount of H2O2 produced was quantified as the area under the curve (AUC) over 20 min, and all data were normalized to AUC produced by mitochondria alone.
- (A) SS-31 dose-dependently reduced the spontaneous production of H2O2 by isolated mitochondria.
- (B) SS-31 dose-dependently reduced the production of H2O2 induced by antimycin in isolated mitochondria.
- To show that the claimed peptides are effective when applied to whole cells, neuronal N2A cells were plated in 96-well plates at a density of 1×104/well and allowed to grow for 2 days before treatment with tBHP (0.5 or 1 mM) for 40 min. Cells were washed twice and replaced with medium alone or medium containing varying concentrations of SS- 02 or SS-31 for 4 hr. Intracellular ROS was measured by carboxy-H2DCFDA (Molecular Probes, Portland, Oreg.). Cell death was assessed by a cell proliferation assay (MTS assay, Promega, Madison, Wis.).
- Incubation with tBHP resulted in dose-dependent increase in intracellular ROS (A) and decrease in cell viability, (B and C). Incubation of these cells with either SS-31 or SS-02 dose-dependently reduced intracellular ROS (A) and increased cell survival (B and C), with EC50 in the nM range.
- Neuronal N2A and SH-SY5Y cells were plated in 96-well plate at a density of 1×104/well and allowed to grow for 2 days before treatment with t-butyl hydroperoxide (tBHP) (0.05-0.1 mM) with or without SS-31 (10-12 M to 10-9 M for 24 h. Cell death was assessed by a cell proliferation assay (MTS assay, Promega, Madison, Wis.).
- Treatment of N2A and SH-SY5Y cells with low doses of t-BHP (0.05-0.1 mM) for 24 h resulted in a decrease in cell viability. (A) 0.05 mM t-BHP induced 50% loss of cell viability in N2A cells and 30% in SH-SY5Y cells. (B) 0.1 mM t-BHP resulted in a greater reduction in cell viability in SH-SY5Y cells. Concurrent treatment of cells with SS-31 resulted in a dose-dependent reduction of t-BHP-induced cytotoxicity. Complete protection against t-BHP was achieved by 1 nM SS-31.
- N2A cells were grown on 96-well plates, treated with t-BHP (0.05 mM) in the absence or presence of SS-31 (10-11 M-10-8 M) at 37° C. for 12-24 h. All treatments were carried out in quadriplicates. N2A cells were incubated with t-BHP (50 mM) with or without SS-31 at 37° C. for 12 h. Cells were gently lifted from the plates with a cell detachment solution (Accutase, Innovative Cell Technologies, Inc., San Diego, Calif.) and washed twice in PBS. Caspase activity was assayed using the FLICA kit (Immunochemistry Technologies LLC, Bloomington, Minn.) According to the manufacturer’s recommendation, cells were resuspended (approx. 5×106 cells/ml) in PBS and labeled with pan-caspase inhibitor FAM-VAD-FMK for 1 h at 37° C. under 5% CO2 and protected from the light. Cells were then rinsed to remove the unbound reagent and fixed. Fluorescence intensity in the cells was measured by a laser scanning cytometer (Beckman-Coulter XL, Beckman Coulter, Inc., Fullerton, Calif.) using the standard emission filters for green (FL1). For each run, 10,000 individual events were collected and stored in list-mode files for off-line analysis.
- Caspase activation is the initiating trigger of the apoptotic cascade, and our results showed a significant increase in caspase activity after incubation of SH-SY5Y cells with 50 mM t-BHP for 12 h which was dose-dependently inhibited by increasing concentrations of SS-31.
- Intracellular ROS was evaluated using the fluorescent probe DCFH-DA (5-(and-6)- carboxy-2′,7′-dichlorodihydrofluorescein diacetate). DCFH-DA enters cells passively and is then deacetylated to nonfluorescent DCFH. DCFH reacts with ROS to form DCF, the fluorescent product. N2A cells in 96 sell plates were washed with HBSS and loaded with 10 µM of DCFDA for 30 min. for 30 min. at 37° C. Cells were washed 3 times with BSS and exposed to 0.1 mM of t-BHP, alone or with SS-31. The oxidation of DCF was monitored in real time by a fluorescence microplate reader (Molecular Devices) using 485 nm for excitation and 530 nm for emission.
- The rate of ROS accumulation in N2A cells treated with 0.1 mM t-BHP was dose- dependently inhibited by the addition of SS-31.
- SS-31 inhibited lipid peroxidation in N2A cells treated with t-BHP. Lipid peroxidation was evaluated by measuring HNE Michael adducts. 4-HNE is one of the major aldehydic products of the peroxidation of membrane polyunsaturated fatty acids. N2A cells were seeded on
glass bottom dish 1 day before t-BHP treatment (1 mM, 3 h, 37° C., 5% CO2) in the presence of absence of SS-31 (10-8 to 10-10 M). Cells were then washed twice with PBS and fixed 30 min with 4% paraformaldehyde in PBS at RT and then washed 3 times with PBS. Cells were then permeabilized, treated with rabbit-anti-HNE antibody followed by the secondary antibody (goat anti-rabbit IgG conjugated to biotin). Cells were mounted in Vectashield and imaged using a Zeiss fluorescence microscope using an excitation wavelength of 460±20 nm and a longpass filter of 505 nm for emission. - (A) Untreated cells (B) cells treated with 1 mM t-BHP for 3 h; (C) cells treated with 1 mM t-BHP and 10 nM SS-31 for 3 h.
- Caco-2 cells were treated with tBHP (1 mM) in the absence or presence of SS-02 (0.1 µM) for 4 h, and then incubated with TMRM and examined under LSCM. In control cells, the mitochondria are clearly visualized as fine streaks throughout the cytoplasm. In cells treated with tBHP, the TMRM fluorescence is much reduced, suggesting generalized depolarization. In contrast, concurrent treatment with SS-02 protected against mitochondrial depolarization caused by tBHP.
- N2A cells in glass bottom dish were treated with 0.1 mM t-BHP, alone or with 1 nM SS-31, for 6 h. Cells were then loaded with 10 µm of dichlorofluorescin (ex/em=485/530) for 30 min at 37° C., 5% CO2. Then cells were subjected 3 times wash with HBSS and stained with 20 nM of Mitotracker TMRM (ex/em=550/575 nm) for 15 min at 37° C. and examined by confocal laser scanning microscopy.
- Treatment of N2A cells with t-BHP resulted in loss of TMRM fluorescence indicating mitochondrial depolarization. There was also a concomitant increase in DCF fluorescence indicating increase in intracellular ROS. Concurrent treatment with 1 nM SS-31 prevented mitochondrial depolarization and reduced ROS accumulation.
- SH-SY5Y cells were grown on 96-well plates, treated with t-BHP (0.025 mM) in the absence or presence of SS-31 (10-12 M-10-9 M) at 37° C. for 24 h. All treatments were carried out in quadriplicates. Cells were then stained with 2 mg/ml Hoechst 33342 for 20 min, fixed with 4% paraformaldehyde, and imaged using a Zeiss fluorescent microscope (Axiovert 200 M) equipped with the Zeiss Acroplan x20 objective. Nuclear morphology was evaluated using an excitation wavelength of 350±10 nm and a longpass filter of 400 nm for emission. All images were processed and analyzed using the MetaMorph software (Universal Imaging Corp., West Chester, Pa.). Uniformly stained nuclei were scored as healthy, viable neurons, while condensed or fragmented nuclei were scored as apoptotic.
- SS-31 prevents apoptosis induced by a low dose of t-BHP. Apoptosis was evaluated by confocal microscopy with the fluorescent probe Hoechst 33342 (A1) a representative field of cells not treated with t-BHP. (A2) Fluorescent image showing a few cells with dense, fragmented chromatin indicative of apoptotic nuclei. (A3) A representative field of cells treated with 0.025 mM t-BHP for 24 h. (A4) Fluorescent image showing an increased number of cells with apoptotic nuclei. (A5) A representative field of cells treated with 0.025 mM t- BHP and 1 nM SS-31 for 24 h. (A6) Fluorescent image showing a reduced number of cells with apoptotic nuclei.
- (B) SS-31 dose-dependently reduced the percent of apoptotic cells caused by 24 h treatment with a low dose of t-BHP (0.05 mM).
- Isolated guinea pig hearts were perfused in a retrograde manner in a Langendorff apparatus and subjected to various intervals of ischemia-reperfusion. Hearts were then fixed immediately and embedded in paraffin. Immunohistochemical analysis of 4-hydroxy-2-nonenol (HNE)-modified proteins in the paraffin sections was carried out using an anti-HNE antibody.
- (A) Immunohistochemical analysis of 4-hydroxy-2-nonenol (HNE)-modified proteins in paraffin sections from guinea pig hearts aerobically perfused 30 min with (a) buffer; (b) 100 nM SS-02; (c) 100 nM SS-20 and (d) 1 nM SS-31, then subjected to 30 min ischemia and reperfused for 90 min with same peptides. Tissue slices were incubated with anti-HNE antibody. (e) Background control: staining without primary antibody.
- (B) Immunohistochemical analysis of HNE-modified proteins in paraffin sections from guinea pig hearts aerobically perfused 30 min with buffer; then subjected to 30 min ischemia and reperfused with (a) buffer; (b) 100 nM SS-02; (c) 100 nM SS-20 and (d) 1 nM SS-31 for 90 min with same peptides. Tissue slices were incubated with anti-HNE antibody. (e) Background control staining without primary antibody.
- Isolated guinea pig hearts were perfused in a retrograde manner in a Langendorff apparatus with a cardioplegic solution (St. Thomas solution) without or with SS-31 (1 nM) for 3 min. and then clamped and stored at 4° C. for 18 h. Subsequently, the hearts were remounted in the Langendorff apparatus and reperfused with Krebs-Henseleit solution at 34° C. for 90 min. Hearts were then rapidly fixed and paraffin-embedded.
- (A) SS-31 significantly improved coronary flow in hearts after 18 h cold ischemic storage. The shaded area represents 18 h of cold ischemia.
- (B) Immunohistochemical analysis of HNE-modified proteins in paraffin sections from guinea pig hearts stored without (a) or with (b) SS-31 (1 nM). (c) Background staining without primary antibody.
- (C) SS-31 prevents apoptosis in endothelial cells and myocytes in isolated guinea pig hearts subjected to warm reperfusion after prolonged (18 h) cold ischemia. Apoptosis was assessed by the TUNEL stain (green) and nuclei are visualized by DAPI (blue).
- (A) SS-31 improves mitochondrial potential in islet cells isolated from mouse pancreas. Pancreas was harvested from mice and islet cells were prepared according standard procedures. In some studies, SS-31 (1 nM) was added to all isolation buffers used throughout the isolation procedure. Mitochondrial potential was measured using TMRM (red) and visualized by confocal microscopy.
- (B) SS-31 reduces apoptosis and increases viability in islet cells isolated from mouse pancreas. Pancreas was harvested from mice and islet cells were prepared according standard procedures. In some studies, SS-31 (1 nM) was added to all isolation buffers used throughout the isolation procedure. Apoptosis was ascertained by flow cytometry using annexin V and necrosis by propidium iodide.
- Mouse pancreatic islet cells were untreated (a), or treated with 25 µM tBHP without or with 1 nM SS-31 (c). Mitochondrial potential was measured by TMRM (red) and reactive oxygen species were measured by DCF (green) using confocal microscopy.
- MPTP is a neurotoxin that selectively destroys striatal dopamine neurons and can be used as an animal model of Parkinson’s Disease. MPP+, a metabolite of MPTP, targets mitochondria, inhibits complex I of the electron transport chain and increases ROS production. MPP+ is used in cell culture studied because cells are unable to metabolize MPTP to the active metabolite. MPTP is used for animal studies.
- (A) SS-31 protects dopamine cells against MPP+ toxicity. SN-4741 cells were treated with buffer, 50 µM MPP+ or 50 µM MPP+ and 1 nM SS-31, for 48 h, and the incidence of apoptosis was determined by fluorescent microscopy with Hoechst 33342. The number of condensed fragmented nuclei was significantly increased by MPP+ treatment. Concurrent treatment with SS-31 reduced the number of apoptotic cells.
- (B) SS-31 dose-dependently prevented loss of dopamine neurons in mice treated with MPTP. Three doses of MPTP (10 mg/kg) was given to mice (n=12) 2 h apart. SS-31 was administered 30 min before each MPTP injection, and at 1 h and 12 h after the last MPTP injection. Animals were sacrificed one week later and striatal brain regions were immunostained for tyrosine hydroxylase activity.
- (C) SS-31 dose-dependently increased striatal dopamine DOPAC (3,4-dihydroxyphenylacetic acid) and HVA (homovanillic acid) levels in mice treated with MPTP. Three doses of MPTP (10 mg/kg) was given to mice (n=12) 2 h apart. SS-31 was administered 30 min before each MPTP injection, and at 1 h and 12 h after the last MPTP injection. Animals were sacrificed one week later and dopamine, DOPAC and HVA levels were quantified by high pressure liquid chromatography.
- The loss of cell viability induced by 100 µM tBHP was accompanied by a significant increase in LDH release in SH-SY5Y (
FIG. 18A ) and N2A cell (FIG. 18B ). (Concurrent treatment of cells with SS-31 resulted in dose-dependent decrease in LDH release in both SH-SY5Y (P<0.01) and N2A cells (P<0.0001). LDH release was reduced significantly by 0.1 and 1 nM of SS-31 in both cell lines (P<0.05). SS-20, the control non- scavenging peptide, did not protect against tBHP-induced cytotoxicity in N2A cells (FIG. 18B ). - The translocation of phosphatidylserine from the inner leaflet of the plasma membrane to the outer leaflet is observed early in the initiation of apoptosis. This can be observed with Annexin V, a phospholipid binding protein with high affinity for phosphatidylserine.
FIG. 19A shows that untreated N2A cells showed little to no Annexin V staining (green). Incubation of N2A cells with 50 mM tBHP for 6 h resulted in Annexin V staining on the membranes of most cells (FIG. 19B ). Combined staining with Annexin V and propidium iodide (red) showed many late apoptotic cells (FIG. 19B ). Concurrent treatment of N2A cells with 1 nM SS-31 and 50 µM tBHP resulted in a reduction in Annexin V-positive cells and no propidium iodide staining (FIG. 19C ), suggesting that SS-31 protected against tBHP-induced apoptosis. - The morphological appearance of cells treated with tBHP was also consistent with apoptosis. N2A cells incubated with 50 µM tBHP for 12 h became rounded and shrunken (
FIG. 20A , panel b). Staining with Hoechst 33324 showed increased number of cells with nuclear fragmentation and condensation (FIG. 20A , panel b). These nuclear changes were abolished by concurrent treatment with 1 nM SS-31 (FIG. 20A , panel c′). The number of apoptotic cells was dose-dependently reduced by concurrent treatment with SS-31 (P<0.0001) (FIG. 20B ). - An increased number of cells with condensed nuclei was also observed when SH- SY5Y cells were treated with 25 µM tBHP for 24 h, and the number of apoptotic cells was dose-dependently reduced by concurrent treatment with SS-31 (P<0.0001) (
FIG. 20C ). - Incubation of N2A cells with 100 µM tBHP for 24 h resulted in a significant increase in pan-caspase activity that was dose-dependently prevented by co-incubation with SS-31 (P<0.0001 (
FIG. 21A ). A N2A cells treated with 50 µM tBHP for 12 h showed intense staining (red) for caspase-9 activity (FIG. 21B , panel b). Note that cells that show nuclear condensation all showed caspase-9 staining. Concurrent incubation with 1 nM SS-31 reduced the number of cells showing caspase-9 staining (FIG. 21B , panel c). - Intracellular ROS production is an early and critical event in oxidant-induced cytotoxicity. Treatment of N2A cells with 100 µM tBHP resulted in rapid increase in intracellular ROS, as measured by DCF fluorescence, over 4 h at 37° C. (
FIG. 22A ). Concurrent treatment with SS-31 dose-dependently reduced the rate of ROS production, with 1 nM SS-31 effectively reducing ROS production by >50%. The reduction in intracellular ROS was confirmed by fluorescent microscopy with DCF (FIG. 22B ). Treatment with N2A cells with 50 µM tBHP caused significant increase in DCF fluorescence (green), and this was significantly reduced by co-incubation with 1 nM SS-31 (FIG. 22C ). - Treatment with low doses of tBHP (50-100 µM) for 24 h resulted in a significant decrease in mitochondrial function as measured by the MTT assay in both cell lines. Only viable mitochondria containing NADPH dehydrogenase activity are capable of cleaving MTT to the formazan. A 50 µM tBHP induced 50% loss of mitochondrial function in N2A cells (
FIG. 23A , P<-0.01) and 30% loss of mitochondrial function in SH—SY5Y cells (FIG. 23B , P<0.01). Concurrent treatment with SS-31 dose-dependently reduced tBHP-induced mitochondrial toxicity in both N2A (FIG. 23A ; P<0.0001) and SHSY5Y cells (FIG. 23B ; P<0.0001). The non-scavenging peptide, SS-20, did not protect against tBHP-induced mitochondrial dysfunction in N2A cells (FIG. 23A ). Treatment of N2A cells with SS-31 alone had no effect on mitochondrial function. - In a cell culture model of N2A cells overexpressing either wild type or mutant (69A-SOD1, the mutant cells were significantly more sensitive to H2O2-induced cell death both at 0.04 mM and 1 mM concentrations. This cell-death was significantly reduced by addition of SS-31 in concentration between 1 and 100 µM to the medium 1 h after exposure to H2O2 (
FIG. 24 ). - Treatment with 5 mg-kg SS-31 i.p. started at 30 days of age of G93A transgenic familial amyotrophic lateral sclerosis (ALS) mice (high copy number, B6SJL-Tg(SOD1-G93A)1Gur/J) led to a significant delay of disease onset as defined by the appearance of tremor and hind limb clasping as well as deterioration in the rotarod performance, the average age of onset in the control group was 88+7 days, in the SS-31 treated group 95+6 days (p<0.05, Logrank (Mantel-Cox)). Survival was significantly increased by SS-31 treatment from 130±12 to 142+12 day (i.e., 9%) (p<0.05, Logrank (Mantel-Cox)) (
FIG. 25 ). Treatment was well tolerated and no side effects were observed. There was a gender effect on survival which has been observed in previous studies with this model as well in G93A mice in this background with males having a shorter life span than females (average of 5 days). This gender difference was seen in both groups and not modified by the treatment. - Motor performance was significantly improved in the SS-31 treated mice between
day 100 and 130 (p<0005, Repeated measures ANOVA followed by Fisher’s PLSD) (FIG. 26 ). - Stereological cell counts in the lumbar spinal cord revealed a significant cell loss in the vehicle treated G93A mice as compared to non-transgenic littermate control animals. The cell loss was significantly ameliorated by administration of SS-31 (
FIG. 27 ). Immunostaining for markers of oxidative and nitrosative stress (4-hydroxynonenenal, 3-nitrotyrosine) showed increased levels of lipid peroxidation and protein nitration in the spinal cord of G93A as compared to control mice. This was markedly reduced in the SS-31 treated mice (FIGS. 28, 4 - hydroxynonenenal;FIGS. 29, 3 -nitrotyrosine). - Ascorbate and GSH, in addition to cysteine were determined in the postischemic cortex and striatum. While cysteine levels were generally decreased in both hemispheres after ischemia, they were significantly higher in the ipsilateral side compared to the contralateral side (
FIGS. 30A and B ). By contrast, the levels of ascorbate and GSH, the major water-soluble intracellular antioxidants in brain, were progressively decreased in the ipsilateral side within a few hours of reperfusion (FIGS. 30C-F ). Antioxidant reduction was significant in both cortex and striatum at 6 h and was further reduced at 24 h, at a time when the infarct is visible. - To test the efficacy of SS-3 1on redox status, cysteine, ascorbate and GSH levels were determined 6 h after 30 min transient middle cerebral artery occlusion (MCAO) in mice treated intraperitoneally (i.p.) with saline (vehicle), SS-31 (2 mg/kg) or SS-20 (2 mg/kg) upon reperfusion. Values in
FIG. 31 are expressed as percent increase (cysteine) and percent depletion (ascorbate and GSH) in the ipsilateral side compared to the contralateral side. Absolute values were originally expressed as nmoles/mg protein as shown inFIG. 30 and converted to percent difference. The percent ipsilateral cysteine increase was similar among vehicle-, SS-31-, and SS-20-treated groups (FIG. 31A ). Percent ipsilateral depletion of ascorbate was marginally but not significantly affected in both SS-31 and SS-20-treated animals (FIG. 31B ). In contrast, ischemia-induced GSH depletion in the cortex was significantly attenuated in SS-31-treated animals compared to the vehicle-treated group (FIG. 31C ). - The degree of ipsilateral GSH depletion in SS-20-treated mice was not significantly different from that of vehicle-treated mice (
FIG. 31C ). The data show that SS-31 assists in maintaining antioxidant status and protects against ischemia-induced depletion of GSH in the cortex. - To address whether SS-31-induced attenuation in GSH depletion is associated with neuroprotection, mice were subjected to 30 or 20 min MCAO and then treated with vehicle or SS-31 (2 mg/kg, i.p.) upon reperfusion) and at 6 h, 24 h, 48 h after MCAO. Infarct volumes and hemispheric swelling were determined at 3 days after ischemia. SS-31 treatment resulted in moderate but significant reduction in infarct volume following both 30 min (24% reduction) and 20 min (30% reduction) ischemia, (
FIGS. 32A-C ). Treatment with SS-31 also significantly attenuated hemispheric swelling in both 30 and 20 min ischemic paradigms (FIG. 32D ). There was no difference in cerebral blood flow (CBF) reduction during MCAO (FIG. 32E ) and reperfusion at 10 min (FIG. 32F ) between vehicle- and SS-31 -treated groups, indicating that the neuroprotective effect by SS-31 occurs via mechanisms other than altered CBF during and after the ischemic insult. - Islets are tightly adherent cell clusters and entry of peptides/proteins may be impaired given their architecture.
FIG. 33A shows that SS-31 readily penetrates intact mouse islets; in four consecutive experiments, the mean (±SE) of [3H]SS-31 uptake was 70.2±10.3 pmol/mg of protein. - Mitochondrial depolarization and the release of cytochrome c into the cytoplasm are critical antecedent events to cell death. TMRM, a fluorescent cationic indicator is taken up into mitochondria in a potential dependent manner.
FIG. 33B confocal laser scanning microscopic imaging of TMRM treated islets shows that the islets from mice treated with SS-31 exhibit greater uptake of TMRM compared to islets from mice not treated with SS-31. - To investigate whether the SS-31 optimizes islet isolation and results in increased islet yield, islet donor mice were pre-treated with SS-31. SS-31 resulted in a significantly higher islet cell yield compared to untreated mice the mean± (SE) islet yield from the pancreata harvested from SS-31 pre-treated mice was 291±60 islets per pancreas (N=6 separate islet isolations from 28 pancreata) compared to 242±53 islets per pancreas retrieved from the control mice (N=6 separate islet isolations from 30 pancreata) (P=0.03, Two-tailed Pvalue calculated with Mann-Whitney test).
- SS-31 treatment, in addition to enhancing islet yield resulted in a significant decrease in early as well as late, islet cell apoptosis. Dual parameter flow cytometry analyses of islet cells stained with both Annexin V and propidium iodide demonstrated that the treatment of islet donor mice with SS-31 reduced the percentage of early apoptotic cells (Annexin V alone positive cells) from 11.4±2.4% to 5.5±1.0% (
FIG. 34A , P=0.03). SS-31 treatment reduced late apoptosis/early necrosis (Annexin V+/PI+cells) from 22.7±4.7% to 12.6±1.8 (FIG. 34B , P=0.03) and increased islet cell viability (Annexin V-/PI-cells) from 47±5.1% to 62±3.5% (FIG. 34D , P=0.03)). SS-31 treatment of islet donor mice, however, did not reduce the percentage of necrotic cells (PI+cells: 20±3.2% vs. 19±4.7%, P=1.0). - The SS-31 treatment associated decrease in islet cell apoptosis and enhanced viability had a beneficial functional consequence. In a marginal islet cell mass transplantation model, 0 of 8 recipients of islets isolated from pancreas harvested from the control mice had successful reversal of hyperglycemia (defined as three consecutive blood glucose levels<200 mg/dl), whereas sustained normoglycemia occurred in 5 of ten recipients of islets isolated from pancreas from the SS-31 treated donor mice (
FIG. 35 ). It is worth noting that reversal of hyperglycemia was prompt (byday 1 post-transplant) and discontinuation SS-31 treatment of the islet graft recipient onday 10 did not result in return of hyperglycemia demonstrating a sustained effect of SS-31 treatment on islet cell function.
Claims (12)
1. A method for preventing loss of dopamine-producing neurons in a mammal having or suspected of having Parkinson’s disease, the method comprising administering to the mammal an effective amount of a peptide having the formula D-Arg-Dmt-Lys-Phe-NH2.
2. The method according to claim 1 , wherein the mammal is a human.
3. The method according to claim 1 , wherein the peptide is administered orally, topically, intranasally, systemically, intravenously, subcutaneously, intramuscularly, intracerebroventricularly, intrathecally, or transdermally.
4. The method of claim 1 , wherein the peptide is mixed with a pharmaceutically acceptable carrier.
5. A method for treating amyotrophic lateral sclerosis (ALS) in a mammal, the method comprising administering to the mammal an effective amount of a peptide having the formula D-Arg-Dmt-Lys-Phe-NH2.
6. The method according to claim 5 , wherein the mammal is a human.
7. The method according to claim 5 , wherein the peptide is administered orally, topically, intranasally, systemically, intravenously, subcutaneously, intramuscularly, intracerebroventricularly, intrathecally, or transdermally.
8. The method of claim 5 , wherein the peptide is mixed with a pharmaceutically acceptable carrier.
9. A method for inhibiting LDL oxidation in a mammal, the method comprising administering to the mammal an effective amount of a peptide having the formula D-Arg-Dmt-Lys-Phe-NH2.
10. The method according to claim 9 , wherein the mammal is a human.
11. The method according to claim 9 , wherein the peptide is administered orally, topically, intranasally, systemically, intravenously, subcutaneously, intramuscularly, intracerebroventricularly, intrathecally, or transdermally.
12. The method of claim 9 , wherein the peptide is mixed with a pharmaceutically acceptable carrier.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/493,551 US20230149501A1 (en) | 2004-01-23 | 2021-10-04 | Methods for reducing oxidative damage |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53884104P | 2004-01-23 | 2004-01-23 | |
US11/040,242 US7550439B2 (en) | 2004-01-23 | 2005-01-21 | Methods for reducing oxidative damage |
US11/428,188 US7781405B2 (en) | 2004-01-23 | 2006-06-30 | Methods for reducing oxidative damage |
US12/843,333 US8618061B2 (en) | 2004-01-23 | 2010-07-26 | Methods for reducing oxidative damage |
US14/100,626 US9623069B2 (en) | 2004-01-23 | 2013-12-09 | Methods for reducing oxidative damage |
US14/955,412 US9950026B2 (en) | 2004-01-23 | 2015-12-01 | Methods for reducing oxidative damage |
US15/956,941 US20190328821A1 (en) | 2004-01-23 | 2018-04-19 | Methods for reducing oxidative damage |
US16/798,085 US20210015887A1 (en) | 2004-01-23 | 2020-02-21 | Methods for reducing oxidative damage |
US17/493,551 US20230149501A1 (en) | 2004-01-23 | 2021-10-04 | Methods for reducing oxidative damage |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/798,085 Continuation US20210015887A1 (en) | 2004-01-23 | 2020-02-21 | Methods for reducing oxidative damage |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230149501A1 true US20230149501A1 (en) | 2023-05-18 |
Family
ID=34826019
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/040,242 Active 2025-08-08 US7550439B2 (en) | 2004-01-23 | 2005-01-21 | Methods for reducing oxidative damage |
US11/428,188 Active 2027-09-12 US7781405B2 (en) | 2004-01-23 | 2006-06-30 | Methods for reducing oxidative damage |
US12/843,333 Active 2025-07-26 US8618061B2 (en) | 2004-01-23 | 2010-07-26 | Methods for reducing oxidative damage |
US14/100,626 Active US9623069B2 (en) | 2004-01-23 | 2013-12-09 | Methods for reducing oxidative damage |
US14/955,412 Active US9950026B2 (en) | 2004-01-23 | 2015-12-01 | Methods for reducing oxidative damage |
US15/956,941 Abandoned US20190328821A1 (en) | 2004-01-23 | 2018-04-19 | Methods for reducing oxidative damage |
US16/798,085 Abandoned US20210015887A1 (en) | 2004-01-23 | 2020-02-21 | Methods for reducing oxidative damage |
US17/493,551 Pending US20230149501A1 (en) | 2004-01-23 | 2021-10-04 | Methods for reducing oxidative damage |
Family Applications Before (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/040,242 Active 2025-08-08 US7550439B2 (en) | 2004-01-23 | 2005-01-21 | Methods for reducing oxidative damage |
US11/428,188 Active 2027-09-12 US7781405B2 (en) | 2004-01-23 | 2006-06-30 | Methods for reducing oxidative damage |
US12/843,333 Active 2025-07-26 US8618061B2 (en) | 2004-01-23 | 2010-07-26 | Methods for reducing oxidative damage |
US14/100,626 Active US9623069B2 (en) | 2004-01-23 | 2013-12-09 | Methods for reducing oxidative damage |
US14/955,412 Active US9950026B2 (en) | 2004-01-23 | 2015-12-01 | Methods for reducing oxidative damage |
US15/956,941 Abandoned US20190328821A1 (en) | 2004-01-23 | 2018-04-19 | Methods for reducing oxidative damage |
US16/798,085 Abandoned US20210015887A1 (en) | 2004-01-23 | 2020-02-21 | Methods for reducing oxidative damage |
Country Status (14)
Country | Link |
---|---|
US (8) | US7550439B2 (en) |
EP (1) | EP1722807A4 (en) |
JP (1) | JP4931604B2 (en) |
KR (1) | KR101159254B1 (en) |
CN (1) | CN1938042B (en) |
AU (1) | AU2005208821B8 (en) |
BR (1) | BRPI0507053A (en) |
CA (7) | CA2971931C (en) |
HK (1) | HK1102289A1 (en) |
IL (5) | IL177030A (en) |
NZ (1) | NZ549393A (en) |
RU (1) | RU2376028C2 (en) |
WO (1) | WO2005072295A2 (en) |
ZA (1) | ZA200607013B (en) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104225574B (en) * | 2003-02-04 | 2017-01-11 | 科内尔研究基金会 | Methods for preventing mitochondrial permeability transition |
EP2604621B1 (en) | 2003-05-01 | 2015-10-21 | Cornell Research Foundation, Inc. | Method and carrier complexes for delivering molecules to cells |
JP4931604B2 (en) * | 2004-01-23 | 2012-05-16 | コーネル リサーチ ファウンデイション インコーポレイテッド | Methods for reducing oxidative damage |
US8822542B2 (en) | 2004-10-20 | 2014-09-02 | Vanderbilt University | Isoketal scavengers and mitigation of disorders involving oxidative injury |
GB0517090D0 (en) | 2005-08-19 | 2005-09-28 | Tcp Innovations Ltd | ApoE mimetic agents |
CN102552874B (en) * | 2005-09-16 | 2015-04-22 | 科内尔研究基金会 | Methods for reducing CD36 expression |
AU2014203126B2 (en) * | 2005-09-16 | 2016-03-10 | Cornell Research Foundation, Inc. | Methods for reducing cd36 expression |
AU2019257440B2 (en) * | 2005-09-16 | 2021-12-16 | Cornell Research Foundation, Inc. | Methods for reducing CD36 expression |
CA2658881C (en) | 2006-07-25 | 2015-09-15 | Hough Ear Institute | Methods for treating acute acoustic trauma |
EP2114427B1 (en) | 2007-01-30 | 2014-06-25 | New York University | Peptides for treatment of conditions associated with nitric oxide |
JP4461159B2 (en) * | 2007-06-14 | 2010-05-12 | ヤマハファインテック株式会社 | Printed circuit board inspection apparatus and inspection method |
SI2252312T1 (en) * | 2008-02-07 | 2014-08-29 | Cornell University, | Methods for preventing or treating insulin resistance |
JP5677096B2 (en) * | 2008-02-26 | 2015-02-25 | コーネル ユニヴァーシティー | Methods for preventing and treating acute kidney injury |
DE102008061044A1 (en) * | 2008-12-11 | 2010-06-17 | Henkel Ag & Co. Kgaa | Composition with antioxidant peptides |
US20100331265A1 (en) * | 2009-03-20 | 2010-12-30 | Tompkins Ronald G | Methods for the prevention and treatment of burn injuries and secondary complications |
WO2011008202A1 (en) * | 2009-07-15 | 2011-01-20 | Vanderbilt University | Isoketal scavengers and mitigation of disorders involving oxidative injury |
US20110039766A1 (en) * | 2009-08-12 | 2011-02-17 | Szeto Hazel H | Methods for preventing or treating metabolic syndrome |
EP3318264A1 (en) * | 2009-08-24 | 2018-05-09 | Stealth Peptides International, Inc. | Methods ans compositions for preventing or treating opthalmic conditions |
EP2764871A1 (en) * | 2009-10-05 | 2014-08-13 | Cornell University | Methods for the prevention or treatment of heart failure |
CN103751763A (en) * | 2009-12-31 | 2014-04-30 | 康肽德生物医药技术有限公司 | Methods for the prevention or treatment of vessel occlusion injury |
US20130190244A1 (en) * | 2009-12-31 | 2013-07-25 | Stealth Peptides International, Inc. | Methods for performing a coronary artery bypass graft procedure |
EP2528934A4 (en) * | 2010-01-25 | 2013-08-21 | Univ Cornell | Aromatic-cationic peptides and uses of same |
WO2011106717A1 (en) * | 2010-02-26 | 2011-09-01 | University Of Florida Research Foundation, Inc. | Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy |
US8697657B2 (en) * | 2010-03-15 | 2014-04-15 | Stealth Peptides International, Inc. | Combination therapies using cyclosporine and aromatic cationic peptides |
US20110245182A1 (en) * | 2010-04-06 | 2011-10-06 | Perricone Nicholas V | Topical Uses of Szeto-Schiller Peptides |
US20110245183A1 (en) * | 2010-04-06 | 2011-10-06 | Perricone Nicholas V | Topical Uses of Szeto-Schiller Peptides |
EP2566880A4 (en) * | 2010-05-03 | 2014-10-08 | Stealth Peptides Int Inc | Aromatic-cationic peptides and uses of same |
HUP1000243A2 (en) | 2010-05-06 | 2012-01-30 | Avidin Kft | 8-hidroxy-quinoline derivatives |
EP2590664B1 (en) * | 2010-07-09 | 2019-03-27 | Stealth Peptides International, Inc. | Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury |
WO2012009171A2 (en) * | 2010-07-15 | 2012-01-19 | The Schepens Eye Research Institute, Inc. | Compositions and methods of treatment of corneal endothelium disorders |
JP6121904B2 (en) | 2010-09-08 | 2017-04-26 | ハロザイム インコーポレイテッド | Methods for evaluating and identifying or developing conditionally active therapeutic proteins |
US20120083452A1 (en) * | 2010-09-30 | 2012-04-05 | Perricone Nicholas V | Topical Anesthetic Uses of Szeto-Schiller Peptides |
JP6099574B2 (en) | 2011-02-04 | 2017-03-22 | ハフ イヤ インスティテュート | How to treat traumatic brain injury |
JP2014518213A (en) * | 2011-06-14 | 2014-07-28 | ステルス ペプチドズ インターナショナル インコーポレイテッド | Aromatic cationic peptides and uses thereof |
CN102327600A (en) * | 2011-09-14 | 2012-01-25 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | RX31 peptide for preventing and curing radiation damage |
CA3123992A1 (en) | 2011-09-29 | 2013-04-04 | Mayo Foundation For Medical Education And Research | Aromatic-cationic peptides and methods for using same |
EP2768516A4 (en) * | 2011-10-17 | 2015-08-19 | Univ Cornell | Aromatic-cationic peptides and uses of same |
EP2817018A4 (en) * | 2012-02-22 | 2015-09-23 | Stealth Peptides Int Inc | Methods and compositions for preventing or treating ophthalmic conditions |
EP2817021B1 (en) * | 2012-02-23 | 2019-01-02 | Cornell University | Aromatic-cationic peptides and uses of same |
EA201400993A1 (en) | 2012-03-08 | 2015-05-29 | Галозим, Инк. | ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR, ACTIVE IN CERTAIN CONDITIONS AND METHODS OF THEIR APPLICATION |
CN107320712A (en) | 2012-03-30 | 2017-11-07 | 康德生物医疗技术公司 | For preventing and treating neuropathic method and composition |
HUE046924T2 (en) | 2013-03-01 | 2020-03-30 | Stealth Biotherapeutics Corp | Methods and compositions for the prevention or treatment of barth syndrome |
EP3673913A1 (en) | 2013-03-01 | 2020-07-01 | Stealth Biotherapeutics Corp | Methods for the treatment of mitochondrial disease |
CA2916977A1 (en) | 2013-06-26 | 2014-12-31 | Stealth Biotherapeutics Corp | Methods and compositions for detecting and diagnosing diseases and conditions |
WO2014210062A1 (en) * | 2013-06-26 | 2014-12-31 | Stealth Peptides International, Inc. | Methods for the regulation of matrix metalloproteinase expression |
CA2920020C (en) | 2013-08-02 | 2023-03-14 | Stealth Biotherapeutics Corp | Methods and compositions for the prevention and treatment of friedreich's ataxia |
CA2925475A1 (en) * | 2013-09-27 | 2015-04-02 | Cornell University | Use of aromatic-cationic peptides to treat cholesterol-induced mitochondrial dysfunction |
JP6434523B2 (en) * | 2013-09-30 | 2018-12-05 | コーネル ユニヴァーシティー | Cardiolipin targeting peptide inhibits beta amyloid oligomer toxicity |
US9982014B2 (en) | 2013-10-23 | 2018-05-29 | Kaneka Corporation | Tetrapeptide compound and method for producing same |
WO2015084875A1 (en) * | 2013-12-02 | 2015-06-11 | Stealth Peptides International, Inc. | Compositions and methods for treating vitiligo |
WO2015095077A1 (en) * | 2013-12-16 | 2015-06-25 | Cornell University | Methods and compositions for treating and preventing cognitive dysfunction |
US10053490B2 (en) | 2014-01-22 | 2018-08-21 | Agency For Science, Technology And Research | Antimicrobial peptidomimetics |
US9314457B2 (en) | 2014-06-19 | 2016-04-19 | The University Of Utah Research Foundation | Methods of treating and preventing vascular instability diseases |
ES2869430T3 (en) | 2014-06-25 | 2021-10-25 | Flamma Spa | Procedure for preparing D-arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-L-phenylalaninamide |
HUE055687T2 (en) | 2014-06-30 | 2021-12-28 | Flamma Spa | Process for the production of d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide |
WO2016004093A2 (en) * | 2014-07-01 | 2016-01-07 | Stealth Biotherapeutics Corp | Therapeutic compositions including galectin-3 inhibitors and uses thereof |
WO2016200364A1 (en) * | 2015-06-08 | 2016-12-15 | Stealth Peptides International, Inc. | THERAPEUTIC COMPOSITIONS INCLUDING SkQ COMPOUNDS AND USES THEREOF |
US11266716B2 (en) * | 2015-10-22 | 2022-03-08 | The Feinstein Institutes For Medical Research | Use of dermcidin in sterile inflammatory conditions |
CA3006698A1 (en) * | 2015-11-30 | 2017-06-08 | Peter Schiller | Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome |
RU2613910C1 (en) * | 2015-12-08 | 2017-03-21 | Федеральное государственное бюджетное учреждение науки Государственный научный центр Российской Федерации - Институт медико-биологических проблем Российской академии наук (ГНЦ РФ - ИМБП РАН) | Method for skeletal muscle and myocardium tissue hypoxia determination during physical inactivity |
US20170224764A1 (en) * | 2016-02-10 | 2017-08-10 | Cornell University | Therapeutic targeting of mitochondria to prevent osteoarthritis |
CN107041946A (en) * | 2017-03-24 | 2017-08-15 | 南京大学 | Applications of the compound SS 31 on treatment atherosclerosis and relevant disease medicine or preparation is prepared |
CA3100943A1 (en) * | 2018-05-23 | 2019-11-28 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Cardiac-specific targeting-peptide (ctp), compositions, and uses thereof |
US20230190676A1 (en) * | 2020-07-09 | 2023-06-22 | Musc Foundation For Research Development | Methods of protecting cells from insults |
IL301158A (en) | 2020-09-09 | 2023-05-01 | Social Profit Network | Methods and compositions for delivery of biotin to mitochondria |
CN114773433B (en) * | 2022-06-23 | 2022-09-06 | 北京肿瘤医院(北京大学肿瘤医院) | CD25 targeted polypeptide, molecular probe and application |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5118670A (en) * | 1988-12-14 | 1992-06-02 | Massachusetts Institute Of Technology | Process and composition for increasing brain dopamine release |
US6417210B1 (en) * | 1998-01-09 | 2002-07-09 | Mor-Research Applications Ltd. | Treatment of dyskinesias and Parkinson's disease with riluzole and levodopa |
US9623069B2 (en) * | 2004-01-23 | 2017-04-18 | Cornell Research Foundation, Inc. | Methods for reducing oxidative damage |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
SG64368A1 (en) * | 1988-06-30 | 1999-04-27 | Astra Ab | Dermorphin analogs their methods of preparation pharmaceutical compositions and methods of therapeutic treatment using the same |
US5602100A (en) * | 1988-06-30 | 1997-02-11 | Astra Ab | Dermorphin analogs having pharmacological activity |
US5670617A (en) * | 1989-12-21 | 1997-09-23 | Biogen Inc | Nucleic acid conjugates of tat-derived transport polypeptides |
US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
US5674534A (en) | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
IS4261A (en) | 1994-02-21 | 1995-08-22 | Astra Aktiebolag | New peptide opioids for the treatment of pain and their use |
EP0747092B1 (en) * | 1995-06-09 | 2003-12-03 | Hisamitsu Pharmaceutical Co., Inc. | Matrix for iontophoresis |
US5849761A (en) * | 1995-09-12 | 1998-12-15 | Regents Of The University Of California | Peripherally active anti-hyperalgesic opiates |
PT971709E (en) | 1996-10-07 | 2003-09-30 | Lilly Co Eli | NEW UTEAN COMPOUNDS AS NEURO-PROTECTIVE AGENTS |
US5885958A (en) * | 1997-03-25 | 1999-03-23 | Administrators Of The Tulane Educational Fund | Mu-opiate receptor peptides |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
US6221355B1 (en) * | 1997-12-10 | 2001-04-24 | Washington University | Anti-pathogen system and methods of use thereof |
CA2329709A1 (en) * | 1998-04-24 | 1999-11-04 | Mitokor | Compounds and methods for treating mitochondria-associated diseases |
US6472378B2 (en) | 1998-08-31 | 2002-10-29 | Pro-Neuron, Inc. | Compositions and methods for treatment of mitochondrial diseases |
US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
SE9900961D0 (en) | 1999-03-16 | 1999-03-16 | Astra Ab | Novel compounds |
CA2386540A1 (en) * | 1999-10-04 | 2001-04-12 | University Of Medicine And Dentistry Of New Jersey | Novel carbamates and ureas |
US6759520B1 (en) * | 1999-10-28 | 2004-07-06 | The New England Medical Center Hospitals, Inc. | Chimeric analgesic peptides |
US20050192215A1 (en) * | 2000-01-21 | 2005-09-01 | Malabika Ghosh | Methods and materials relating to novel polypeptides and polynucleotides |
AU2001277908A1 (en) | 2000-07-18 | 2002-01-30 | Cornell Research Foundation Inc. | Medicinal uses of mu-opioid receptor agonists |
US6900178B2 (en) * | 2000-09-12 | 2005-05-31 | University Of Kentucky Research Foundation | Protection against ischemia and reperfusion injury |
WO2002044126A2 (en) | 2000-11-28 | 2002-06-06 | Guilford Pharmaceuticals Inc. | Bisubstituted carbocyclic cyclophilin binding compounds and theirus |
JP2004532187A (en) | 2001-01-25 | 2004-10-21 | ギルフォード ファーマシュウティカルズ インコーポレイテッド | Trisubstituted carbocyclic cyclophilin binding compounds and their uses |
US20030077826A1 (en) | 2001-02-02 | 2003-04-24 | Lena Edelman | Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC) |
CN104225574B (en) * | 2003-02-04 | 2017-01-11 | 科内尔研究基金会 | Methods for preventing mitochondrial permeability transition |
EP2604621B1 (en) | 2003-05-01 | 2015-10-21 | Cornell Research Foundation, Inc. | Method and carrier complexes for delivering molecules to cells |
WO2005032481A2 (en) * | 2003-09-30 | 2005-04-14 | Scios Inc. | Quinazoline derivatives as medicaments |
CN102552874B (en) * | 2005-09-16 | 2015-04-22 | 科内尔研究基金会 | Methods for reducing CD36 expression |
-
2005
- 2005-01-21 JP JP2006551350A patent/JP4931604B2/en active Active
- 2005-01-21 CA CA2971931A patent/CA2971931C/en active Active
- 2005-01-21 CN CN2005800082000A patent/CN1938042B/en active Active
- 2005-01-21 CA CA2851972A patent/CA2851972C/en active Active
- 2005-01-21 CA CA2887797A patent/CA2887797C/en active Active
- 2005-01-21 CA CA2971929A patent/CA2971929C/en active Active
- 2005-01-21 EP EP05711878A patent/EP1722807A4/en active Pending
- 2005-01-21 CA CA3024434A patent/CA3024434A1/en not_active Abandoned
- 2005-01-21 BR BRPI0507053-8A patent/BRPI0507053A/en not_active Application Discontinuation
- 2005-01-21 NZ NZ549393A patent/NZ549393A/en not_active IP Right Cessation
- 2005-01-21 CA CA2971928A patent/CA2971928C/en active Active
- 2005-01-21 RU RU2006130431A patent/RU2376028C2/en not_active IP Right Cessation
- 2005-01-21 KR KR1020067016975A patent/KR101159254B1/en active IP Right Grant
- 2005-01-21 CA CA2554166A patent/CA2554166C/en active Active
- 2005-01-21 US US11/040,242 patent/US7550439B2/en active Active
- 2005-01-21 WO PCT/US2005/002119 patent/WO2005072295A2/en active Application Filing
- 2005-01-21 AU AU2005208821A patent/AU2005208821B8/en not_active Expired
-
2006
- 2006-06-30 US US11/428,188 patent/US7781405B2/en active Active
- 2006-07-23 IL IL177030A patent/IL177030A/en active IP Right Grant
- 2006-08-22 ZA ZA2006/07013A patent/ZA200607013B/en unknown
-
2007
- 2007-09-24 HK HK07110349.0A patent/HK1102289A1/en unknown
-
2010
- 2010-07-26 US US12/843,333 patent/US8618061B2/en active Active
-
2013
- 2013-12-09 US US14/100,626 patent/US9623069B2/en active Active
-
2014
- 2014-11-18 IL IL235772A patent/IL235772A/en active IP Right Grant
-
2015
- 2015-02-25 IL IL237407A patent/IL237407B/en active IP Right Grant
- 2015-02-25 IL IL237408A patent/IL237408B/en not_active IP Right Cessation
- 2015-12-01 US US14/955,412 patent/US9950026B2/en active Active
-
2018
- 2018-01-02 IL IL256703A patent/IL256703B/en active IP Right Grant
- 2018-04-19 US US15/956,941 patent/US20190328821A1/en not_active Abandoned
-
2020
- 2020-02-21 US US16/798,085 patent/US20210015887A1/en not_active Abandoned
-
2021
- 2021-10-04 US US17/493,551 patent/US20230149501A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5118670A (en) * | 1988-12-14 | 1992-06-02 | Massachusetts Institute Of Technology | Process and composition for increasing brain dopamine release |
US6417210B1 (en) * | 1998-01-09 | 2002-07-09 | Mor-Research Applications Ltd. | Treatment of dyskinesias and Parkinson's disease with riluzole and levodopa |
US9623069B2 (en) * | 2004-01-23 | 2017-04-18 | Cornell Research Foundation, Inc. | Methods for reducing oxidative damage |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230149501A1 (en) | Methods for reducing oxidative damage | |
US20230293624A1 (en) | Methods for preventing or treating mitochondrial permeability transition | |
MXPA06008342A (en) | Methods for reducing oxidative damage |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |